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ABSTRACT 
 
A biofilm is a layer of microbial cells that is firmly attached to surfaces and 
enclosed in a matrix of polysaccharide material. Biofilms pose a problem to the 
environment, industry and the medical field causing a variety of chronic infections 
particularly in the ear, nose and throat like chronic and recurrent tonsillitis. 
Therefore, development of new therapeutic strategies against biofilm-forming 
pathogens is essential in the management of biofilm-associated tonsillar diseases. 
One hundred and forty (140) palatine tonsils were collected from 70 patients 
undergoing tonsillectomy at University Malaya Medical Centre (UMMC) and the 
type of microorganisms and their antimicrobial susceptibility of both swab and 
biopsy tonsillar specimens were identified. The presence of bacterial biofilms in the 
excised tonsils was detected via Scanning Electron Microscopy and Confocal Laser 
Scanning Microscopy, and the ability of tonsillar bacterial isolates to form biofilms 
was determined via Congo Red Agar method and Microtiter Plate assay. A culture 
filtrate from novel soil bacterial species of Paenibacillus haemolyticus strain 139SI 
was tested for its acute toxicity in rats and evaluated for its antibiofilm activity both 
in vitro via Microtiter Plate assay and in vivo using a rat model of chronic lung 
infection. The soil bacterial filtrate was purified via High Performance Liquid 
Chromatography, and the selected compounds were tested against clinical isolates 
for their antibiofilm activity. The most potential antibiofilm compounds were 
further analysed via Liquid Chromatography-Mass Spectrometry. Two main groups 
of clinical cases were classified as infected tonsils represented by 49 (70%) cases of 
recurrent tonsillitis, 9 (12.85%) cases of chronic tonsillitis in addition to non-
infected (hypertrophied) tonsils represented by 12 (17.14%) cases of obstructive 
sleep apnea. The presence of bacterial biofilms was detected in 42 (60%) patients. 
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A total number of 464 bacterial isolates were recovered from tonsillar specimens 
with 184 (39.65%) Staphylococcus aureus isolates as the most common followed 
by 86 (18.53%) of Haemophilus influenzae isolates. Three susceptibility patterns 
were found among S. aureus isolates with 89.4% being susceptible to all tested 
antimicrobial agents, 10.6% resistant to fusidic acid and 0.5% resistant to both 
methicillin and fusidic acid. The antimicrobial agent co-trimoxazole showed the 
highest rate of resistance among all bacterial isolates including 55 (98.2%) isolates 
of Group B Streptococci and 11 (78.5%) isolates of Group A Beta-Haemolytic 
Streptococci, 14 (56%) isolates of Group G Streptococci, 10 (32.2%) isolates of 
Haemophilus pararinfluenzae and 27 (31.3%) isolates of Haemophilus influenzae. 
The soil bacterial filtrate of Paenibacillus haemolyticus strain 139SI showed no 
signs of toxicity and a significant antibiofilm activity was detected in the lungs of 
chronically-infected rats. Four potential antibiofilm compounds of the bacterial 
filtrate namely FR4, FR5, FR8 and FR13 were identified. The compound FR5 with 
a molecular weight of 253.237 and a molecular formula of C8H20N3O4P exhibited 
the strongest antibiofilm activity. In conclusion, discovery of an antibiofilm activity 
from a novel soil bacterial species of Paenibacillus haemolyticus strain 139SI adds 
an important dimension in the search for new potent compounds against biofilm 
infections.  
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ABSTRAK 
 
Biofilm merupakan satu lapisan sel-sel mikrob yang melekat pada permukaan dan 
terbenam dalam bahan matriks polisakarida. Biofilm mewakili masalah kepada 
alam sekitar, industri dan bidang perubatan menyebabkan pelbagai jangkitan kronik 
terutama di telinga, hidung dan tekak seperti tonsilitis kronik dan berulang. 
Biofilms mewakili masalah alam sekitar, industri dan dalam bidang perubatan, ia 
menyebabkan pelbagai jangkitan kronik terutama di telinga, hidung dan tekak 
seperti tonsilitis kronik dan berulang. Oleh itu, pembangunan strategi baru 
terapeutik terhadap patogen pembentukan-biofilm adalah penting di dalam 
pengurusan bioflm-penyakit berkaitan tonsillar. Seratus empat puloh (140) tonsil 
palatin telah dikumpulkan daripada 70 pesakit yang menjalani pembedahan 
tonsilektomi di Pusat Perubatan Universiti Malaya (PPUM) dan telah mengenal 
pasti jenis mikroorganisma dan kerentanan antimikrobial mereka bagi kedua-dua 
swab dan spesimen biopsi tonsillar. Kehadiran biofilm bakteria dalam tonsil 
dibuang telah dikesan melalui Pengimbasan Mikroskop Elektron dan Laser 
Confocal Mikroskop Pengimbasan, dan keupayaan isolat bakteria tonsillar 
membentuk biofilm telah ditentukan melalui kaedah Agar Merah dan asai 
Microtiter Plat. Turasan kultur dari sepsis novel bacteria tanah Paenibacillus 
haemolyticus  strain 139SI telah diuji untuk ketoksikan akut pada tikus dan telah 
dinilai untuk aktiviti antibiofilm secara in vitro melalui asai Mikrotiter Plat dan in 
vivo dengan menggunakan model tikus jangkitan paru-paru kronik. Turasan 
bakteria tanah telah ditulenkan melalui Kromatografi Cecair Prestasi Tinggi, dan 
sebatian yang dipilih telah diuji terhadap isolat klinikal untuk aktiviti antibiofilm 
mereka. Sebatian antibiofilm yang paling berpotensi seterusnya dianalisis melalui 
Kromatografi Cecair Spektrometri Jisim. Dua kumpulan utama kes-kes klinikal 
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telah diklasifikasikan sebagai tonsil yang dijangkiti adalah diwakili oleh 49 (70%) 
kes tonsilitis berulang dan 9 (12.85%) kes tonsilitis kronik, dan sebanyak 12 
(17.14%) kes adalah tonsil yang tidak dijangkiti (hypertrophied) diwakili oleh 
apnea tidur obstruktif. Kehadiran biofilm bakteria telah dikesan dalam 42 (60%) 
orang pesakit. Sejumlah 464 isolat bakteria telah diasingkan dari spesimen tonsillar 
dan telah didapati Staphylococcus aureus mempunyai jumlah terbanyak iaitu 184 
(39.65%) isolat dan diikuti dengan Haemophilus influenzae sebanyak 86 (18.53%) 
isolat. Tiga corak kerentanan telah ditemui di kalangan isolat S. aureus di mana 
sebanyak 89.4% adalah sensitive kepada semua agen antimikrobial yang diuji, 
10.6% isolat S. aureus mempunyai kerintangan terhadap antibiotik asid fusidik dan 
0.5% kerintangan terhadap antibiotik metisilin. Agen antimikrobial co-trimoxazol 
telah menunjukkan kadar kerintangan tertinggi di kalangan semua isolat bakteria 
dan ini termasuklah 55 (98.2%) isolat Streptococci Kumpulan B, 11 (78.5%) isolat 
Streptococci Beta-hemolitik Kumpulan A, 14 (56%) isolat Streptococci Kumpulan 
G, 10 (32.2%) isolat Haemophilus pararinflunzae dan 27 (31.3%) isolat 
Haemophilus  influenzae. Turasan bakteria tanah Paenibacillus haemolyticus strain 
139SI tidak menunjukkan tanda-tanda sebarang ketoksikan dan terdapat aktiviti 
antibiofilm yang ketara telah dikesan di dalam paru-paru tikus yang dijangkiti 
secara kronik. Empat sebatian antibiofilm berpotensi dari turasan bacteria telah 
dinamakan sebagai FR4, FR5, FR8 dan FR13. Sebatian FR5 mempunyai activiti 
antibiofilm paling tinggi dan berat molekulnya adalah 253.237  dengan formula 
C8H20N3O4P. Kesimpulannya, dengan penemuan aktiviti antibiofilm dari spesis 
novel bakteria tanah Paenibacillus haemolyticus strain 139SI akan menambah satu 
dimensi penting untuk carian sebatian baru berpotensi terhadap jangkitan biofilm. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Definition of Biofilms  
  Majority of the living biomass on earth is determined by the biological activity 
of microorganisms (King et al., 2009). Basically, any accumulation of living microbes 
on a surface is typically referred to as biofilm or slime (Bott, 2011). Biofilms can be 
defined as complex microbial communities consisting of either single bacterial or fungal 
species or even multiple diverse species that are attached to a surface (Dowd et al., 
2008). These microorganisms synthesize and secrete slimy or sticky substances that 
anchors the biofilm structure firmly to living (biotic) or non-living (abiotic) surfaces 
(Costerton et al., 1995; Stoodley et al., 2002). These biofilms are considered dynamic 
hydrated structures distributed widely throughout the natural, industrial and medical 
settings that can have dangerous and costly effects (Cooper and Okhiria, 2006).   
 Bacteria are considered the best example of microorganisms with respect to 
surface attachment and biofilm formation (Lindsay and von Holy, 2006). Traditionally, 
it was known that bacteria are growing in free-living or planktonic populations (Fux et 
al., 2003). However, in natural ecosystems bacteria tend to form communities of sessile 
cells embedded in a self-produced extracellular matrix (ECM) forming what is called a 
biofilm (Costerton et al., 1999). The most important characteristic of a biofilm structure 
is the production of ECM, which is a complex of proteins, nucleic acids and 
extracellular polymeric substances or exopolysaccharide (EPS) (Seminara et al., 2012). 
The different definitions of bacterial biofilms differ mainly in whether the cells have to 
be attached to a surface or whether the bacteria exist in a structured community 
(Bjarnsholt, 2011). The classical definition of bacterial biofilms is aggregations of 
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bacterial cells that are attached to biotic or abiotic surfaces and enclosed in a self-
produced matrix of extracellular polymeric substance (EPS) and other elements 
depending on the environment they are growing in (Donlan, 2002). In the medical field, 
a biofilm is defined as a layer of sessile cells embedded in an exopolysaccharide  matrix 
that is resistant to most antimicrobials and host defences (Bjarnsholt, 2011).  
 Because biofilm-associated bacteria differ phenotypically from their free-living 
counterparts (Donlan, 2002), the new definition must take into consideration other 
physiological characteristics like the altered growth rate and the expression of specific 
genes that planktonic bacteria do not (Donlan and Costerton, 2002), which leads us to a 
unified definition of bacterial biofilms as the predominant life form of all bacterial 
species in their natural habitat whether environmental or pathogenic (Wolcott and 
Ehrlich, 2008). At the most basic level a biofilm can be described as bacteria embedded 
in a thick, slimy barrier of sugars and proteins that protects the bacteria from external 
threats  (Phillips et al., 2010). Our simplified definition of a biofilm is a slimy layer of 
microbes attached to a surface.  
 
 
Figure 1.1 Scanning electron micrograph of a biofilm on metal surface. Adapted 
from (Donlan and Costerton, 2002).   
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1.2 Historical Background of Biofilms 
 Since the early days of microbiology up until the middle of the twentieth 
century, bacteria were viewed as being free-floating single cells referred to as the 
planktonic state (Atlas and Bartha, 1997). However, the study of bacterial biofilms goes 
back to the seventeenth century when Dutch microbiologist Antonie van Leewenhoek 
examined for the first time in 1684 the accumulation of microorganisms in a dental 
plaque on his own teeth calling it animalcules (Donlan and Costerton, 2002). He 
observed that the animalcules (bacteria) inside the previously mentioned plaque were 
protected against vinegar in contrast to the bacteria outside the plaque, which explains 
one of the major hallmarks of biofilms, i.e. tolerance against antimicrobial agents 
(Bjarnsholt, 2011). However it was only around the mid 1920's when Winogradsky, 
Cholodny and Conn made an important observation in biofilm research stating that 
bacteria growing on soil-submerged glass slides for a specific time interval are different 
from those they cultured from seawater (Lappin-Scott, 1999). 
 One of the pioneers of biofilms research is ecologist Claude ZoBell (Lappin-
Scott, 1999) who in 1933 described the concept of marine bacterial attachment to 
submerged slide surfaces (ZoBell and Allen, 1933) and designed an apparatus to study 
bacterial attachment to surfaces (ZoBell and Allen, 1934). Other findings by ZoBell 
included the presence of bacteria as sessile phase rather than free-living planktonic 
phase on the surface of a sterile glass with seawater inside (ZoBell, 1936). In 1933, 
Henrici presented for the first time photomicrographs of bacterial  aggregations 
describing the water bacteria as non-free floating organisms growing upon submerged 
surfaces (Henrici, 1933). Another contribution to biofilm research was achieved in 1940 
when Heukelekian and Heller reported that surface characteristics are important factors 
for bacterial adhesion (Heukelekian and Heller, 1940) which represent a crucial factor 
in the control of infectious caused bacterial biofilms (Cortés et al., 2011). The field of 
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environmental microbiology accepted the concept of bacterial aggregations almost 20 
years before medical field (Bjarnsholt, 2011). Due to the fact that bacterial aggregations 
have long been used in waste water treatment plants, and the first article using the term 
biofilm was by Rogovska et al. that was published in 1961 in Mikrobiologiya 
(Bjarnsholt, 2011).   
 In 1971, Marshall provided evidence via Scanning Electron Microscopy (SEM) 
that attached bacteria were associated with the surface by fine extracellular polymeric 
fibrils (Marshall et al., 1971). Moreover, in 1976, a correlation between the biological 
and physiological properties of bacteria to their behaviour in natural habitats was 
reported (Marshall, 1976). In 1977, electron microscopic observations showed that 
bacteria within a biofilm were embedded in a fibrous highly hydrated 
exopolysaccharide matrix whose chemical composition was species-specific 
(Sutherland, 1977). The medical field started to describe clumps of bacteria in 1977, 
then Høiby et al., described the aggregations of Pseudomonas aeruginosa in patients 
with chronically infected lungs (Hoiby, 1977). However, the concept of bacterial 
biofilm was not practically established until 1978 when Costerton presented for the first 
time the unified theory of bacterial biofilm formation which stated that in all aquatic 
systems with sufficient concentrations of nutrients, sessile populations of bacteria form 
glycocalyx-embedded structures called biofilms that are adherent to surfaces in medical, 
natural, and industrial ecosystems (Costerton et al., 1978).  
In the late 1980s, advances in the field of light microscopy by the invention and 
use of Confocal Laser Scanning Microscopy (CLSM) led scientists to realize that 
bacterial biofilms consist of microcolony communities (Costerton et al., 1999) and that 
attachment to a surface is a key element for colonization and biofilm formation 
(Whittaker et al., 1996). New aspects of biofilms were investigated in 1990 such as the 
characteristics of spatial and temporal heterogeneity and involvement of inorganic or 
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abiotic substances in the biofilm matrix. (Characklis and Marshall, 1990; Donlan and 
Costerton, 2002). In 1991, the use of CLSM revolutionized the study of biofilms 
(Costerton et al., 1994) by reporting that sessile bacteria grow in matrix-enclosed 
communities inter-connected with less-dense regions of permeable water channels 
(Caldwell et al., 1992; Lawrence et al., 1991). However, it was only in 1993 when the 
American Society for Microbiology (ASM) recognized the biofilm mode of growth as 
an important bacterial trait (Bjarnsholt, 2011).   
 In 1995, Costerton et al. stated that bacterial adhesion triggers the expression of 
certain genes that controls the production of specific components necessary for biofilm 
formation (Costerton et al., 1995) and that the process of biofilm formation is regulated 
by specific genes transcribed during the initial stage of cell attachment (Costerton and 
Lappin-Scott, 1995; Donlan and Costerton, 2002). In light of all these findings, our 
knowledge and understanding of biofilms has expanded which will help us explore new 
strategies for a better management of bacterial biofilms in various fields  
 
 
1.3  Formation of Biofilms 
 The formation of a three-dimensional biofilm structure involves a coordinated 
series of molecular events controlled by an inter-bacterial communication mechanism 
called Quorum Sensing (QS) (Davies et al., 1998). It is understood now that bacteria 
undergo many changes during their transition from planktonic to sessile organisms 
forming the community of a biofilm (O'Toole et al., 2000). However, the biofilm 
phenotype and the rate of microbial attachment to a surface or substratum depends on 
many factors including the type of organism and its cell surface structures such as 
fimbriae, EPS, and flagella (Donlan, 2002), the type of substratum (Costerton and 
Lappin-Scott, 1995), the rate of liquid flow over the surface (Brown and Smith, 2003) 
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and characteristics of the aqueous medium such as pH, nutrient levels (Cowan et al., 
1991), ionic strength (Fletcher, 1988) and temperature (Donlan et al., 1994). The 
development and formation of bacterial biofilms occurs in different stages depending on 
the condition of the attachment surface (Lindsay and von Holy, 2006), it can be 
categorized into five stages represented by reversible or initial attachment, irreversible 
attachment, maturation-1 or colonization, maturation-2 and detachment or dispersion 
(Sauer et al., 2002).  
 The first stage of biofilm formation is represented by the initial or reversible 
attachment of bacterial cells to a surface which occurs via different mechanisms 
including sedimentation (van Loosdrecht et al., 1990), active movement and electro-
kinetic or thermodynamic properties (Flemming et al., 1998) such as electrostatic 
charge (Fletcher, 1987), hydrophobicity (Allison et al., 1990) and surface free energy 
(Van der Mei et al., 1992). This type of non-specific attachment is considered the 
weakest point in connecting the cells to surface (Busscher et al., 1995) and it will lead 
eventually to a balance distribution between the adhering and non-adhering cells (van 
Loosdrecht et al., 1990).  
 The second stage is the irreversible attachment were bacterial cells are being 
stimulated via membrane-bound sensory proteins leading to the production of 
exopolysaccharide (Boyd and Chakrabarty, 1995) that triggers the formation of cell-to-
cell bridges that glue cells to the surface (Donlan, 2002; Hall-Stoodley et al., 2004). The 
third stage in the establishment of biofilm is colonization or maturation-1 (Zottola and 
Sasahara, 1994) were bacterial cell density increases and the population reaches a 
critical threshold leading them to communicate via secretion of low molecular weight 
signals (Davies et al., 1998), these signals eventually trigger the expression of virulence 
factors in a process called quorum sensing (Pearson et al., 1995; Schauder and Bassler, 
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2001). Bacteria start to grow and form microcolonies that are considered the building 
blocks of the biofilm structure (Costerton et al., 1994).  
 As the biofilm structure starts to grow, the fourth stage which is maturation-2 
begins when cell clusters reach their maximum thickness (Davies et al., 1998) 
exhibiting a complex architecture comprising of microcolonies embedded in a matrix of 
EPS and separated by permeable water channels that are used for the circulation of 
nutrients and transport of waste products (Costerton et al., 1994; Stoodley et al., 1994). 
The formed biofilm will eventually find its way to stabilize the interactions between the 
bacterial species through changes in their symbiotic relationships leading to alter the 
function of the whole biofilm population (Hansen et al., 2007). 
 The fifth and final stage is the detachment or dispersion of bacterial cells from 
the biofilm structure, this stage is considered highly important due to its role in 
spreading new colonizers into neighbouring sites (Stoodley et al., 2001) leading to 
contaminate and infect both industrial (Zottola and Sasahara, 1994) and clinical settings 
(Nickel et al., 1994). Based on the frequency and area of detachment (Bryers, 1988), 
bacterial cells detach from their biofilms via erosion which is a detachment of single 
cells and sloughing which is a loss of biofilm mass (Characklis, 1990). The detachment 
of cells from the biofilm structure is a complicated process (Purevdorj et al., 2002) 
because it must include a signal that triggers the release of certain enzymes that can 
degrade the components of biofilm’s matrix as well as the conversion of cells into the 
planktonic phenotype (Costerton, 2007). An example of detachment enzymes is the 
lyase enzyme in P. aeruginosa which is synthesized and stored in the periplasmic space 
(Boyd and Chakrabarty, 1994) and is released to digest the matrix (alginate) upon 
detachment (Costerton, 2007). A simplified description of the biofilm life cycle can be 
summarized into three major steps as shown in (Figure 1.2).   
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Figure 1.2 The three essential steps of biofilm formation. Adapted from (Stoodley 
and Dirckx, 2003).  
  
 
1.4  Biofilms in Nature and Industrial Settings  
 Microbial biofilms are considered vital components of the natural environment 
that can cause both beneficial and harmful effects (Centre for Biofilm Engineering, 
1990). Bacteria within biofilms have the ability to form on a wide range of surfaces 
including natural aquatic ecosystems, industrial water piping, living tissues and 
indwelling medical devices (Donlan, 2002). In natural environments, biofilms can 
negatively affect the environment via consuming atmospheric gases that can change the 
climate, mobilizing toxic elements and creating oxygen depletion zones in areas like 
lakes, rivers and coastal environments (Center for Biofilm Engineering, 1990). This is 
mainly due to the fact that biofilm bacteria are more adaptable to survive certain threats 
like bacteriophages and amoebas in comparison to their free-living counterparts 
(Costerton et al., 1999). In industrial settings, biofilms or biofouling shows resistance to 
chemical biocides making them hard to remove (Costerton et al., 1995).   
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 The challenges associated with the accumulation of bacteria on the surfaces of 
industrial processing equipment is represented by blockage in water circuits that leads 
to increased pressure loss, reduced heat transfer in heat exchangers (Whitehouse et al., 
1986), interference with the function of chemical additives and surface corrosion of 
equipment through depolarisation of oxygen that encourages the growth of anaerobic 
bacteria (Bott, 2011). Because bacterial biofilms cause serious problems in industrial 
water systems, developing methods to sample and monitor those biofilms could make a 
major contribution in reducing climate change, equipment damage and product 
contamination (Donlan and Costerton, 2002).  
The cost of unwanted biofilm accumulation on the surface of industrial 
equipment can represent a large proportion of the total operating cost (Bott, 2011). 
Many attempts have been made at the stage of equipment design to reduce such 
operating problems, for example the idea of making the equipment larger to overcome 
the fouling problem or the type of construction material used should be more expensive 
to reduce the microbial accumulation and potential corrosion problems. However, these 
attempts will eventually increase capital costs (Bott, 2011). The presence of biofilms 
will reduce the flow area and will create a rough surface to the fluid flow in equipment 
such as heat exchangers, therefore  the pumping energy requirement and the associated 
cost will become higher  in addition to the large carbon dioxide emission from 
combustion process that leads to significant climate changes that will add more 
problems to the global warming phenomenon (Bott, 2011). Even though the potential 
problems due to biofouling may have been recognised at the design stage, it may still be 
necessary to take effective approaches to prevent or restrict the development of biofilms 
on the surfaces of industrial equipment.  
On the other hand, there are many potential applications of microbial biofilms in 
industry such as bioremediation (Singh et al., 2006), production of fine chemicals (Li, et 
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al., 2006), fermentation (Kunduru and Pometto, 1996), biofiltration (Cohen, 2001), 
wastewater treatment (Nicolella et al., 2000), biofuel production (Wang and Chen, 
2009) and generation of electricity in microbial fuel cells (Rabaey et al., 2007). An 
example of the beneficial effects of bacterial biofilms is the reduction of acid water 
drainage by establishing a biofilm biobarrier to keep oxygen from reaching subsurface 
water (Costerton and Dirckx, 1996).   
 
 
1.5 Biofilms in Health and Medicine    
From a medical perspective, both commensal and pathogenic microorganisms 
form biofilm-like structures that are associated with epithelial or endothelial lining, 
attachment on teeth or medical implant surfaces, intestinal or vaginal mucus layer or 
even being embedded in the lung tissue (Bryers, 2008). Biofilm formation has a 
negative impact on health due to that fact that microorganisms growing within biofilms 
are significantly less susceptible to antibiotics and host defences than their planktonic 
counterparts (Bryers, 2008). Modern medicine is facing the spread of bacterial biofilm 
infections (Fux et al., 2005). Many biofilm infections are notoriously difficult to resolve 
and are associated with chronic or recurrent infections. It has been reported that biofilm 
infections affect almost all tissues and structures in the human body including the ear, 
nose, throat, mouth, eye, lung, heart, kidney, gall bladder, pancreas, nervous system, 
skin, bone, as well as any implanted medical devices (Wolcott and Ehrlich, 2008). 
These infections represent many clinical challenges, including diseases with 
uncultivable species, chronic inflammation and rapidly acquired antibiotic resistance 
(Bryers, 2008). In addition to the fact that bacteria in a biofilm mode of growth are 
difficult to be detected in routine diagnostic labs in addition of being resistant to host 
immune defences (Fux et al., 2005).   
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 The Centres for Disease Control and Prevention (CDC) estimates that about 
65% of all bacterial infections are associated with biofilms (Goodman et al., 2011; 
Lewis, 2007), other literature report higher prevalence that can reach up to 80% (Hall-
Stoodley et al., 2004; Parsek and Singh, 2003). Thus, the impact of biofilm infections 
on healthcare is significant and requires immediate attention (Wolcott and Ehrlich, 
2008). The attachment of bacteria on medical devices that are in contact with the human 
body provides a starting point for the onset of clinical infections (Renner and Weibel, 
2011). Biofilm formation on various medically–related surfaces like surgical implants, 
catheters, and contact lenses affect their function and provides the opportunity for 
pathogenic bacteria to enter the human body and thus cause biofilm-associated 
infections (Bryers, 2008) through the production and release of endotoxins that will 
eventually trigger an immune response in patients (Donlan and Costerton, 2002).  
 
 
1.6 Biofilm Infections  
 Advances in medical practice over the decades led to the proper management of 
acute bacterial infections (Costerton et al., 2003), however another type of infectious 
diseases, i.e. chronic infections, is being recognized as more persistent over longer 
periods and highly resistant to common therapeutics and the host defences (Costerton et 
al., 2003). It has been noticed that bacterial biofilms are the cause of various chronic 
infections including cystic fibrosis (CF), recurrent tonsillitis, chronic rhinosinusitis 
(CRS), chronic wound infections, chronic otitis media (OM), chronic urinary tract 
infections (UTI), periodontitis and device-associated infections (Hall-Stoodley and 
Stoodley, 2009). These infections are usually associated with pathogenic or 
opportunistic bacteria either as single species or as a polymicrobial community (Hall-
Stoodley and Stoodley, 2009).  
12 
 
 There are several common features for any chronic infection associated with 
biofilms, including a non-aggressive initial stage where an antibiotic therapy is usually 
prescribed (Wolcott and Ehrlich, 2008). These therapies typically treat the symptoms 
caused by planktonic cells detached from the biofilm yet it fails to kill the sessile cells 
within the biofilm itself (Marrie et al., 1982). The next stage will be a severe subsequent 
infection that is again treated with antibiotics (Wolcott and Ehrlich, 2008). However, 
the infection will eventually get worse especially when treatment is stopped or 
withdrawn which might lead to the decision of removing the infected tissue or organ by 
surgery (Wolcott and Ehrlich, 2008). Biofilm infections are difficult to be cleared by the 
host defences even in individuals with a strong immune response (Khoury et al., 1992). 
Therefore, the modern view to chronic infections requires multidisciplinary efforts to 
develop therapeutic agents that target sessile bacterial cells and their biofilm phenotype 
(Costerton et al., 1999). 
Common sites of primary biofilm infections are the mouth, catheter entries and 
implanted medical devices (Stoodley et al., 2003). Once bacteria enter the circulatory 
system, they can reach all parts of the body causing secondary biofilm infections in sites 
such as the brain, kidneys, intervertebral spaces and the bones around implanted 
medical devices (Stoodley et al., 2003). Examples of the possible entry points of 
biofilm bacteria are shown in (Figure 1.3).  
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Figure 1.3  Sites of primary and secondary biofilm infections. Adapted from 
(Stoodley et al., 2003).   
 
 
1.6.1 Oral Infections  
 Bacterial biofilms of the oral cavity present a unique opportunity to investigate 
the inter-bacterial interactions and the impact of those interactions on host pathology 
(Palmer Jr. et al., 2011). The oral cavity contains about 700 bacterial species, many of 
which form biofilms through sequential accumulations on tooth surfaces (Palmer Jr. et 
al., 2011). Many of these are microbes are harmless, however some are pathogenic and 
can cause various infections (Costerton and Lange, 1999). In the absence of an adequate 
oral hygiene, ecological shifts occur within the microbial community which initiate two 
oral infections: caries and periodontal diseases (Palmer Jr. et al., 2011). Dental caries or 
tooth decay result from a controlled metabolic process in the biofilm plaque that disturb 
the mineral balance at the biofilm-tooth interface leading to many clinical 
manifestations from white spot lesions to overt cavities and tooth destruction (Baelum 
14 
 
et al., 2008). Periodontal diseases are complex polymicrobial biofilm infections that 
involve interactions between oral bacteria and the host leading to accumulation of 
plaque at the gingival margin that eventually cause gingivitis (Palmer Jr. et al., 2011). It 
has become clear that oral biofilm infections are considered the origin of many 
pathogenic organisms to disseminate into distant body sites causing various systemic 
diseases (Li et al., 2000). An example of oral biofilm infections is illustrated in (Figure 
1.4). 
 
 
Figure 1.4 Oral biofilm infection forming a dental plaque Adapted from (Costerton 
and Lange, 1999).  
 
 
1.6.2 Device-Associated Infections  
 Medical devices have gained a lot of importance in the past decades due to the 
higher demands of elderly patients suffering from degenerative diseases, the 
technological advances that can replace many functions of the body by such devices and 
the broad availability of health insurance in some countries (Darouiche, 2004; Zimmerli 
and Trampuz, 2011). However, implantation of medical devices is considered an 
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important source of nosocomial infections especially during the perioperative period 
(Roumbelaki et al., 2008) due to the fact that bacteria can attach to non-living surfaces, 
including those of indwelling devices, and form biofilms that are highly resistant to 
antimicrobial treatment (Donlan, 2001). The pathogenesis of implant-associated 
infection involves interactions between the microorganism with the device that result in 
the formation of a biofilm and interactions of host defences with the implant that result 
in immunological response (Darouiche, 2001).  
Biofilms on indwelling medical devices are composed of different bacterial 
species that may originate from the skin of patients or healthcare workers when entry 
ports are exposed (Donlan, 2001). One of the most common otolaryngological device-
associated infections is ventilator-associated pneumonia which is correlated associated 
with injures on the tracheal epithelial surface during tracheal intubation (Pneumatikos et 
al., 2009). These injures provide a rapid and direct access of bacteria from the upper 
into the lower respiratory tract allowing the biofilm formation on the surface of 
endotracheal tube (ETT) (Pneumatikos et al., 2009). For a better understanding of 
biofilms on indwelling medical devices, development of reliable sampling and 
measurement techniques is crucial to investigate the role of biofilms in the pathogenesis 
of such infections (Donlan, 2001).  
 
 
1.6.3 Wound Infections   
 Chronic wound infections represent a burden to healthcare systems causing 
significant morbidity and mortality to mankind (Kirketerp-Møller et al., 2011). Biofilms 
in healed surgical wounds were first observed in 1985 when sutures were examined by 
scanning electron microscopy showing cocci bacteria encased in extracellular material 
and attached to the intradermal surface of the closures (Gristina et al., 1985). Increasing 
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evidence has focused on the potential role of bacterial biofilms in the pathology of 
chronic wounds suggesting that biofilms are one of the aetiological factors in wound 
chronicity (Kirketerp-Møller et al., 2011). This may explain why chronic wounds are 
difficult to heal despite adequate treatment and opens new paths for the search for more 
effective therapeutic approaches (Bjarnsholt et al., 2008). Bacterial biofilms in the 
wound interfere with the host immune system leading to facilitate a chronic 
inflammation of the wound that will eventually prevent the healing process (Kirketerp-
Møller et al., 2011).  
Treatment of biofilm wound infections has only temporary effect on both 
inflammation and healing due to the fact that bacteria in biofilm are up to 1000 times 
less susceptible to antibiotics and that the minimal inhibitory concentration (MIC) is not 
reached in the chronic wound fluid (Bjarnsholt et al., 2007). Evidence obtained by 
molecular analyses of chronic wound specimens from patients with diabetic foot ulcers, 
pressure ulcers, and venous leg ulcers suggested diverse polymicrobial biofilms (James 
et al., 2008). The prevalence of bacterial biofilms in specimens from chronic wounds 
relative to acute wounds provides an insight that biofilms may be more abundant in 
chronic wounds (James et al., 2008). Therefore, understanding bacterial biofilms will 
provide more insights to discover and design new treatments for chronic wound patients 
(Kirketerp-Møller et al., 2011).  
  
1.6.4 Upper Respiratory Tract Infections 
 The upper respiratory tract (URI) including the ear, nose and throat (ENT) 
represent a natural habitat for a broad range of microorganisms such as commensal 
bacteria as well as potential pathogens (Garcia-Rodriguez and Fresnadillo Martinez, 
2002). However, these bacteria can sometimes find ways to overcome the defence 
barriers of such locations and establish chronic infections that poses a challenge to both 
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medical practice and healthcare system (Morris, 2007). Infections in the URI such as 
acute otitis media, acute rhinosinusitis and acute pahryngotonsillitis are diseases that 
occur with extremely high frequency (Yamanaka, 2011). It has become clear that ENT 
chronic infections are becoming more resistant to common antimicrobial therapies 
(Vlastarakos et al., 2007) due to the fact that bacteria may persist on mucosal surfaces 
through the formation of biofilms (Kania et al., 2007).  
 Although most infections in otorhinolaryngology are of viral origins and are 
considered self-limited, bacterial infections are responsible for a significant degree of 
morbidity and have the potential to become life-threatening (Morris, 2007). The 
presence of biofilms in URT has been demonstrated in chronic otitis media, 
cholesteatoma, and chronic adenoiditis among other important diseases (Post et al. 
2007). These biofilms play important roles resulting in their difficult eradication by 
means of resistance to immune clearance (Costerton et al., 1987) and spreading new 
invaders to the surrounding tissues causing infections to recur and become chronic 
(Vlastarakos et al., 2007). Moreover, the chronic nature of some ENT infections like 
chronic tonsillitis (CT), chronic rhinosinusitis (CRS), chronic otitis media (COM) and 
otitis media with effusion (OME) makes their diagnosis and management even more 
difficult (Vlastarakos et al., 2007). The role of bacterial biofilm infections in the upper 
respiratory tract has been the subject of various papers due to their persistence, 
difficulties in culturing samples and resistance to therapeutic management (Morris, 
2007). Such infections when occur in localized areas like the throat may either affect the 
mucosa of whole nasopharynx and oropharynx causing pharyngitis or may localize to 
the lymphoid tissue causing tonsillitis (Ludman, 1981). 
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1.6.4.1 Chronic and Recurrent Tonsillitis 
 The palatine tonsils (PT) are dense compact bodies of lymphoid tissue that are 
located in the lateral wall of the oropharynx (Kenna and Amin, 2009). It belongs to 
nasal-associated lymphoid tissue (NALT) that is part of a lymphatic tissue arrangement 
called Waldeyer's ring (WR) (Hellings et al., 2000). Palatine tonsils are positioned at 
the openings of both digestive and respiratory tracts making them the first line of 
defence against inhaled and ingested microorganisms as shown in (Figure 1.5) (Perry 
and Whyte, 1998). The condition of tonsillitis, i.e. inflammation of the palatine tonsils, 
is considered one of the most common infectious diseases in children despite the 
widespread use of antibiotics (Chole and Faddis, 2003). It occurs when the activity of 
pathogens surpasses the activity of tonsillar lymphoid cells (Scadding, 1990).  
 
 
Figure 1.5 The lymphatic tonsillar tissue of Waldeyer’s ring including the 
nasopharyngeal tonsil (Adenoid), tubal tonsils, palatine tonsils and 
lingual tonsil. Adapted from (Perry and Whyte, 1998).    
 
Traditionally, Group A Beta-Haemolytic Streptococci (GABHS) has been 
considered the only important bacteria in the development of acute tonsillitis (Klein, 
1975). However, there is increasing evidence that other bacteria can cause acute, 
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recurrent and even chronic tonsillitis such as Streptococcus pneumoniae, 
Staphylococcus aureus and Haemophilus influenzae (Brodsky et al., 1988; Brook, 
1987). Although these bacteria are classified as colonizers of the tonsils, they are now 
believed to become pathogenic in the presence of a recurrent bacterial infection 
(Brodsky, 1989). A clinical case of recurrent tonsillitis is shown in (Figure 1.6).  
 Chronic tonsillitis represents the most frequent lesion of the pharynx 
inflammatory pathology with multiple complications both locally and on distant sites 
(Gaffney and Cafferkey, 1998; Mattila et al., 2001; Mogoanta et al., 2008). It can be 
also the location of some specific infections such as tuberculosis and syphilitic lesions 
(Bourbeau, 2003). Chronic inflammation of the tonsils is usually caused by frequent 
attacks of acute tonsillar infections that fail to respond to therapy leading to cause 
scarring in the crypts of tonsils (Ludman, 1981). The fact that tonsillar infections may 
recur even when they are caused by organisms shown to be susceptible in vitro (Brook, 
2001) led to the hypothesis that biofilm-forming bacteria within the crypts of 
chronically infected tonsils can resist both antibiotics and host defences (Chole and 
Faddis, 2003) and they may play a key role in the morbidity associated with tonsillar 
and/or adenotonsillar diseases (Al-Mazrou and Al-Khattaf, 2008).  
Previous reports demonstrated that hypertrophied or enlarged tonsils are not 
necessarily an indication for tonsillectomy, i.e. surgical removal of tonsils, (Mattila and 
Tarkkanen, 1998) due to the fact that tonsils usually get enlarged during childhood and 
will eventually return back to their normal size in adolescence (Bergler et al., 1999). 
Despite the high prevalence of chronic and recurrent tonsillitis among both paediatric 
and adults patients, a general agreement is still lacking in identifying the main causative 
organisms (Cowan and Hibbert, 1997) in addition to the insufficient data addressing the 
presence of biofilms on the surfaces of tonsils (Al-Mazrou and Al-Khattaf, 2008).  
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Figure 1.6 Clinical examination of a patient with recurrent tonsillitis. Curtsey of Dr. 
Rahmat Omar, University Malaya Medical Centre. T = enlarged palatine 
tonsil. 
 
 
1.6.4.2 Chronic Adenotonsillits 
 The nasopharyngeal tonsil (adenoid) is a median mass lymphoid tissue that is 
located in the roof and posterior wall of the nasopharynx (Susan et al., 2005). Both PT 
and adenoid are part of Waldeyer’s ring providing defences through the production of 
immunoglobulins and the development of both B and T cells (Kenna and Amin, 2009). 
Adenotonsillar diseases, i.e. adenoiditis and recurrent tonsillitis, are common 
otolaryngological disorders caused by persistent bacterial infections (Zautner, 2012). 
Chronic adenotonsillar infection and/or hypertrophy are thought to be caused by 
resistant bacteria such as Staphylococcus aureus, Haemophilus sp. and Streptococcus 
sp. that persist within biofilm communities (Don et al., 2005). The recurrent or chronic 
inflammation of the adenoids and tonsils leads to a chronic activation of both cellular 
and humoral immune response, resulting in enlargement or hypertrophy of the lymphoid 
tissue (Zautner, 2012). This hypertrophic tissue is the cause for various clinical 
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symptoms including obstruction of the upper airways, snoring and sleep apnea for 
adenoiditis or sore throat, dysphagia and halitosis for recurrent tonsillitis (Zautner, 
2012). Tonsillar and adenotonsillar hypertrophy that cause obstructive sleep apnea 
(OSA) and/or chronic adenotonsillitis are still the commonest indications for 
adenotonsillectomy (T&A) (Al-Mazrou and Al-Khattaf, 2008). However, treatment 
strategies should target not only the removal of a mechanical obstacle of the airways but 
the elimination of a possible aetiological cause of a persisting biofilm infection 
(Zautner, 2012).  
 
1.6.4.3 Chronic Otitis Media 
 The role of biofilms in the persistence of chronic, mucosal-based ENT infections 
was first recognized in otitis media (Post et al., 2007). Chronic otitis media (OM) is one 
of the most common paediatric infections in which children receive antibiotics or 
undergo surgery (Hall-Stoodley et al., 2006). Chronic OM includes both otitis media 
with effusion (OME) and recurrent otitis media (Hall-Stoodley et al., 2006). Otitis 
media with effusion can result in conductive hearing loss, which has been linked to the 
delayed development of speech and socialization skills (Bennett et al., 2001).  
Chronic suppurative otitis media (CSOM) is one of the most common infections 
of childhood and is associated with significant morbidity (Roland, 2002; Verhoeff et al., 
2006). CSOM is usually caused by the presence of bacteria in the middle ear and 
mastoid cavity, which lead to the onset of a biofilm-associated chronic infection 
(Roland, 2002). These bacteria are introduced into the middle ear either from the 
external auditory canal through the perforation or from the nasopharynx though 
Eustachian tube (Dohar et al., 2005). Microbiological studies of OME using highly 
sensitive techniques such as polymerase chain reaction (PCR) have demonstrated that 
traditional culturing methods are insufficient to detect the bacteria in OME (Post, 2001). 
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There is evidence that OME is associated with resistance to antibiotics which led to the 
hypothesis that biofilm-associated bacteria are involved in such infections (Ehrlich et 
al., 2002). Moreover, the presence of biofilm bacteria on the surface of middle-ear 
mucosa rather than free-floating ones may explain the recalcitrant nature of  OME (Post, 
2001).   
 
1.6.4.4 Chronic Rhinosinusitis  
Chronic Rhinosinusitis (CRS) is one of the most common medical conditions 
affecting up to 16% of the population with an estimated cost of over $6 billion annually 
in the United States (Suh et al., 2010). Patients with CRS demonstrate worse quality of 
life (QOL) scores than those suffering from other diseases like chronic obstructive 
pulmonary disease, congestive heart failure, back pain, or angina (Suh et al., 2010). 
Despite the large socioeconomical impact of CRS, its pathophysiology remains largely 
unknown. One proposed aetiological factor of the chronic nature of this disease is the 
involvement of bacterial biofilms (Kilty and Desrosiers, 2008). The genetic shift in the 
biofilm bacteria as well as the multiple expressed phenotypes creates a complex 
community of pathogens, some of which will survive therapeutic treatments (Hunsaker 
and Leid, 2008). The challenges associated with the management of CRS patients may 
focus more on the biofilm present in the sinuses. However, it is important to mention 
that sinus cultures cannot be expected to provide a complete picture of the aetiology of 
chronic sinusitis. Therefore new diagnostic method and innovative treatment plans will 
be necessary to provide a lasting treatment of CRS (Hunsaker and Leid, 2008).  
 
1.6.5 Lower Respiratory Tract Infections 
Lower Respiratory Tract Infections (LRTI) are one of the leading causes of the 
morbidity and mortality in the world (Murray and Lopez, 1997). They are not a single 
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disease but a group of specific infections each with a different epidemiology, 
pathogenesis, clinical presentation and outcome (Mishra et al., 2012). It has been 
suggested that there is a correlation between biofilm formation and signs and symptoms 
of lower respiratory tract infections (Chen et al., 2007). Evidence explored the 
relationship between endotracheal tubes biofilms and lower respiratory tract infection 
via microscopic observation of biofilms on the surface of endotracheal tubes (ETTs) 
removed from neonates treated with intubated mechanical ventilation (Chen et al., 
2007). Examples of LRTIs that are biofilm-related; ventilator-associated pneumonia 
(VAP) and cystic fibrosis.  
 
1.6.5.1 Cystic Fibrosis 
Cystic Fibrosis (CF) represent the most common life-threatening autosomal 
recessive genetic disease among Caucasian children (Brussow, 2012). The life 
expectancy of most CF patients is determined by the development of a lung disease due 
to the failure in clearing thick mucus secretions from the lung that leads to chronic 
coughing followed by a frequent pneumonia infection (Brussow, 2012). The 
opportunistic pathogen Pseudomonas aeruginosa is significantly associated with the 
environment of CF-affected lungs where it can produce exopolysaccharide glycocalyx 
called alginate that makes the bacterium firmly adhere to lung epithelium that leads to 
the formation of a biofilm (Potera, 1999; Yan et al., 2008).  
Alginate is believed to increase resistance to both the host immune system and 
antibiotic therapy (May et al., 1991). Evidence indicates that P. aeruginosa is more 
resistant to antibiotics when they are in the biofilm mode of growth, as they appear to be 
in the lungs of CF patients (May et al., 1991; Wu et al., 2004). It has been reported that 
80%-90% of CF patients have biofilm of Pseudomonas aeruginosa in their lungs (Yan 
et al., 2008). Microscopic investigations addressing the location of P. aeruginosa in CF 
24 
 
lungs revealed that destruction of CF lungs is correlated with the presence of mucus 
(alginate) produced by P. aeruginosa growing in biofilm layers on the respiratory zone, 
whereas non-mucoid bacteria are rarely observed (Figure 1.7) (Bjarnsholt et al., 2009). 
This strongly suggests that the conductive respiratory zone serves as a reservoir for 
bacteria to grow as biofilms that is protected against antibiotics and host defences 
(Bjarnsholt et al., 2009).  
 
 
Figure 1.7  Development of a biofilm infection in the lung of Cystic Fibrosis. A, 
Surface of the alveolar epithelium is guarded by macrophages. B, 
Alveolar phagocytes are unable to engulf biofilm bacteria. C, Biofilm 
fragments grow in the colonized lung and release planktonic cells. D, The 
mature biofilm becomes calcified to form a long-term pulmonary nidus. 
Adapted from (Costerton et al., 2003).   
 
 
1.7  Biofilms and Antibiotic Resistance   
 One of the most important features of bacterial biofilms is their resistance to 
antimicrobial agents and the host immune system (Ciofu and Tolker-Nielsen, 2011). 
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Although antibiotics may decrease the number of bacteria in biofilms, they will not 
completely eliminate them which may have important clinical consequences such as 
persistence of infections that are biofilm-related (Ciofu and Tolker-Nielsen, 2011). It 
has been reported that biofilm bacteria are 1000 times more resistant to antibiotics than 
their free-living counterparts indicating that some of the mechanisms that mediates 
resistance varies between sessile and planktonic bacteria (Nickel et al., 1985) which 
may lead to discrepancies between in vitro results and in vivo response (El-Azizi et al., 
2005). Therefore, shifting the mode of antibiotic regimens to include sessile bacteria 
rather than planktonic will improve the methods of treatment especially against biofilm-
associated infections (Wolcott and Ehrlich, 2008). The resistance of biofilms to 
antibiotic treatment is often referred to as antibiotic tolerance, which is a physiological 
condition that allows the bacteria to survive in the presence of antibiotic concentrations 
above their planktonic minimal inhibitory concentration. (Ciofu and Tolker-Nielsen, 
2011). The mechanisms that explain the antibiotic tolerance of biofilms can be 
categorised in the five groups. 
  
 
1.7.1 Restricted Penetration of Antimicrobials 
 The bacteria within the biofilm structure are embedded in a matrix that includes 
exopolysaccharide (EPS), extracellular DNA and protein (Ciofu and Tolker-Nielsen, 
2011). Effective antibiotics must cross the physical barrier of biofilm’s matrix in order 
to reach the encased sessile bacteria and therefore eliminate the biofilm infection (Ciofu 
and Tolker-Nielsen, 2011). The increased synthesis of exopolysaccharide that will slow 
down and retard the penetration of antimicrobials is considered a successful mechanism 
for biofilms to develop tolerance (Cheema et al., 1986). However, evidence suggests 
that restricted penetration of antibiotics through biofilms may occur in cases where the 
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antibiotic binds to components of the biofilm matrix itself (Ciofu and Tolker-Nielsen, 
2011). Evidence suggested that oxygen limitation and low metabolic activity appear to 
be more important factors for the tolerance of biofilms (Walters et al., 2003). However, 
delayed penetration might play a role in the tolerance to certain antibiotics such as 
aminoglycosides especially in Cystic Fibrosis (CF) lungs where antibiotic 
concentrations are too low to penetrate the EPS matrix (Ciofu and Tolker-Nielsen, 
2011).   
 
1.7.2 Differential Physiological Activity 
 The existence of bacterial populations with different physiological activities in 
biofilms appears to be a mechanism against environmental threats (Bjarnsholt et al., 
2009). Evidence suggests that differential physiological activity within the biofilm is 
caused by bacterial consumption of oxygen and nutrients leading to slow growth of 
sessile bacteria due to limitation in nutrients making them less susceptible to 
antimicrobial agents (Brown et al., 1988). Previous studies showed that it is possible to 
kill majority of the cells in a biofilm by combined antimicrobials that can target 
different physiological subpopulations within a biofilm such as the combination of 
colistin and tetracycline against biofilms of P. aeruginosa PAO1 in flow-chambers 
(Pamp et al., 2008). Another example is the combination of colistin and ciprofloxacin 
used against P. aeruginosa in CF patients (Hansen et al., 2008).  
 
1.7.3 Formation of Persister Cells  
 Another type of bacteria that participates in antibiotic tolerance of biofilms are 
the so-called persister cells (Brooun et al., 2000; De Groote et al., 2009). Persister cells  
are spore-like cells that may survive an antimicrobial challenge (Stewart and Dirckx, 
2001a), they represent slowly or non-dividing bacteria that are less susceptible to 
27 
 
antibiotics than the bulk of the population. They are generally believed to be the result 
of a small subpopulation of bacteria that differentiates into a dormant state (Spoering 
and Lewis, 2001). These cells are thought to escape the activity of antibiotics that target 
fundamental cellular processes such as DNA replication, translation, and cell wall 
synthesis due to their reduced metabolism (Bjarnsholt, 2011; Spoering and Lewis, 
2001). The pathways leading to the formation of persister cells are still unknown, 
however evidence suggested that bacterial toxin/antitoxin systems may play a role in 
Escherichia coli (Lewis, 2000). Moreover, it has been reported that fluctuations in the 
expression of toxin and antitoxin genes can lead to unbalanced toxin/antitoxin systems 
that allows the formation of persister subpopulations thus making it escape killing by 
antibiotics (Vazquez-Laslop et al., 2006).  
 
1.7.4 Specific Tolerance Factors    
In addition to tolerance caused by the mechanisms described above, certain gene 
products that are produced specifically within biofilms may exhibit unique functions 
that can increase the antibiotic tolerance of the biofilm community (Ciofu and Tolker-
Nielsen, 2011). An example of a biofilm-specific tolerance factor that occurs only in 
biofilms is quorum-sensing (QS) which has been reported to be involved in tolerance of 
P. aeruginosa biofilms to the antibiotics tobramycin and kanamycin in addition to 
hydrogen peroxide (Bjarnsholt et al., 2005; Hassett et al., 1999). Another example is the 
ndvB gene of P. aeruginosa PA14 which encodes an enzyme involved in the synthesis 
of periplasmic glucans that binds to the antibiotic tobramycin leading to prevent 
bacterial cell death and thus enhance tolerance (Mah et al., 2003). A novel efflux pump 
of P. aeruginosa PA14 that is expressed only during the biofilm mode of growth and 
mediates resistance to tobramycin, gentamicin, and ciprofloxacin has been reported also 
as biofilm-specific tolerance factor (Zhang and Mah, 2008).   
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Because the presence of antibiotics is considered a harsh environment even for 
bacteria within biofilms, therefore other conventional resistance mechanisms that are 
not biofilm-specific will be also activated (Ciofu and Tolker-Nielsen, 2011). An 
example of non-biofilm specific tolerance factor are antibiotic degrading enzymes such 
beta lactamases which play a crucial role in the development of resistance of bacteria to 
beta-lactams (Bagge et al., 2000). It has been reported that the presence of beta-
lactamases in the biofilm matrix will lead to the hydrolysis of beta-lactam antibiotics 
before they reach the bacterial cells (Nichols et al., 1989). The source of beta-lactamase 
in biofilms is thought to be from a sacrificial layer of bacteria that release these 
enzymes into the extracellular space when exposed to antibiotics (Ciofu and Tolker-
Nielsen, 2011).  
Another possible source of beta-lactamase in biofilms may be membrane 
vesicles containing beta-lactamase released by resistant bacteria (Ciofu et al., 2000). 
Another example of non-biofilm-specific tolerance factors are the conventional efflux 
pump systems that can be up-regulated in response to certain triggers such as the up-
regulation of efflux pumps during biofilm formation by E. coli isolates from urinary 
tract infection that helps in the removal of toxic substances and antibiotics (Kvist et al., 
2008). Has been suggested that potential use of efflux-pumps inhibitors and beta-
lactamase inhibitors might improve the efficacy of antibiotic treatment against biofilm 
infections (Ciofu and Tolker-Nielsen, 2011). Other mechanisms that mediate biofilm 
tolerance include increased resistance to UV light (Bose and Ghosh, 2011), altered 
metabolism activity (Bose and Ghosh, 2011) and genetic exchange due to accumulation 
of genetic elements that facilitates horizontal gene transfer (Li et al., 2002). Some of 
these mechanisms are illustrated in (Figure 1.8). 
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Figure 1.8  Mechanisms of biofilm tolerance to antibiotics. Adapted from (Stewart 
and Dirckx, 2001b).  
 
 
1.8  Biofilms and Host Immune Responses  
 Since the early days of immunology, many studies have investigated the various 
mechanisms of immune responses to different microorganisms (Jensen et al., 2010). 
However, the majority of these studies focused on studying the planktonic state of these 
infectious agents, therefore less is known about the immune responses to the presence 
of biofilm-associated infections. Nevertheless, more recent in vivo and in vitro studies 
have revealed both innate as well as adaptive immune responses to biofilms (Jensen et 
al., 2010). The host immune system plays a key role in the clearance of bacterial 
infections (Fux et al., 2003). However, persistent bacteria represent an important factor 
in the development of chronic infections (Høiby et al., 1995). This persistence is mainly 
due to the formation of biofilm communities that possess an arsenal of resistance 
mechanisms to overcome the immune response particularly in immune compromised 
patients (Fux et al., 2003).  
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 The innate immune system is the first line of the defensive mechanisms in 
protecting the host from invading microbial pathogens (Akira et al., 2001). It is 
designed to recognize a broad spectrum of foreign antigens present on numerous 
microorganisms (Moser and Jensen, 2011). The ability to detect invading 
microorganisms is accomplished by pattern recognition receptors (PRRs) that recognize 
conserved pathogen-associated molecular patterns (PAMPs) and signal their presence 
which will result in activation of host response (Jensen and Moser, 2011). Even though 
several classes of PRRs and their ligands are known, PRRs specific for biofilm-growing 
microorganisms have not yet been identified (Jensen and Moser, 2011). One of the 
examples of PRPs that have been intensively studied for its interaction with biofilms are 
the complement receptors. However the role of compliment receptors during biofilm 
infections is still not yet well established due to difficulties in establishing the presence 
of biofilms in clinical samples and the ability of biofilm bacteria to establish an 
infection in spite the activation of complement systems, therefore no cases of biofilm 
infections have been reported for patients with complement deficiency so far (Jensen 
and Moser, 2011). Another example of PRPs that is active against biofilm infections are 
the Toll-Like Receptors (TLRs) that are integral membrane glycoproteins with 
cytoplasmic domains transmitting intracellular signalling (Akira et al., 2001). Evidence 
for the involvement of TLRs in biofilm infections has mainly come from chronically 
infected CF patients and from dental plaques (Jensen and Moser, 2011). Because the 
pathogen recognition capacity of neutrophils mostly rely on TLRs (Parker et al., 2005), 
investigations of TLRs on the neutrophils of chronically infected CF patients have 
recently been highlighted (Jensen and Moser, 2011).  
 The adaptive immune response is characterized by a higher degree of specificity 
and memory in comparison with the innate response (Moser and Jensen, 2011). It 
recognizes species or even strain specific antigens, this memory is characterized by a 
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clonal expansion of specialized lymphocytes during the first exposure resulting in a 
significantly faster and stronger affinity response (Moser and Jensen, 2011). Activation 
of the adaptive immune response during a biofilm infection follows the same 
mechanisms as during an infection with the same microorganism during a non-biofilm 
forming infection. However, the effector mechanisms of the immune system against 
biofilm infections are insufficient in eliminating the pathogen. Therefore, the difference 
between the adaptive immune response to a biofilm and a non-biofilm infection lies in 
the impaired clearance of the microorganism that may contribute to the pathology of the 
infection itself (Hoiby et al., 2001; Schaudinn et al., 2009).  
 In biofilm infections, the persistent bacteria can resist the antibodies, phagocytes 
as well as other components of the host response and the surrounding tissue will be 
subject to oxidative radicals and enzymes released from the host itself (Moser and 
Jensen, 2011). In addition to various pathogen-specific virulence factors the release of 
proteases and other exoenzymes from the host cells can result in degradation of 
important surface molecules on the immune cells and thereby contribute to the impaired 
anti-biofilm effect of the host (Horvat and Parmely, 1988; McCormick et al., 1997). An 
important feature of biofilm infections is the release of specific antigens by sessile cells 
(Cochrane et al., 1988) that will stimulate the production of antibodies and cytokines by 
the host (Leid et al., 2002). However, the difficulty of these antibodies to penetrate the 
biofilm’s EPS can cause deposition of immune complexes and oxidative burst of 
macrophages that will damage the local host environment more than the biofilm itself 
(Høiby, et al., 1995).   
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1.9  Examination of Biofilms 
 Biofilm formation is one of the known virulence factors of many pathogens and 
it is considered as a marker of virulence that can be detected phenotypically (Jain and 
Agarwal, 2009). Early detection and management of potentially pathogenic bacteria and 
their ability to form biofilms is essential to prevent biofilm-associated infections (Jain 
and Agarwal, 2009). There are a variety of in vitro and in vivo systems available to 
examine bacterial biofilms (Merritt et al., 2011). Biofilm model systems are essential to 
gain a better understanding of the mechanisms involved in biofilm formation and 
resistance to both therapeutics as well as immune defences (Coenye and Nelis, 2010).  
 
1.9.1 In vitro Biofilm Model Systems  
 Two main approaches are employed to study biofilm formation in vitro, static 
systems and chemostat or continuous-flow systems (Merritt et al., 2011). Among the 
most frequently used systems is the Microtiter plate (MTP) assay were biofilms are 
grown on the bottom of a microtiter plate well and detected quantitatively (Christensen 
et al., 1985; Shakeri et al., 2007). This method was originally developed to study the 
attachment of coagulase-negative Staphylococcus aureus to plastic tissue culture plates 
(Christensen et al., 1985), but has been since used to study many other bacterial species 
(Peterson et al., 2011). Advantages of MTP assay include higher throughput, low cost, 
simplicity allowing less labour and no specialised equipment in addition to offer the 
opportunity to process large numbers of compounds and samples making it ideal for 
screening purposes (Niu and Gilbert, 2004) like screening for antimicrobial and anti-
biofilm effects (Shakeri et al., 2007) of various active compounds including antibiotics 
(Amorena et al., 1999), disinfectants (Pitts et al., 2003), chemicals such as quorum 
sensing inhibitors (QSI) (Brackman et al., 2009) and medicinal plant extracts (Quave et 
al., 2008). Another method for the detection of biofilm-forming pathogens is Congo 
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Red Agar (CRA) were the formation of biofilms is examined qualitatively (Jain and 
Agarwal, 2009). Other in vitro systems include flow displacement biofilm model, cell-
culture-based model and microfluidic devices (Jain and Agarwal, 2009).  
 
1.9.2 In vivo Biofilm Model Systems 
 There are different in vivo biofilm models that uses a variety of animals to 
mimic variety of diseases (Rumbaugh and Carty, 2011). The main advantage of using 
animal models in studying medical biofilms is to include the host defences and complex 
bodily fluids that are difficult to replicate in vitro (Rumbaugh and Carty, 2011). This is 
particularly important when studying the toxicity, bioavailability, clearance and 
absorbance effects of therapeutics on microorganisms in a biofilm (Rumbaugh and 
Carty, 2011). The most common approach that can reflect a typical human cause of 
infection were biofilms can be evaluated at different points, is to infect a vertebrate 
animal with an organism of choice (Rumbaugh and Carty, 2011). One major advantage 
of this approach is that it can use strains of organisms that lack virulence factors and 
determine the contribution of various genes in the biofilm formation (Nallapareddy et 
al., 2006; Swords et al., 2004). Another approach, which can be more reflective of the 
natural infection process of biofilms in vivo, is to allow the animal’s normal microflora 
to initiate the infection (Leknes et al., 2005). However, it has a limitation that there are 
major differences in the composition of the microflora between some animals and 
humans (Marsh, 1995). Therefore, great consideration must be given when choosing the 
bacterial and animal species and experimental models to use (Rumbaugh and Carty, 
2011). Examples of in vivo biofilm models are periodontal models, foreign-body models 
and soft-tissue models (Rumbaugh and Carty, 2011). The advantages of using in vivo 
models of biofilm-associated soft-tissue infections are the wide range of indications that 
can be performed on a variety of animal species. However, detection of biofilms on host 
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tissue is challenging and the need for certain surgical skills can pose an obstacle in 
performing the experiment (Rumbaugh and Carty, 2011). Clinical indications for these 
models include endocarditis, otitis media, keratitis, sinusitis, wound infections and 
chronic lung infections (Rumbaugh and Carty, 2011).  
 
1.9.3 Microscopic Methods for Imaging Biofilms 
 Microscopy allows the visualization of bacterial biofilms either on an artificial 
surface (Yanagihara et al., 2000) or on the host tissue itself (Schaber et al., 2007). Much 
of the early investigations to examine biofilms relied heavily on the use of light and 
electron microscopy (SEM) (Donlan and Costerton, 2002). Light Microscopy (LM) is 
the essential tool for biofilm observation either directly or through a histologic section 
(An and Friedman, 1997). The use of LM coupled with different stains such as 
Haematoxylin & Eosin (H&E) is one of the simplest most common methods to view the 
bacteria involved in an infection (Rumbaugh and Carty, 2011). However, a 
disadvantage to examine biofilms via LM is the difficulty in distinguishing bacterial 
cells from host tissue when using H&E due to its property in staining all nucleic acids 
(Rumbaugh and Carty, 2011). For higher magnification and better visualization of 
biofilm cells, researchers have used both Scanning Electron Microscopy (SEM) and 
Transmission Electron Microscopy (TEM) (Rumbaugh and Carty, 2011). The most 
frequent system is SEM were it can capture highly detailed images of the biofilm 
(Rumbaugh and Carty, 2011). However, a disadvantage is encountered when samples 
are fixed in a series of dehydration steps leading to reduce the total volume of biofilm’s 
matrix and alter its architecture (Akiyama et al., 2003).  
 For a fundamental understanding and proper examination of bacterial biofilms, 
detection must include both the bacteria and its glycocalyx matrix (Kania et al., 2007). 
The most effective and non-destructive approach for studying biofilms in tissue samples 
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is via Confocal Laser Scanning Microscopy (CLSM) (Oliveira and Cunha Mde, 2010) 
coupled with a double staining technique (Kania et al., 2007). This will allow the ability 
to visualize thick biofilm sections and observe the location of the microbial populations 
within the hydrated EPS, thus providing a more realistic image of the biofilm in situ 
(Rumbaugh and Carty, 2011).  
 
 
1.10  Control of Biofilms 
 The emerging resistance of pathogenic bacteria to antibiotics remains a serious 
challenge to medicine and healthcare (Guo et al., 2012). Examples of this challenge is 
the resistance of Staphylococcus aureus to methicillin (Moran et al., 2006), the 
resistance of Pseudomonas aeruginosa and Clostridium difficile to fluoroqinolones (Hsu 
et al., 2005; Loo et al., 2005) and the resistance of Salmonella to multiple drugs (Chen 
et al., 2004). The rate at which new antimicrobial agents are being discovered and 
approved doesn’t match the rate at which the currently used antibiotics become less 
effective which makes it crucial to search for new antimicrobial agents that are active, 
safe and environmentally-friendly (Guo et al., 2012). Current approaches to search for 
new antibiotics include metabolic engineering (Khosla and Keasling, 2003), synthetic 
chemistry (Piel, 2002), genomic or metagenomic approaches (Koehn and Carter, 2005; 
Poulsen et al., 2011) and identifying new microorganisms for their ability to produce 
bioactive natural products (Jensen et al., 2007). Traditional treatment of bacterial 
infections is based on compounds that kill or inhibit the growth of bacteria (Geddes, 
2000). In the case of biofilms, evidence suggests that a single compound is not 
sufficient to eradicate the infection because such treatment will leave persistent bacteria 
to colonize neighbouring sites and will lead to the development of antibiotic resistance 
(Drenkard, 2003).    
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Recently, the pharmaceutical industry has acknowledged the importance of 
biofilm infections (Alhede et al., 2011), however, there are still no commercially 
available antibiotics that can specifically target the biofilm mode of growth in addition 
to the increase resistance to available antibiotics (Boucher et al., 2009). The 
development of biofilm specific drugs focuses on three major strategies which are 
prevention of biofilm formation, removal of biofilm and weakening of biofilm (Alhede 
et al., 2011). Prevention of biofilm formation includes mechanisms such as the use of 
antibodies and pilicides (Alhede et al., 2011). Whereas removal of biofilms include the 
use of bacteriophage (Sulakvelidze et al., 2001), bacteriophage lytic enzymes (Fischetti, 
2005), probiotics (Hong et al., 2005), antimicrobial peptides (De Smet and Contreras, 
2005), electrical currents (Del Pozo et al., 2008), and dispersal signals (Davies and 
Marques, 2009). Moreover, weakening of biofilms includes the use of quorum sensing 
inhibitors (QSI), Inhibition of type III secretion and surface coatings (Alhede et al., 
2011). Example of antibiofilm strategies are the Polysaccharide Intercellular Adhesin 
(PIA) enzymes that are produced by the gene products of icaADBC operon, making the 
ica genes a potential target for biofilm inhibition (Oduwole et al., 2010). These 
enzymes have therapeutic benefits that can be used as biomaterial coating agent to 
reduce device-related infections (Oduwole et al., 2010).  
 The development of substances that can specifically inhibit bacterial virulence 
such antipathogenic drugs are assumed to prevent the development of resistant strains 
thus inhibit biofilm formation (Bryers, 2008). A recent approach to combat such 
biofilms includes the blockage of regulatory systems that control the expression of 
virulence factors (Bryers, 2008) such as anti-adhesion therapy (Casadevall et al., 2004), 
disrupting iron metabolism (Kaneko et al., 2007), and up-regulating the promoters for 
biofilm detachment (Boles et al., 2005).   
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1.11 Microbial Natural Products  
 The traditional definition of natural products is that they are chemical (carbon) 
compounds isolated from diverse living organisms and may derive from primary or 
rather secondary metabolism of living organisms (Berdy, 2005). The primary 
metabolites such as polysaccharides, proteins, nucleic and fatty acids are common in all 
biological systems. However, the secondary metabolites are chemically and 
taxonomically diverse compounds with various functions that are characteristic mainly 
to some specific type of organisms (Berdy, 2005). Natural products continue to play an 
important role in the discovery and development of new compounds during drug 
development (Lang et al., 2008). An important part of the natural products is a group of 
small molecular secondary metabolites of microorganisms that usually exhibits 
biological activities (Berdy, 2005).  
 The natural environment remains a rich reservoir for microorganisms capable of 
producing potent antimicrobial agents (Clardy et al., 2006). Many efforts worldwide 
focus on isolating natural products from terrestrial and marine macro- and 
microorganisms (Lang et al., 2008) Screening for microbial natural products, i.e. 
bioactive secondary metabolites,  represents an important step towards the discovery of 
novel therapeutic chemicals (Courtis et al., 2003; Gillespie et al., 2002) due to the fact 
that these natural products are the origin of most of the antibiotics in the market today 
(Pelaez, 2006). Many of these compounds are produced by the organism in response to 
extreme environments such as competition for space and nutrient in addition to potential 
predators (Proksch, 1994).  
Although some secondary metabolites like extracellular polysaccharides (EPS) 
are synthesized by a wide range of bacteria and have been proven to be involved in 
pathogenicity (Campos et al., 2004), recent findings suggested that some 
polysaccharides secreted from some bacteria inhabiting natural ecosystems possess the 
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ability to negatively regulate biofilm formation (Jiang et al., 2011; Qin et al., 2009). 
The advantages of natural products compared to their synthetic counterparts is that they 
are largely unexplored, have unmatched chemical diversity with biological potency 
(Verdine, 1996), are considered as powerful pathfinders in the investigations of cellular 
functions (Zhang, 2005), and can help in the design of synthetic compounds 
(Breinbauer et al., 2002). In addition, the research on these products has led to the 
discovery of novel mechanisms of action (Urizar et al., 2002).  
 
1.11.1 Bioactive Metabolites of Marine Bacteria  
 Bacteria are one of the main producers of the antagonistic substances in 
terrestrial environment. Many activities have been reported from marine bacteria 
including antibiotic, antiviral, antifungal, and anti-yeast activities (Bhakuni and Rawat, 
2005; Buck et al., 1962). Examples of such marine bacteria include the ichthyotoxic 
Pseudomonas piscicida that exhibits a significant antagonism to various 
microorganisms, Pseudomonas bromoutilis that produces the antibiotic bromo pyrrole 
active against many Gram-positive bacteria (Lovell, 1966) and Serratia marcescens that 
produces a red coloured antibiotic named prodigiosin with antifungal and anticancer 
activities (Bennett and Bentley, 2000; Llagostera et al., 2003). The formation of 
antibiotic substances from such bacteria indicates that marine microbes are capable of 
producing new and unusual types of antibiotic substances when compared to the 
terrestrial ones some of which will be useful in developing medicine and  
pharmaceuticals (Bhakuni and Rawat, 2005).  
It has been shown that extracts of marine actinomycetes act as a quorum sensing 
inhibitor (QSI) exhibiting antibiofilm activity against Vibrio harveyi by attenuating the 
signal molecules N-acylated Homoserine Lactones (You et al., 2007). Another marine 
bacteria with reported antibiofilm activity is Bacillus pumilus from Palk Bay that 
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inhibits the quorum-sensing-mediated virulence factors in Gram-negative bacteria 
(Nithya et al., 2010a).  
  
1.11.2 Bioactive Metabolites of Soil Bacteria  
 Despite the fact that soil is arguably the most useful and valuable habitat on 
earth, it is still considered one of the least understood ecosystems that needs to be 
further explored (Handelsman et al., 1998). Evidence shows that less 0.1% of soil the 
microorganisms are readily cultured using current techniques (Torsvik et al., 1990) and 
the other 99.9% are still emerging as vast collection of novel genetic diversity (Torsvik 
et al., 1996). This great diversity will probably lead to further diversity even within 
species which current phylogenetic analysis cannot resolve (Handelsman et al., 1998). 
Estimates are that a gram of soil might contain 1,000-10,000 species of unknown 
microorganisms (Torsvik et al., 1990). Soil carries the highest concentrations of 
microbial populations when compared to any other habitat, it still remains an important 
source of microbial natural products (Whitman et al., 1998).   
 In the past, a large number of soil organisms, mainly Actinomycetes and fungi, 
have been isolated and screened for valuable products (Vandamme, 1994). Bacteria on 
the other hand play a major role in the complex diversity of microorganisms in soil due 
to the fact that a large portion of them are still not identified (De Vos, 2011). New 
groups of bacteria have been identified in soil that appear to differ greatly from the 
cultured bacteria that they could represent new phyla or even new kingdoms of life 
(Borneman et al., 1996). In addition to new natural products, novel soil bacteria are also 
of strategic importance in the discovery of new bioactive secondary metabolites 
(Saravanan et al., 2012). Therefore, taxonomically novel soil bacteria are of strategic 
importance in the discovery of new bioactive secondary metabolites (Saravanan et al., 
2012). 
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1.11.3 Soil Bacterial Species of Paenibacillus  
 The genus Paenibacillus was first identified in 1993 based on a comparative 
analysis of 16S rRNA sequences of 51 species belonging to the genus Bacillus (Ash et 
al., 1991; Ash et al., 1993). The newly proposing genus of Paenibacillus comprised of 
aerobic or facultatively anaerobic rod-shaped, endospore-forming bacteria (Montes et 
al., 2004). At that time, the genus comprised 11 species, with P. polymyxa as the type 
species (Seldin, 2011). To date, there are 150 species of Paenibacillus approved and 
validated according to the bacterial nomenclature list by Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH Braunschweig (DSMZ), Germany. (May 
2013). This bacteria are harbouring strains of medical, industrial and agricultural 
importance (Seldin, 2011). In order to identify and analyse the properties of 
Paenibacillus from a mixed environment, preparation of a pure culture is essential 
(Bodour et al., 2003). The microbe of interest can be cultivated, selected and enriched 
by using an enrichment culture that will provide favourable growth conditions for the 
organisms of interest and unfavourable for the competing organisms (Bento et al., 2005; 
Sen, 2010; Willumsen and Karlson, 1997). In the past few years, the 16S ribosomal 
RNA (16S rRNA) gene sequence has become the gold standard method for accurate 
identification of microorganisms, as it relates to bacterial taxonomy and the discovery 
of novel bacteria (Sintchenko, 2010). This method is particularly important in the case 
of slow-growing bacteria, uncultivable bacteria and bacteria with unusual phenotypic 
profiles in which it will allow for the discovery of new bacterial species and genera 
(Clarridge, 2004; Hall et al., 2003; Woo et al., 2008).  
 Although some species of Paenibacillus like P. larvae cause disease in larval 
honeybees, no Paenibacillus species has been reported as a human pathogen (Govan et 
al., 1999). Strains of Paenibacillus spp. produce various antimicrobial agents such as 
lantibiotics (He et al., 2007), lipopeptides (Martin et al., 2003), macrolides (Wu et al., 
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2011), immunomodulators, antitumor agents (Rodrigues et al., 2006), and non-
ribosomally synthesized compounds that are active against a wide range of bacteria, 
fungi, and oomycetes (Ongena and Jacques, 2008).   
 Interest in Paenibacillus spp. as a source of new antimicrobials has been 
increasing (Guo et al., 2012). They are widely distributed in the environment, 
particularly soil were some of them promote the growth of plant are involved in 
nitrogen fixing (Khianngam et al., 2009; McSpadden Gardener, 2004; von der Weid et 
al., 2002).  
 
1.11.4 Identification of Microbial Natural Products 
The bioactive metabolites produced by bacteria in natural environments could be 
a mixture of several class of chemical compounds (Bhakuni and Rawat, 2005). 
Chemically these compounds can be classified either as amino acids, peptides, 
nucleosides, alkaloids, terpenoids, sterols, saponins or polycyclic (Bhakuni and Rawat, 
2005). Since the chemical nature of these compounds are unknown, it is not possible to 
follow any specific technique for the separation of the constituents of that complex 
mixture (Bhakuni and Rawat, 2005).  
The process of separation involves the extraction of significant amounts of the 
desired organism to obtain the crude extracts mixture followed by separation of the 
mixture that can be achieved by fractionation with organic solvents. Each of these 
fractions is then subjected to biological assays in order to identify the possible bioactive 
compounds that can then be isolated by a bioassay-guided fractionation process (Lang 
et al., 2008). If the separation is good, the biological activity may concentrate in a 
particular fraction (Bhakuni and Rawat, 2005) which will eventually lead to yield pure 
compounds that can be then characterized by various techniques such as Mass 
Spectrometry (MS), Ultraviolet (UV), Infrared (IR), and Nuclear Magnetic Resonance 
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(NMR) spectroscopy (Lang et al., 2008). However, the therapeutic applications of some 
natural products has declined during the last decade due to certain limitations such as 
the competition from chemically-synthetic compounds as a source of new drugs 
(Pelaez, 2006), the redundancy of strains and compounds within natural-product 
libraries (Handelsman et al., 1998), the lack of a systematic exploitation of natural 
ecosystems (Czaran et al., 2002), the labour-intensive and time consuming approaches 
used in characterizing such active compounds (Monaghan et al., 1995) and the need for 
an extensive media optimization and scale-up when producing large quantities for drug 
profiling (Strobel, 2002). 
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2CHAPTER TWO 
LITERATURE REVIEW 
 
2.1  Prevalence of Biofilm Infections in Otorhinolaryngology  
 According to the United States, microbial infections that are associated with 
biofilms make up to 80% of all human infections (Stowe et al., 2011) leading the U.S. 
Centres for Disease Control and Prevention (CDC) to declare biofilms as one of the 
most important medical problems of the century (Davies, 2003). Various studies had 
shown that chronic infections including the ear, nose and throat are associated with 
biofilms (Hall-Stoodley et al., 2006; Kania et al., 2007). Therefore, 
otorhinolaryngology as well as other medical disciplines are facing the challenge of 
biofilm-related infections (Vlastarakos et al., 2007) which makes it crucial to develop 
novel strategies for the prevention and treatment of such infections (Vlastarakos et al., 
2007).  
 In a prospective study made by Psaltis et al., they compared the presence of 
bacterial biofilms on the sinus mucosa of 38 Chronic Rhinosinusitis (CRS) patients and 
9 control patients using CLSM. Bacterial biofilms were found in 44% of CRS patients 
whereas no biofilms were present in any of the controls which support the hypothesis 
that biofilms may play a role in the pathogenesis of CRS (Psaltis et al., 2007). The study 
of recurrent acute otitis media (RAOM) presented by Zuliani et al., pointed out the 
variety of biofilm-related infections noting that biofilms were present in the adenoids 
that were collected by his team stating that the degree to which biofilms are present in 
relation to controls is striking and should not be ignored (Zuliani et al., 2006). Another 
study by Zulianai et al., described by a comparative microanatomic investigation of 
adenoid mucosa using SEM in patients with recurrent acute otitis media (RAOM) and 
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obstructive sleep apnea (OSA) (27 female and 41 male; age range, 3 months to 15 
years) (Zuliani et al., 2009). The study showed evidence of bacterial biofilms covering 
the entire surface of adenoids removed from patients with RAOM with an average of 
93.53% of their mucosal surface covered, versus an average of 1.01% coverage from 
patients with OSA (Zuliani et al., 2009). A similar study was performed by Coticchia 
and co-workers, demonstrated that the adenoids removed from patients with CRS had 
dense mature biofilms covering 94.9% of their mucosal surface compared with 1.9% 
coverage on the adenoids removed from patients with OSA (Coticchia et al., 2007). 
Moreover, the mechanical removal of these biofilms may explain the observed clinical 
benefit associated with adenoidectomy in this group of patients (Coticchia et al., 2007).  
 Direct detection of biofilms on biopsy specimens from children with otitis media 
effusion (OMED) and recurrent otitis media supports the hypothesis that these chronic 
middle-ear disorders are biofilm-related (Cryer et al., 2004). Ramadan et al., 
demonstrated in their study that biofilms were present in patients undergoing surgery 
for CRS. However, none of the patients without CRS had any evidence of biofilms 
(Costerton et al., 1999). Even though researchers had described new methods that 
effectively remove biofilms, studies did not prove that these biofilms actually caused 
the CRS and RAOM. Therefore, more investigations are needed to prove that biofilms 
are the causative agents for such conditions (Zuliani et al., 2006). There is also evidence 
for the possible presence of bacterial biofilms on frontal sinus stents in patients with 
chronic sinusitis who underwent Functional Endoscopic Sinus Surgery (FESS) and 
these stents may actually serve as biofilm reservoirs (Perloff and Palmer, 2004).  
 Study by Chole et al., examined the palatine tonsils that had been surgically 
removed due to infection and obstruction by SEM and TEM was found that bacteria 
were seen within the tonsillar crypts of 11 of 15 infected tonsils and in 3 of 4 
hypertrophied tonsils (Chole and Faddis, 2003), which indicates that there is strong 
45 
 
anatomical evidence for the presence of bacterial biofilms in chronically diseased 
tonsils. Another study by Kania et al., demonstrated the presence of  mucosal biofilms 
in most 17 of 24 patients with tonsillitis (70.8%) by direct visualization of bacteria and 
glycocalyx using CLSM with double fluorescent staining on tonsils and compared the 
findings with the results of scanning electron microscopy analysis (Kania et al., 2007). 
Al-Mazrou and Al-Khattaf studied the presence of bacterial biofilms on the epithelial 
surfaces of tonsils and adenoids in children undergoing adenotonsillectomy (T&A) (Al-
Mazrou and Al-Khattaf, 2008) and their results showed adherent biofilm formation in 
46 patients (61%). Among 26 patients with infections, adherent biofilm formation was 
detected in 22 (85%), whereas in the group of 44 patients with obstruction only 18 were 
found to have biofilms (41%).  
 A study by Winther et al., used LM to determine the location of bacteria and 
their biofilm in the adenoid tissue and in the mucus overlying the adenoid (Winther et 
al., 2009). They reported the bacterial biofilms were present on 8 of 9 adenoids and 
bacteria were not found in the parenchyma of the adenoids below the epithelial surface 
whereas planktonic bacteria were present in 7 adenoids in areas not subject to mucus 
flow (Winther et al., 2009). Review by Lipton and Gozal provided a comprehensive 
analysis of the morbidity and treatment of OSA in children. However, the conclusion 
was that they were still unable to determine an appropriate cost-effective guidelines for 
treatment and therefore efforts to develop novel and more effective therapies should be 
taken into consideration (Lipton and Gozal, 2003).   
 
 
2.2  Worldwide Antibiofilm Discoveries   
 There are several examples of naturally produced compounds that inhibit the 
process of biofilm formation, one class of which are the antagonists of quorum sensing 
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or anti-quorum sensing molecules (Maximilien et al., 1998). The first observation came 
from the marine red alga Delisea pulchra which secretes N-acyl homoserine lactones 
(AHL) analogs, called furanones, and that their activity correlates with reduced surface 
colonization of the plant by bacteria (Maximilien et al., 1998). Study by Hentzer et al., 
demonstrated that a synthetic halogenated furanone compound is capable of interfering 
with the AHL-mediated QS system in P. aeruginosa and that furanone treatment 
destabilized biofilms making the treated bacteria sensitive to antibiotics while the 
untreated highly resistant, suggesting that it has potential to be used as a novel treatment 
for biofilm-associated infections (Hentzer et al., 2002).  
 Recently, the metabolomics approach has been used to classify metabolites 
based on metabolite profiling studies (Kim et al., 2009) allowing rapid analyses of 
complex data and the determination of novel compounds (Rochfort, 2005; Want et al., 
2005). In an effort to find viable sources of antibiofilm agents, many researchers have 
started to extract and analyse natural products from microorganism inhabiting natural 
ecosystems (Donia and Hamann, 2003). In a study by Ren et al., it has be shown that 
the QS antagonist (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone 
(furanone) from the marine alga Delisea pulchra inhibits biofilm formation in E. coli 
without inhibiting its growth (Ren et al., 2004). Another study showed that the 
metabolites of a marine Actinomycete strain A66 inhibit biofilm formation by Vibrio in 
marine ecosystem (You et al., 2007). Thenmozhi et al., demonstrated that extracts from 
coral associated Bacillus horikoshii inhibit biofilm formation of Streptococcus pyogenes 
(Thenmozhi et al., 2009). Compounds having anti-biofilm activity and secreted from 
microorganisms living in natural environments like marine and soil ecosystem, can 
range from furanone to complex polysaccharide (Abu Sayem et al., 2011). Recent 
findings suggest that some polysaccharides secreted from marine and non-marine 
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organisms also possess the ability to negatively regulate biofilm formation (Jiang et al., 
2011; Qin et al., 2009).  
 Many studies used Liquid Chromatography-Mass Spectrometry (LC-MS) as a 
metabolite profiling tool which allows more comprehensive metabolite analyses (Bino 
et al., 2004; Silas et al., 2005) allowing high sensitivity, high-throughput and ability to 
identify components in complex samples (Krug et al., 2008). A study by Kim et al., 
presented an approach for the high-throughput screening of secondary metabolites from 
4 bacterial strains of Myxococcus xanthus (Kim et al., 2009). Their results detected 22 
metabolite peaks of the bacterial crude extracts via Electrospray Ionization-Mass 
Spectrometry (ESI-MS) followed by metabolite profiling via m/z value, retention time, 
and MS/MS fragmentation pattern analyses. Among the peaks, one unknown compound 
peak was identified as analogous to the myxalamid A, B, C series and further analysis 
identified a new compound (Kim et al., 2009).  
 Recent study by Moon et al., examined the effect of FDA-approved iron 
chelators deferoxamine (DFO) and deferasirox (DFRA) against planktonic and biofilm 
cells of Prevotella intermedia in order to evaluate the possibility of the iron chelators as 
alternative controlling agents against P. intermedia (Moon et al., 2013). Their results 
showed DFRA partially inhibited the bacterial growth and considerably prolonged the 
bacterial doubling time however DFO was unable to completely inhibit the bacterial 
growth in the concentration range tested. In addition, crystal violet binding assay for the 
assessment of biofilm formation by P. intermedia showed that DFRA significantly 
decreased the biofilm-forming activity as well as the biofilm formation, while DFO was 
less effective (Moon et al., 2013).  
 Another recent study by Alves et al., evaluated the in vitro effects of four natural 
substances of farnesol, xylitol, lactoferrin and salicylic acid on the biofilm mass formed 
by Enterococcus faecalis and Staphylococcus epidermidis via crystal violet assay to 
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assess their potential use as root canal irrigants (Alves et al., 2013). Their results 
showed that combination of farnesol and xylitol was the most effective agent against E. 
faecalis biofilms. Similarly, combinations involving farnesol, xylitol, and lactoferrin 
reduced the biomass of S. epidermidis biofilms as well concluding that combinations of 
antibiofilm substances have potential use in endodontic treatment to combat biofilms 
(Alves et al., 2013).   
 Another study by Payne et al., involved screening of a library of small molecules 
for the ability to inhibit the biofilm formation of Staphylococcus aureus. The authors  
presented evidence that the polyphenolic compound tannic acid inhibits the biofilm 
formation of S. aureus in multiple biofilm models without inhibiting bacterial growth 
via a mechanism dependent upon the putative transglycosylase IsaA (Payne et al., 
2013). In addition, the same investigators developed a rodent model for S. aureus throat 
colonization and found that the consumption of tannin-containing drinks like tea 
reduced the colonization of S. aureus via an IsaA-dependent mechanism. These findings 
provide insight into a molecular mechanism by which polyphenolic compounds, such as 
tannins, influence the surface colonization of S. aureus and act as antibiofilm agents 
(Payne et al., 2013).   
 A study by Liu et al., used a collection of β-peptoid-peptide hybrid oligomers 
displaying different amino acid/peptoid compositions and chain lengths to study their 
antimicrobial activity against Staphylococcus epidermidis both in planktonic and 
biofilm cultures and compare their effects with those of the common antibiotic 
vancomycin via susceptibility tests, time-kill assays and microscopic observations (Liu 
et al., 2013). Their results showed that all tested peptidomimetics were bactericidal 
against both exponentially growing and stationary-phase S. epidermidis cells with 
similar killing kinetics and that Chiral and guanidinylated hybrids exhibited the fastest 
killing effects against slow-growing cells and had more favourable antibiofilm 
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properties than analogues only containing lysine or lacking chirality in the β-peptoid 
residues. Concluding that this class of peptidomimetics may contain promising 
antimicrobial alternatives for the prevention and treatment of multidrug-resistant S. 
epidermidis infections. (Liu et al., 2013).  
   
 
2.3 Current Research of Biofilm in Malaysia 
 Many studies have been conducted in Malaysia to address the problems and 
ways to combat biofilms in various fields. In 2010, we have reported the presence of 
bacterial biofilms among clinical samples via an oral presentation at the annual 
scientific meeting paper awards of the Malaysian Society of Otorhinolaryngology Head 
and Neck Surgeons (MSO-HNS). We have reported and compared the identification of 
bacterial biofilms among patients undergoing tonsillectomy for chronic and recurrent 
tonsillitis using various microscopic techniques (Rahmat et al., 2010).  
 In the same year, we have participated in the same year at the Innovation and 
creativity EXPO 2010 University of Malaya and reported a study entitled “Discovery of 
Novel Properties from Bacterial Culture Supernatant via A Rapid and Simple Method 
towards Developing Anti-Quorum Sensing and Anti-Biofilm Drugs” (Rahmat et al., 
2010). The novelty of this work lies in the discovery of an antibiofilm property from a 
novel soil bacterial culture filtrate as an environmentally-friendly naturally-produced 
compound against clinically important pathogens allowed us to win the gold medal 
award and the best category award (Appendixes 1A, 1B, 2A).   
 Moreover, we have participated in the 21
st
 International Invention, Innovation & 
Technology Exhibition (ITEX 2010) held in Kuala Lumpur by presenting a study 
entitled “Biofilm profile of chronic and recurrent tonsillitis using various microscopic 
techniques and their outcome on the diagnosis and treatment of biofilm-related 
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infections” (Rahmat et al., 2010) for which we have won the ITEX silver medal 
(Appendixes 1C, 2B).     
 Another study by us reported the potential activity of a cell-free supernatant 
isolated from a taxonomically novel bacterial species that was originally isolated from 
an agricultural soil. This study was presented as a poster presentation at the 15
th
 
Biological Science Graduate Congress/University of Malaya (Appendix 2C). We 
reported the in vivo activity of this compound in disrupting and breaking down the 
bacterial biofilm caused by Pseudomonas aeruginosa using a rat model of chronic lung 
infection (Saad et al., 2010). Moreover, the bioactive property from the novel 
indigenous soil bacterial species was also reported and presented by us under the name 
soil-derived biocleaner at the Malaysian Technology Expo at Putra World Trade Centre 
and the Innovation and creativity EXPO, University of Malaya, Kuala Lumpur (Salmah 
et al., 2010).  
 A study by Tan and Tay from University of Malaya described the killer 
phenotypes of tropical environmental yeasts and the inhibition effects of their culture 
filtrates on the biofilm of Candida albicans (Tan and Tay, 2011). Their study showed 
more than 50% reduction in the metabolic activity of C. albicans biofilm after exposure 
to the culture filtrates of the nine killer yeasts suggesting the purification and 
characterization of toxin and metabolites to be essential for understanding the killing 
effects of their selected yeasts (Tan and Tay, 2011). Another study from University of 
Malaya was conducted by Ramli et al. where they investigated the effects of 
environmental factors such as temperature, growth medium, pH and glucose on biofilm 
formation among 28 Burkholderia pseudomallei clinical isolates acquired from 
University Malaya Medical Centre (UMMC) and obtained from different sites of 
infection such as wounds, respiratory tract, urine, splenic biopsy, pus and blood in order 
to study the variations between different strains (Ramli et al., 2012).  
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 Study by Siddiqui et al. from Universiti Malaysia Pahang assessed the novel 
biological anti-quorum sensing (QS) of Piper beetle extract to control membrane 
biofouling in order to allow sustainable performance of membrane bioreactors for 
wastewater treatment (Siddiqui et al., 2012). Their results demonstrated the occurrence 
of the N-acyl-homoserine-lactone (AHL) autoinducers, correlate QS activity and 
membrane biofouling mitigation indicating that extracts from the plant Piper beetle 
could be a novel agent to target autoinducers for mitigation of membrane biofouling 
(Siddiqui et al., 2012).  
 Another study addressing the approach of QSIs was performed by Anbazhagan 
et al. from University of Malaya where they reported the detection of N-acyl-
homoserine lactone (AHL) signalling molecules among 50 biofilm-forming clinical 
isolates of Acinetobacter spp. obtained from University Malaya Medical Centre using 
the Chromobacterium violaceum CV026 biosensor monitor system (Anbazhagan et al., 
2012). Only two isolates of this species produced the AHL molecules which led them to 
conclude signal molecules aid in biofilm formation and pathogenicity of the clinical 
isolates including drug resistance (Anbazhagan et al., 2012).  
 A study by Torey and Sasidharan from University Sains Malaysia was carried 
out to evaluate the inhibitory effect of methanol extract of Cassia (C.) spectabilis leaves 
against biofilm forming Candida albicans using disc diffusion assay and broth dilution 
method and examined via Scanning Electron Microscopy and Confocal Laser Scanning 
Microscopy (Torey and Sasidharan, 2011). Their results revealed that the methanol 
extract of C. spectabilis showed anti-yeast activity against C. albicans with a minimum 
inhibitory concentration (MIC) value of 6.25 mg/ml and that the main changes observed 
after exposure to the extract treatment were cellular damage and disruption in the 
biofilms of C. albicans indicating an in vitro antibiofilm activity of C. spectabilis leaves 
extract against Candida biofilms (Torey and Sasidharan, 2011).  
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 A study by Odeyemi from the National University of Malaysia aimed to 
investigate biofilm production among Vibrio species isolated from Siloso Beach, 
Singapore where sea water samples were collected and plated on Congo Red Agar 
(CRA) and the biofilm producing colonies were further transferred into a selective 
medium for isolating Vibrio species. (Odeyemi, 2012). The results of the study revealed 
46 biofilm positive bacteria were isolated after 24 h incubation on CRA concluding that 
open sea water for bathing or other recreational purposes could pose danger to human 
health and marine life in addition of being a vehicle of transmitting pathogens from one 
country to another especially if no disease or infection symptoms were noticed before 
departure of the infected tourist (Odeyemi, 2012).   
 A study by Nawawi et al. from Universiti Kebangsaan Malaysia addressed the 
microbially-influenced corrosion of metal surfaces by comparing the potential corrosion 
of 2 strains of marine sulfate reducing bacteria on stainless steel using electrochemical 
techniques (Nawawi et al., 2012). The results revealed that differences of Rp value that 
were recorded between two bacterial strains mostly depend on the corrosiveness of the 
metabolomics substances produced and production rate of biofilm directly influenced 
by proportional with the bacteria growth (Nawawi et al., 2012).  
 A study by Jassim et al., from Universiti Putra Malaysia explored new 
approaches of phage-based bio-process of specifically pathogenic Escherichia coli 
bacteria in food products within a short period (Jassim et al., 2012). Their results 
revealed that E. coli biofilms contaminating food products were reduced >3 log cycles 
upon using the phage cocktail of 140 highly lytic designed phages concluding proper 
prevention methods of pathogenic E. coli achieved in this study can replace the current 
chemically less effective decontamination techniques (Jassim et al., 2012).   
 Another study from Universiti Putra Malaysia was conducted by Atshan et al. 
Their investigation aimed to demonstrate whether the characteristics of biofilm 
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formation are consistently similar among isolates variations of methicillin-resistant 
Staphylococcus aureus (MRSA) (Atshan et al., 2012). The methods used to evaluate 
these characteristics were a modified Congo red agar (CRA) assay, a microtiter plate 
(MTP) assay, Light Microscopy (LM), Scanning Electron Microscopy (SEM) and the 
Polymerase Chain Reaction (PCR). Their results indicated that differences in biofilm 
production capacities are caused by the differences in surface protein A (Spa) type and 
are not due to differences in MLST and SCCmec types (Atshan et al., 2012).  
 A study by Ibrahim et al. from Universiti Teknologi Malaysia was conducted to 
characterise and study the microbial flocs formed from raw textile wastewater in a 
prototype Aerobic Biofilm Reactor system for their potential use in the treatment of 
textile wastewater (Ibrahim et al., 2009). Their results revealed that after 90-100 days of 
operation, microbial flocs of loose irregular structures were obtained from the reactor 
with good settling velocity and sludge volume index and that the molecular analysis of 
the flocs via 16S rRNA sequencing showed 98% homology to those of Bacillus sp., 
Paenibacillus sp. and Acromobacter sp. The authors concluded that when the flocs were 
used for the treatment of raw textile wastewater, they showed good removal activity 
indicating their potential application (Ibrahim et al., 2009).  
 A study by Shunmugaperumal and Ramamurthy from the International Medical 
University in Kuala Lumpur was carried out to assess the anti-adherent and antibiofilm 
activities of Magnesium fluoride MgF(2) nanoparticles-stabilized oil-in-water nanosized 
emulsion over glass coupons against pathogenic microorganisms like Escherichia coli 
and Staphylococcus aureus (Shunmugaperumal and Ramamurthy, 2012). The results 
showed massive biofilm formation on non-emulsion-coated surfaces while emulsion-
coated surfaces dramatically restricted bacterial colonization suggesting that MgF(2) 
nanoparticles-stabilized emulsion is effective in restraining bacterial colonization on 
glass surfaces and that increased antibiofilm action would be expected when these 
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nanoparticles are coated on other types of biomaterial surfaces such as intraocular lenses 
and catheters (Shunmugaperumal and Ramamurthy, 2012).  
 
 
2.4  Importance of this Study 
It has been observed that many ENT infections are becoming less susceptible to 
common treatment and more related to the presence of biofilms (Nixon and Bingham, 
2006). Many studies had shown that mucosa-related ENT chronic infections are 
biofilm-related such as the study conducted by Palmer, which has identified the 
presence of biofilms in sinonasal mucosa and on stents removed after frontal sinus 
surgery from human patients (Palmer, 2006). Another investigation was conducted to 
study the relation between chronic inflammation of the tonsils, clinical features, and the 
presence of biofilms in the crypts in patients presenting with obstructive hypertrophy 
and recurrent upper airway pathology (Diaz et al., 2011). Their results showed that all 
patients had tonsillar hypertrophy (Grade III or IV), for which 77.28% of tonsils 
harboured biofilms in their crypts demonstrating that symptoms like harsh raucous 
sound, tonsillar and adenoid hypertrophy, apnea, and cervical adenopathies are clearly 
related to the presence of biofilm in tonsils. This finding enabled them to propose that 
biofilms are involved in the pathogenesis of tonsils and adenoids hypertrophy (Diaz et 
al., 2011) 
However, studies on the presence of bacterial biofilms on lymphatic tissue 
surfaces are still lacking (Kania et al., 2007). Therefore, we have selected the palatine 
tonsil as our clinical specimen because it is the only easily accessible human lymphoid 
tissue which often is considered as an example for lymphoid organs (Nave et al., 2001), 
its remarkable role in the immunological defence of the body (Mogoanta et al., 2008), 
tonsillitis is one of the most common infectious diseases of the upper respiratory tract 
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and that tonsillectomy is the most frequent surgical procedures performed worldwide 
(Kania et al., 2007). In addition, the presence of biofilms in the tonsils has been 
reported mainly using tools that might have destructive effects on the integrity of 
biofilm structure such as SEM and TEM (Chole and Faddis, 2003; Parsek and Singh, 
2003) which emphasizes the importance of visualizing and studying biofilms using a 
non-destructive approach like CLSM.  
Failure of antibiotics to eradicate the pathogenic bacteria that are responsible for 
otorhinolaryngologic diseases has led to the hypothesis that these bacteria may be 
presented in a biofilm structure (Drago et al., 2012). A recent study was conducted to 
evaluate the ability of bacterial isolates recovered from tonsillar biopsies and swabs od 
pediatric patients to form biofilms in vitro. The ability of Staphylococcus aureus, 
Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae to form 
biofilms was evaluated spectrophotometry via MTP assay (Drago et al., 2012). The 
results showed that 44.7% of the intraoperative samples were either moderate or strong 
biofilm producers compared with 27% of isolates at 6 months after surgery concluding 
that the ability to form biofilm decreased in bacteria isolated after tonsillectomy which 
suggests a role for biofilm in pathogenesis of recurrent and chronic pharyngeal diseases 
such as tonsillitis (Drago et al., 2012). Therefore, in our study, we collected the palatine 
tonsils from patients undergoing elective tonsillectomy and/or adenoidectomy for 
various tonsillar diseases due to infection and/or obstruction, then we detected the 
presence of biofilms microscopically using the three main microscopic tools LM, SEM 
and CLSM and correlate the microscopic finding with the clinical manifestations of 
tonsillar diseases that are due to infection and/or obstruction. This was followed by an 
assessment to the ability of tonsillar bacterial isolates to form biofilm by means of 
spectrophotometry in order to test the hypothesis that chronic and recurrent tonsillitis 
are biofilm-related. 
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Important properties of biofilm-growing bacteria are different from those of 
planktonic bacteria and this has significant diagnostic and therapeutic consequences 
(Hoiby et al., 2010). In clinical specimens such as biopsies and swabs, biofilm can be 
visualized by light microscopy, however, a more precise identification of bacteria 
within biofilm can only be done by DNA hybridization techniques (Hoiby et al., 2010), 
and identification of the components of biofilm’s matrix require specialized staining 
techniques such double staining (Bjarnsholt et al., 2009). Traditional culturing 
techniques may not be sufficient to culture bacteria in the biofilm mode of growth 
because tit reveals only the properties of planktonic bacteria. Therefore, antibiotic 
susceptibility testing based on routine culturing might give misleading results that do 
not reflect the increased resistance of the bacteria living in biofilms (Hoiby et al., 2010).  
Many studies have reported that biofilm-growing bacteria are more resistant (up 
to 1000-fold) when compared with planktonic bacteria (Anwar and Costerton, 1990; 
Bjarnsholt et al., 2007; Moskowitz et al., 2004) and various methods have been 
developed to test the susceptibility of biofilm bacteria to antibiotic (Anwar et al., 1990). 
However, the clinical relevance of these methods with regard to prediction of clinically 
successful therapies is still not confirmed (Anwar et al., 1990; Moskowitz et al., 2004).   
It has been reported that the antibiotics used to treat pulmonary infections like 
CF are typically chosen based on the results of antimicrobial susceptibility testing of 
bacteria in a planktonic mode of growth (Waters and Ratjen, 2012). Moreover, 
evidences suggested that Pseudomonas aeruginosa grows in biofilms in the airways of 
CF, therefore, choosing antibiotics based on biofilm rather than conventional 
antimicrobial susceptibility testing could potentially improve response to treatment of 
CF infections (Waters and Ratjen, 2012). Therefore, in our study we blindly assessed 
the antimicrobial susceptibility of the tonsillar bacterial isolates by conventional 
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culturing methods and correlate it with the ability of these isolates to form biofilms 
qualitatively and quantitatively.  
The failure of currently available antibiotics in controlling biofilm-associated 
infections makes it crucial to find alternative drugs (Hentzer et al., 2003). The 
administration of antimicrobial agents and biocides has been shown to be useful in 
combating biofilms (Danese, 2002). However, prolonged persistence of these 
compounds in the environment could induce toxicity towards non-target organisms and 
develop resistance among microorganisms (Abu Sayem et al., 2011). This aspect has 
led to the development of more environmentally-friendly bioactive compounds that can 
target a wider range of bacterial infections (Abu Sayem et al., 2011).  
 It has been reported that the genus Paenibacillus has been isolated from various 
ecological habitats, including warm springs (Chou et al., 2007; Saha et al., 2005), 
alkaline soils (Yoon et al., 2005) and agricultural soil (Ma and Chen, 2008). Various 
properties were reported among Paenibacillus species including nitrogen fixation 
(Berge et al., 2002), production of hydrolytic enzymes (Hrabák and Martínek, 2007) 
and antimicrobial substances (Mavingui and Heulin, 1994). However, According to 
DSMZ and to the best of our knowledge, there is no haemolytic activity reported for 
any Paenibacillus species (Salmah et al., 2012). 
Therefore in our study, we tested, purified and characterize the bacterial culture 
filtrate from a taxonomically novel species of Paenibacillus isolated from an 
agricultural soil for its antibiofilm activity in vitro and in vivo against clinically 
important pathogens recovered from tonsillar specimens in order to provide theoretical 
evidence on the prevention and treatment of biofilm-associated infections. It is hoped 
that with the finding of compound(s) with such activity we will contribute in the new 
therapeutic management of biofilm-associated infections such as chronic and recurrent 
tonsillitis.   
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2.5 Objectives of this Study 
The aim of our study was to test the hypothesis that chronic and recurrent 
tonsillitis are biofilm-related and a compound from novel soil bacterial species of 
Paenibacillus strain 139SI exhibits antibiofilm activity against clinically important 
pathogens towards new therapeutic management of biofilm-associated infections. 
Advances in chemical profile analysis such as High Performance Liquid 
Chromatography (Zhang, 2005) and chemical structure characterization such as Liquid 
Chromatography-Mass Spectrometry (Guo et al., 2012) has improved the efficiency of 
the discovery of novel antimicrobials from natural sources (Pelaez, 2006). Therefore, 
these analytical tools have been applied as key methods in our search for new bioactive 
metabolites of Paenibacillus sp. strain 139SI isolated from a Malaysian agricultural soil. 
This particular strain attracted our attention due to its remarkable haemolytic activity in 
vitro and the fact that the genus Paenibacillus is a rich source of compounds with 
potential therapeutic value. Therefore, the following objectives were assessed: 
 
 
1. To detect the presence of biofilms in the palatine tonsils among patients 
undergoing tonsillectomy for chronic and recurrent tonsillitis.      
2. To identify the microorganisms isolated from tonsillar specimens and assess their 
antimicrobial susceptibility and biofilm formation ability.  
3. To analyse and purify the bioactive compounds from a novel soil bacterial culture 
filtrate and assess its toxicity and antibiofilm activity in vitro and in vivo. 
4. To establish an animal model of chronic lung infection treated with compounds 
from novel soil bacterial culture filtrate and evaluate its histopathological effects.  
5. To characterize and identify the potential antibiofilm compounds from soil 
bacterial culture filtrate.        
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3CHAPTER THREE 
MATERIALS AND METHODS 
 
  
A. MATERIALS  
 
3.1  Clinical Specimens  
The clinical specimens in our study were collected from a total number of 70 
patients undergoing elective tonsillectomy and/or tonsillectomy & adenoidectomy 
(T&A) at University Malaya Medical Centre (UMMC). From each patient, 2 surgically 
removed tonsils (left and right side) and 2 surface swabs were collected. Thus, the total 
number of clinical specimens was 280 comprising of 140 tonsillar biopsies and 140 
tonsillar swabs.  
 
 
3.2  Bacterial Isolates 
Bacterial isolates in our study were represented by clinical isolates for which a 
total number of 484 bacterial isolates (302 Gram-Positive and 162 Gram-Negative) 
were recovered from tonsillar swabs and biopsies. Control reference strains for 
microtiter plate (MTP) assay were represented by biofilm forming strain for Gram-
positive Staphylococcus aureus (ATCC 25923), biofilm forming strain for Gram-
negative Pseudomonas aeruginosa (ATCC 27853) and non-biofilm forming strain 
Escherichia coli (ATCC 25922)  (Revdiwala et al., 2011)  
A taxonomically novel bacterial strain namely Paenibacillus haemolyticus strain 
139SI was originally isolated from an agricultural soil in Serdang Agricultural Centre 
(Pusat Pertanian Serdang) Selangor, Malaysia. It was identified via 16S rRNA test and 
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deposited at the American Type Culture Collection (ATCC) with a cataloguing number 
ATCC–BAA-2268  (Salmah et al., 2012) 
 
 
3.3  Chemicals, Reagents, Solutions and Consumables   
The chemicals used in our study were absolute ethanol, xylene, acetone, 
ammonium formate, formic acid, acetonitrile, sucrose and teepol solution. The buffers 
used were phosphate-buffered saline (PBS) tablets and normal saline (0.9% NaCl). The 
compound 2(5H)-Furanone and sodium alginate were used in the chronic lung infection 
model.  
The microbiology consumables included dehydrated culture media for the 
cultivation and growth of bacterial isolates were represented by Brain Heart Infusion 
Agar, Brain Heart Infusion Broth and Tryptic Soy Broth (BD, France). Columbia Agar 
with 5% Sheep Blood and Chocolate II Agar was obtained from ISOLAB, Malaysia. 
Plasticware consumables included inoculating loops volume of 10µl (Jet Bio-Fil), sterile 
conical centrifuge tubes capacity of 15 ml and 50 ml (Jet Bio-Fil), micro centrifuge tube 
capacity of 1.5ml (Eppendorf), disposable Petri dish, sterile, 90 mm x 15 mm (Thermo-
Line) and square weight trays polystyrene. For the in vitro assays, we used tissue 
culture plates with different growth surface areas of 6 and 96 wells (Jet Bio-Fil) and 
disposable pipette tips with various volumes (Jet Bio-Fil). Glassware consumables 
included bijou bottles with aluminium screw cap and a capacity of 7ml (S Murray & 
Co), measuring cylinder, screw cap with different capacities (Schott Duran, Germany) 
and Erlenmeyer flasks narrow neck. For sterilization of soil bacterial supernatant, 
Minisart
® 
cellulose acetate (CA) membrane syringe filters were used with a pore size of 
0.22 μm and a diameter of 47 mm (Sartorius, Germany).  
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Histology consumables included specimen containers, fixative solution of 4% 
glutaraldehyde,   scalpels, forceps, dissection boards, tissue cassettes, metal base molds, 
sectioning blades, biodisposer, slide boxes and paraffin wax. The mounting media 
Dibutyl Phthalate Xylene (DPX) was used in routine histology and as for 
immunohistochemistry staining (IHC), a special mounting medium was prepared with 9 
parts of glycerol and 1 part phosphate buffered saline (PBS) followed by the addition of 
a small amount of an anti-quenching agent, i.e. p-phenylenediamine. Staining solution 
for routine light microscope were Gram stain, H&E stain, whereas for IHC staining 
under CLSM were the double stain of Concanavalin A (Con A) and Propidium iodide.   
 
 
3.4  Experimental Animals 
For our experimental study, a total number of 84 Sprague-Dawley (SD) rats 
were randomly selected including 36 rats (18 males + 18 females) for the acute toxicity 
test and 48 rats (24 males + 24 females) for the chronic lung infection model. All 
animals obtained from Animal Care Unit Centre (ACUC), Faculty of Medicine, 
University of Malaya were 6-8 weeks old and weighed between 150-180 g. Food and 
water was available daily except for the short fasting period prior to dosage 
administration of the tested soil bacterial filtrate. All animals were kept in the animal 
experimental room for at least 3 days prior to dosing to allow for their acclimatization to 
the conditions of experiments. The room was well ventilated and the lighting was 
regulated to reproduce a 12 h cycle of day and night with a temperature maintained at 
around 25°C.  
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3.5  Antimicrobial Agents 
The selected antimicrobial agents that were used in this study to determine the 
antimicrobial susceptibility of bacterial isolates recovered from tonsillar specimens are 
listed in (Table 3.1).   
 
Table 3.1 List of selected antimicrobial agents used in this study.  
 
63 
 
B. METHODS  
 
3.6  Selection of Patients  
A total number of 70 patients diagnosed with different tonsillar diseases 
undergoing elective tonsillectomy and/or tonsillectomy & adenoidectomy (T&A) at 
UMMC were enrolled in this study. The duration for selecting patients and collecting 
their clinical specimens was 10 months starting from October 26, 2009 to July 26, 2010. 
Approval was obtained from UMMC medical ethics committee 
[PPUM/UPP/300/02/02Ref. No. 744.11] (Appendixes 4A, 4B, 4C).   
Prior to surgery, patients who satisfied the inclusion criteria (Table 3.2) were 
selected and enrolled in the study. They were presented at the Otorhinolaryngology 
clinic and the ENT ward at UMMC with signs and symptoms of chronic and recurrent 
tonsillitis in addition to obstructive sleep apnea. The nature of the clinical research in 
terms of methodology, possible adverse effects and complications (as per patient 
information sheet) were explained directly to each adult patient and to a responsible 
relative for each pediatric patient. After knowing and understanding all the possible 
advantages and disadvantages of our clinical research, the patients who agreed 
voluntarily consent of their own free will signed the consent form given to them and 
participate in our study. The English and Malay versions of consent forms by 
responsible relative for our study can be found in (Appendixes 5A, 5B).   
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Table 3.2 Inclusion and exclusion criteria for selecting patients in our study.  
 
 a (Darrow and Siemens, 2002); b (Gozal, 2000); c (Kuhn et al., 1995); d (Greenfeld et al., 2003); e (Loganathan et al., 2006).  
 
 
 
3.7  Collection of Tonsillar Specimens  
Prior to surgery, the Clinical Diagnostic Laboratory (CDL) was informed and 
the technicians stood by to receive the clinical specimens upon collection from the 
operating room. Patients underwent general anaesthesia followed by retraction of the 
uvula and soft palate. At that time, the inner surface of the two palatine tonsils was 
swabbed with a sterile cotton applicator for each side followed by the surgical removal 
of palatine tonsils via blunt dissection method (Loganathan et al., 2006). As soon as the 
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tonsils were removed, they were aseptically cut into 4 pieces with a sterile surgical 
blade and were aseptically put into sterile and labeled containers (Al Ahmary et al., 
2012) and transferred immediately to CDL for processing. 
 
 
3.8  Processing of Tonsillar Specimens  
Upon collecting tonsillar biopsies, specimens were dissected into four parts, 
fixed with an appropriate fixative and then processed accordingly. The first tissue part 
was placed unfixed in a sterile container with no fixative and sent, along with the swabs, 
to the CDL at UMMC for proper isolation and biochemical identification of 
microorganisms. The second tissue part was placed unfixed in a sterile container to be 
processed freshly for immunohistochemistry and viewed via CLSM. The third tissue 
part was fixed with a cold 4% Glutaraldehyde, a common fixative for electron 
microscopy (Westra et al., 2003), and further dissected into 1-mm cubes to be viewed 
via SEM. The fourth tissue part was fixed with 10% neutral buffered formalin, a 
standard fixative used in most laboratories (Westra et al., 2003), to be processed for a 
histopathology examination at the Department of Pathology, Faculty of Medicine, 
University of Malaya.  
 
 
3.9  Isolation and Identification of Tonsillar Bacterial Isolates 
The time between removal of the tonsils and inoculation of the specimen did not 
exceed 20 min. As soon as the tonsillar specimens reached the CDL, biopsies were 
aseptically weighed then dipped in alcohol, air-dried for 5 min and flamed to remove 
surface contamination. Biopsies were placed in thioglycollate broth (THIO), which 
represents an enriched liquid medium for the growth of microaerophilic and anaerobic 
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bacteria, with a volume equivalent to 1:10 dilution on a weight/volume basis (1 ml/gm), 
they then were mechanically homogenized. Serial dilutions of 1:10 and 1:100 were 
accomplished in THIO and each dilution was poured in a nutrient media of blood agar. 
After incubation for 18 to 24 hours, the level of bacterial growth (bacterial load) was 
identified by colony counting (Sasaki and Koss, 1978). Bacterial identification was 
accomplished by routine culturing techniques on selective media such as chocolate agar 
(CHOC), MacConkey agar, fastidious anaerobic agar (FAA) and Kligler Iron Agar 
(KIA) in addition to various biochemical tests specific for each bacterial species (e.g. 
DNAse test for S. aureus; Optochin test, Bile Solubility test, and Bacitracin tests for 
Streptococcus spp.; Indole, Citrate, Malonate utilization, Urease, Oxidase, Methyl Red 
(MR) and Voges-Proskauer (VP) tests for Enterobacteriacea Gram-Negative Bacilli 
(GNB); and XV factor test for Haemophilus spp.).      
 
 
3.10 Antimicrobial Susceptibility via Disk Diffusion Test  
 The most common method of antibiotic susceptibility testing used in clinical 
laboratories is the disk diffusion method (Pierce-Hendry and Dennis, 2010). The test 
was blindly assessed by the technicians at Clinical Diagnostic Laboratories, UMMC 
according to the protocols described previously (Clinical and Laboratory Standards 
Institute, CLSI, 2009b). Briefly, a fixed volume of nutrient broth containing a standard 
concentration of bacteria was smeared evenly onto the surface of Mueller-Hinton agar 
plate (MHA) and disks of filter paper each impregnated with a standard concentration of 
an antibiotic were applied to the plate surface followed by aerobic incubation. Each 
antibiotic diffuses at a different rate, achieving different concentrations in the 
surrounding agar based on its molecular size and chemical properties (Clinical and 
Laboratory Standards Institute, CLSI, 2009b).      
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 The zones of inhibition were measured in millimetres and the edge of these 
zones correlated with the antibiotic concentration that inhibits the growth of the bacteria 
were compared to a standard table of pre-determined zone widths. These widths 
represent the  antibiotic concentrations in the agar that correlate with the concentration 
of antibiotic achievable in the plasma of a patient using a manufacture’s recommended 
dosage (Clinical and Laboratory Standards Institute, CLSI, 2009a). Based on the 
diameter of the inhibition zone and the CLSI interpretative criteria, the results were 
assigned to three categories, susceptible, intermediate, or resistant (Clinical and 
Laboratory Standards Institute, CLSI, 2009b). The raw data for all isolates was obtained 
for further analysis. 
 
 
3.11 Microscopic Detection of Biofilm Presence 
3.11.1 Scanning Electron Microscopy (SEM) 
The protocol for visualizing biofilms in tonsillar tissue specimens using SEM 
was described previously (Kania et al., 2007). Tonsillar biopsies were fixed in a cold 
4% Glutaraldehyde in 0.2 M sodium cacodylate buffer (pH 7.4) for 24 h at 4°C on a 
rotary shaker. The samples were then dehydrated through a graded series of acetone 
solutions (70%, 80%, 90%, 96%, and 100% acetone) for 20 min at room temperature, 
and critical point drying was performed. The specimens were then orientated, mounted 
on metal stubs, and sputter coated with gold (Polaron 5000; Polaron Equipment Ltd, 
Watford, Hertfordshire, England) before imaging. Specimens were examined using 
SEM (INCA x-sight, Oxford instruments, United Kingdom) with digital imaging 
capabilities available at the electron microscope unit at the Faculty of Medicine, 
University of Malaya. The images were collected at an acceleration voltage of 
approximately 5.0 kV, a filament current of approximately 10−10A, and a working 
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distance of approximately 39 mm. All images were digitized as high resolution TIFF 
computer files and were then converted to high-quality JPEG files using commercially 
available software (Kania et al., 2007). 
 
3.11.2 Confocal Laser Scanning Microscopy (CLSM) 
The processing of tonsillar tissue specimens for the purpose of visualizing 
biofilms via CLSM was done as described previously (Kania et al., 2007). To preserve 
the biofilm architecture, tonsillar biopsies were embedded in an optimum cutting 
temperature medium (OCT) and were immediately snap-frozen in a mixture of cold 
isopenthane and liquid nitrogen and stored at –80oC. The frozen tissue specimens were 
cut into a thickness of 10 μm at –24°C using a cryostat (Leica Microsystems, Bensheim, 
Germany) and were fixed in 70% cold acetone for 10 min. The obtained sections were 
then processed for double staining for which they were washed 3 times with phosphate-
buffered saline (PBS) solution and each slide was first stained with 500 μl Propidium 
iodide for 5 min at room temperature to detect the bacterial cells in red, followed by 
staining with 500 μl of Concanavalin A (Con A) fluorescent isothiocyanate (FITC) for 5 
min at room temperature to detect the surrounding glycocalyx matrix in green.   
Sections were then washed in a combined solution of phosphate-buffered saline 
(PBS) and de-mineralized water and were embedded in a mounting medium of 
PBS/Glycerol mix treated with p-phenylenediamine as an anti-quenching agent. The 
tissue sections were examined using CLM (LSM 700. Carl Zeiss, Germany) available at 
Universiti Putra Malaysia (UPM). The microscope was equipped with a krypton-argon 
laser for visualization of Con A FITC (number of signals acquired, 488 nm; emission 
552 disconnecting filter [DF], 32 nm) and Propidium iodide (number of signals 
acquired, 568 nm; emission 605 DF, 32 nm) (Kania et al., 2007). Digital images of the 
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CLSM optical sections were collected using the ZEN 2010 software then converted to 
high-quality JPEG files using commercially available software.  
 
 
3.12 Biofilm Formation Ability  
3.12.1 Quantitative Detection via MTP Assay  
To test the biofilm formation ability of clinical isolates, we used a quantitative 
adherence assay as previously described (Baldassarri et al., 2001; Baldassarri et al., 
2006). Briefly, a 1:10 dilution of overnight cultures in Tryptic Soy Broth (TSB) was 
used to inoculate wells in a 96-well microtiter polystyrene plate. After growth at 37°C 
for 18 h, plates were gently washed three times with PBS to remove free-floating 
bacteria. Bacterial attachment on the bottom of each well was fixed with sodium acetate 
(2%) followed by air drying at 60°C for 1 h before staining with 125 µl of (0.1% w/v) 
Hucker’s crystal violet solution 10 min at room temperature. Excess stain was rinsed off 
by thorough washing with deionized water and plates were kept for drying. The optical 
density (OD) of stained adherent bacteria was determined with an automatic 
spectrophotometer (Novapath microplate reader; Bio-Rad Laboratories, Inc., CA) at 
wavelength of 570 nm (OD570). These OD values were considered as an index of 
bacteria adhering to a surface and forming a biofilm (Snoussi et al., 2008).   
To compensate for possible differences in growth rates under the different 
incubation conditions and for strains with different characteristics, the adherence index 
(AI) was adjusted as an estimate of the density of biofilm which would be generated by 
a culture with an (OD600) of 0.5. Experiment was performed in triplicate and the data 
was then averaged and standard deviation was calculated. Calculation of the A was done 
according to the following formula:  
Adherence Index = mean density of biofilm (OD570) × 0.5/mean growth (OD600).   
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3.12.2 Qualitative Detection via CRA Method 
The ability of tonsillar clinical isolates to produce slime and therefore form 
biofilms was detected qualitatively by CRA method as described by the original method 
developed previously (Freeman et al., 1989). The media was prepared by adding 0.8 g 
of Congo red stain and 36 g of saccharose into 1000 ml of BHI agar. The Congo red 
stain was prepared as a concentrated aqueous solution and autoclaved separately at 
121°C for 15 min then added when the agar had cooled to 55°C. Clinical isolates were 
cultured on CRA plates and incubated for 24-48 h at 37°C (Snoussi et al., 2008) 
followed by 2 days at room temperature (Deighton et al., 1992). The Congo red dye will 
directly interact with certain polysaccharides, forming colored complexes (Jain and 
Agarwal, 2009).    
For an accurate assessment of all the possible chromatic variations exhibited by 
the cultured colonies, a reference eight-color scale was adopted to accurately determine 
all the chromatic variations exhibited by the cultured bacterial colonies. The scale 
ranged from very black to very red and the colorimetric reference scale to evaluate the 
chromatic variations exhibited by the cultured bacterial colonies based on their ability to 
form slime is shown (Table 3.3). Biofilm forming strains were categorized as: very 
black, black and almost black colonies and were all considered as slime producers, 
whereas non-biofilm forming strains were categorized as: very red, red and bordeaux 
colored colonies.  
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Table 3.3 Colorimetric reference scale of bacterial colonies on Congo Red Agar 
 
 
a (Arciola et al., 2002); b (Oliveira and Cunha Mde, 2010); c (Snoussi et al., 2008); d (Deighton et al., 1992); * Pinkish Red (PR) 
colonies usually appear smooth with a darkening at the center.  
 
 
 
3.13 Preparation of Soil Bacterial Strain 139SI 
3.13.1 Gram Staining and Morphology Confirmation  
 The most fundamental phenotypic characterization of bacteria is achieved by 
using Gram stain. A smear of soil bacterial culture was prepared from an overnight 
culture of Paenibacillus haemolyticus strain 139SI grown in an enriched media of BHI 
broth (BD laboratories). A suspension of strain 139SI was smeared onto a clean glass 
slide then fixed with heat and stained according to the procedure of Hucker’s 
modification. 
 Culturing bacteria on blood agar is often considered as a preliminary screening 
method for the ability of those microorganisms to produce biosurfactants on hydrophilic 
media (Plaza et al., 2006; Schulz et al., 1991). Therefore, the bacterial culture was 
streaked onto Colombia agar supplemented with 5% sheep blood (ISOLAC®, ISOLAB 
Malaysia) and plates were incubated for 16–24 h at 37◦C to ensure of its haemolytic 
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reproducibility. Strong haemolytic (β-hemolysis) colonies obtained from the plates were 
further observed for colony and cellular morphology, and Gram staining confirmation. 
The 139SI strains was routinely subcultured and maintained in a glycerol suspension 
(25%, w/v) at −80◦C and BHI-slant agar at room temperature. 
The cellular morphology of strain 139SI was observed under scanning electron 
microscopy using an overnight culture of strains SI grown in BHI broth. To prepare the 
sample for scanning electron microscope, 1 ml of pure bacterial culture was transferred 
into a sterile filter paper (1 ×1 cm) and air dried for 10 min. The sample was rinsed in 
0.1 M phosphate buffer, followed by fixation in 2.5% glutaraldehyde in 0.1 M 
phosphate buffer at room temperature for 4 h. The cells were dehydrated by using series 
of ethanol concentrations: 30%, 50%, 70%, 85%, 95% and 100%, and then two times 
with 100% acetone. Critical point drying was done by Hitachi HCP-2 critical point 
dryer. The samples were then mounted on specimen stubs and sputter-coated with gold. 
The samples were observed by Zeiss DSM 950 scanning electron microscopy at 15 kV 
(Ko et al., 2007).  
 
3.13.2 Bacterial Culture Filtrate of Strain 139SI  
In order to identify and analyze the properties of the isolate, preparation of a 
pure culture is essential and required (Bodour et al., 2003). This is achieved by using an 
enrichment media that can provide favorable growth conditions for the organisms of 
interest (Bento et al., 2005; Sen, 2010; Willumsen and Karlson, 1997). Therefore, an 
overnight culture of strain 139SI was transferred into 50 ml centrifuge tube under sterile 
conductions and the culture was centrifuged at 8000 rpm at 4
◦
C for 20 min to separate 
the cell from the supernatant. The obtained supernatant was subjected to sterile filtration 
to which is considered the optimal method to remove all particles and dead 
microorganisms without any influence of their ingredients, therefore we used syringe 
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filter with a pore size of 0.22 μm for that purpose (Minisart® SARTORIUS, Germany) 
to yield a purified cell-free supernatant (CFS) to be assayed later for its antibiofilm 
activity. 
 
Figure 3.1 Preparation of bacterial culture filtrate from strain 139SI. 
 
  
3.14 In vitro Antibiofilm Activity of 139SI Culture Filtrate 
3.14.1 Determination of Biofilm Inhibition via MTP Assay  
 To determine the effect of the soil bacterial filtrate against the biofilm forming 
tonsillar isolates, MTP assay was performed as described previously by Baldassari et al. 
(2006) and Nithya, et al. (2010b) with few modifications as described by Kalishwaralal 
et al. (2010). Briefly, in each well of the 96-well microtitter plate, we transferred 180 µl 
of sterile BHI broth and inoculated it with 150 µl overnight culture of selected bacterial 
isolates followed by addition of 150 µl of soil bacterial culture filtrate with various 
concentrations (1000-4500 µg/ml). Plates were incubated and wells were stained 
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followed by measurement of the optical densities (Baldassarri et al., 2006; 
Kalishwaralal et al., 2010).  
 The selected Gram-positive isolates were Staphylococcus aureus, Streptococcus 
agalactiae, Group G Streptococci, Streptococcus pyogenes and Streptococcus 
pneumoniae whereas Gram-negative isolates were Haemophilus influenza, 
Haemophilus parainfluenzae, Klebsiella pneumoniae, Citrobacter sp. and Pseudomonas 
aeruginosa. A schematic representation of MTP assay is illustrated showing the 
concentrations used against selected clinical isolates (Figure 3.2). 
 
 
Figure 3.2 MPT assay of 139SI filtrate against selected clinical isolates. 
 
3.14.2 Determination of Biofilm Inhibitory Concentration   
In order to determine the lowest concentration of soil bacterial filtrate that can 
cause visible inhibition in the biofilm formation and significant reduction in the 
readings when compared with the control wells, the Biofilm Inhibitory Concentration  
(BIC) test was performed as described previously (Baldassarri et al., 2006; Nithya et al., 
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2010b) with few modifications as described by Kalishwaralal et al. (2010).  The 
tonsillar bacterial isolate that was selected for the BIC test was a resistant Pseudomonas 
aeruginosa isolate recovered from one of our selected patients diagnosed with chronic 
tonsillitis, this isolate will be used later as the challenge strain to establish the animal 
model of chronic lung infection.  
In each well, a piece of glass cover slip (1 ×1 cm) was placed inside each of the 
6 wells to allow the growth and visualization of the filtrate effect on the tested bacterial 
isolate. We transferred 300 µl of sterile BHI broth into each well of the MTP and 
inoculated it with 160 µl overnight culture of P. aeruginosa followed by addition of 
160ml of various concentrations of soil bacterial filtrate (1000-5000 µg/ml). Plates were 
incubated for 24 h at 37
o
C and the biofilm inhibition was determined 
spectrophotometrically via MTP reader and microscopically via SEM (Baldassarri et 
al., 2006; Nithya et al., 2010a). The positive control used was synthetic 2(5H)-Furanone 
and the negative control was BHI broth media. 
 
 
3.15 Microscopic Observation of Biofilm Inhibition 
3.15.1 Light Microscopy (LM) 
  For visualization of the inhibitory effect of soil bacterial culture effect on 
Pseudomonas aeruginosa biofilms, light microscopy was used to visualize the glass 
pieces (1×1 cm) placed inside the 6-well plates that were treated with our filtrate as 
described previously (Nithya et al., 2010b). After rinsing the free floating culture, the 
glass pieces were stained with crystal violet and were inspected by light microscopy at 
magnification of 10×, 40× and 100×. Visible biofilms were documented with an 
attached digital camera (Nikon, Eclipse, Ti 100). 
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3.15.2 Scanning Electron Microscopy (SEM) 
For visualization of the inhibitory effect of soil bacterial culture effect on P. 
aeruginosa biofilms, scanning electron microscope was used to visualize the bottom of 
each of the 6-wells that were holding the same glass pieces described previously (1×1 
cm) (Nithya et al., 2010b). The bottom of the wells were cut and separated from the 
MTP then were first fixed with 0.1 M cacodylate-buffered 2.5% glutaraldehyde 
containing 0.075% (w/v) ruthenium red and 75 mM lysine for 20 min at room 
temperature. This step was followed by fixation with the same solution but without 
lysine for 2 h and finally fixed with 1% OsO4 plus ruthenium red for an additional hour. 
Samples were dehydrated through a graded series of ethanol. Critical point drying and 
gold coating was performed then examination by SEM (INCA x-sight, Oxford 
instruments) (Baldassarri et al., 2001; Nithya et al., 2010a).  
 
 
3.16 Acute Toxicity Test of 139SI Culture Filtrate 
The novel isolate of Paenibacillus species strain 139SI has been tested 
previously in our laboratory via LD50 test to determine its virulence in experimental 
mice. It was found that none of the mice were affected by the bacterial strain, therefore 
it was used as a non-virulent control strain (Mahsa, 2013). In order to determine the 
safety (non-toxic) dosage of 139SI culture filtrate, acute toxicity test was carried out.  
A total number of 36 Sprague Dawley (SD) rats (18 males and 18 females) were 
used for the acute toxicity test for which all surviving experimental and control group 
animals were sacrificed on day 15 for evaluation of the gross general observations, 
haematological profiles, biochemical parameters of blood and histopathology of liver, 
kidney and lungs (Akhand et al., 2010). The soil bacterial culture filtrate was converted 
into powder by freeze-drying (lyophilizaton) and normal saline was used as a solvent 
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for the lyophilized extract. The control group was used to determine whether the normal 
saline causes any effects when compared with the untreated control (Johnson and 
Besselsen, 2002). However, the acute toxicity group was used to determine the rational 
treatment of the toxicity manifestations of new compounds and for the development of 
safer potential drugs (Al-Bari et al., 2006). Two main doses were decided in the test 
represented by a low dose (2 gm/kg) equivalent to (0.36 gm/180 gm of body weight) 
and a high does (4 gm/kg) equivalent to (0.72 gm/180 gm of body weight). Evaluation 
of the toxicological effect for the two doses was carried out. The flow chart of acute 
toxicity test of our soil bacterial culture filtrate is illustrated (Figure 3.3).  
 
3.16.1 Gross General Observation 
Throughout the course of experiment, monitoring of animals before and after the 
administration of soil bacterial filtrate was carried out by observing for signs of toxicity, 
morbidity and mortality in addition to the behavioural signs such as food intake, 
salivation, muscular weakness, reflexes, piloerection, respiration (dyspnea), convulsion 
and any changes in locomotion such as whether the animals tend to stay quietly or 
actively moving in their cage as described previously (Akhand et al., 2010). The body 
weight of each rat of both groups was taken before the administration of the soil 
bacterial culture filtrate and just prior to sacrifice them. 
 
3.16.2 Biochemical Parameters and Haematological Profile 
 The animals were fasted overnight prior to necropsy and blood collection and 
were anasethized with an intra-muscular (IM) combination of Ketamine and Xylazine (1 
ml of 100 mg/ml Xylazine with 9 ml of 100 mg/ml Ketamine) given at a dose of (0.1 
ml/100g) body weight. Blood was drawn from the jugular vein under anesthesia and 
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samples were collected and immediately send to the CDL at UMMC to be assayed for 
haematological profile and biochemical parameters (Akhand et al., 2010).     
 For biochemical parameters of serum, blood was collected into yellow caped 
VACUETTE
®
 clot activator tube and renal function tests were assessed including 
sodium, potassium chloride, carbon dioxide, anion gap, urea and creatinine. In addition 
to liver function tests including total protein, albumin, globulin, total bilirubin, 
conjugated bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline 
phosphatase and G-glutamyltransferase. For haematological profile of whole blood, it 
was collected into violet caped VACUETTE® EDTA tubes and the total count (TC) of 
RBC and WBC, differential count (DC) of WBC and platelet count were assessed.   
 
3.16.3 Gross Necropsy and Histopathology  
 All surviving animals were anesthetized intra-muscularly by a combination of 
Ketamine and Xylazine and quick sacrificing was performed by exsanguinations of 
jugular vein for blood sample collection. Gross postmortem examinations are performed 
on all terminated animals as described previously (Akhand et al., 2010). After sacrifice, 
the thoracic cavity was opened by an excision through the peritoneum that was extended 
through the sternum and into the neck taking care not to puncture the heart or lungs. The 
rib cage was fully opened and the liver, kidney, and spleen were harvested then fixed 
with 10% neutral buffered formalin (NBF) for 1 day then sliced into pieces and fixed 
again with NBF for 2 days. Fixed tissues were then processed then stained with H&E 
stain and mounted on glass slides with diphenyl xylene (DPX) and observed under light 
microscope.    
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Figure 3.3 Flow chart of acute toxicity test of 139SI bacterial culture filtrate. 
  
 
3.17 In vivo Antibiofilm Activity of 139SI Culture Filtrate 
3.17.1 Preparation of the Infecting (Challenge) Strain  
The challenge strain to establish a chronic lung infection was the multidrug 
resistant strain of Pseudomonas aeruginosa (ampicillin, ampicillin-sulbactam, 
amoxicillin-clavulanic acid, gentamicin and amikacin). This strain was isolated from 
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tonsillar biopsy specimen of a patient diagnosed with chronic tonsillitis. The isolate was 
embedded in an artificial alginate salt to mimic the condition of a biofilm chronic 
infection in the lung. Immobilization of the challenge strain was carried out as described 
previously (Pedersen et al., 1990). The strain was incubated in 100 ml BHI broth for 24 
hours at 37
o
C and the culture was adjusted to yield 10
9 
CFU/ml followed by a 
modification whereby 1 ml of final culture were mixed with 9 ml of 1% sterile sodium 
alginate (Yan et al., 2008). The purpose of adding alginate is to mimic the biofilm 
environment once it is inoculated into the lungs. The suspension was stored in a 
refrigerator at 4
o
C until being used via intratracheal challenge to establish the animal 
model of chronic lung infection.  
 
3.17.2 Establishment of Animal Model of Chronic Lung Infection  
The duration of chronic lung infection model was 14 days and all groups except 
for the negative control were subjected to intratracheal challenge with 1 ml of challenge 
P. aeruginosa strain at day 1 and 3 (Yan et al., 2008). The model comprised of the 
following groups: The first group represents the negative control where no changes 
from the normal state are expected to ensure that an unknown variable is not adversely 
affecting the animals in the experiment, which might result in a false-positive 
conclusion (Johnson and Besselsen, 2002). The second group represents the positive 
control that acts as a standard against which to measure difference in severity among 
experimental groups. It is expected to produce changes and to demonstrate that a 
response can be detected, thereby providing a quality control on the experimental 
groups (Johnson and Besselsen, 2002). The third group is the comparative control 
which is often a positive control with a known treatment that is used for a direct 
comparison to a different treatment (Johnson and Besselsen, 2002). 
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The fourth group was the experimental test group in which treatment effects of 
our soil bacterial culture filtrate were evaluated through the gross and histopathological 
observations of harvested lungs. This group was subjected to an oral administration with 
our soil bacterial culture filtrate at the same concentration, i.e. 4500 µg/ml, which 
showed in vitro activity via BIC test. The treatment was applied daily for each rat at a 
low dose of 30 mg/kg from day 1 until the sacrifice on day 15. Experimental design of 
the animal model of chronic lung infection is illustrated (Figure 3.3). 
 
3.17.3 Lung Index of Macroscopic Pathology   
The qualitative analysis of macroscopic lung pathology included abscess, 
consolidation, atelectasis and hemorrhage was expressed as the Lung Index of 
Macroscopic Pathology (LIMP), which was calculated by dividing the area of the left 
lung showing pathologic changes by the total area of the same lung (Song et al., 1998). 
In addition, the gross pathological changes in the lungs were also assigned four different 
scores according to the severity of the inflammation previously described (Johansen et 
al., 1994; Johansen et al., 1993). The scores were I. Normal lungs; II. Swollen lungs, 
hyperemia, and small atelectasis (<10 mm
2
); III. pleural adhesions and atelectasis (<40 
mm
2
); and IV, abscesses, large atelectasis, and hemorrhages (Yan et al., 2008).  
 
3.17.4 Histopathology Scoring of the Lungs 
The lung pathology was assigned microscopically as described previously (Yan 
et al., 2008). One of four scores according to the severity of the inflammation were set 
to assess the histopathological effects. These include the following scores:  
1. Normal histology. 
2. Mild focal inflammation. 
3. Moderate to severe focal inflammation with areas of normal lung tissue. 
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4. Severe inflammation to necrosis or severe inflammation throughout the lung.  
The cellular alterations were classified as acute or chronic inflammation by a 
scoring system based on the proportions of neutrophils (PMNs) and mononuclear 
leukocytes (MNs) in the inflammatory foci. Acute inflammation was defined as an 
inflammatory infiltration in which PMNs were predominant (≥90% PMNs with ≤0% 
MNs), whereas chronic inflammation was defined as a preponderance of MNs (≥90% 
with ≤10% PMNs), which included lymphocytes and plasma cells, and the presence of 
granulomas (Johansen et al., 1994; Song et al., 1998). The lung tissue with pathological 
changes were fixed, embedded in paraffin wax and sectioned prior to staining with both 
H&E stain and double stain to evaluate the severity of microscopic pathology by light 
microscopy and CLSM, respectively (Wu et al., 2004). In order to confirm the cellular 
morphology of the infecting Pseudomonas aeruginosa isolate embedded in alginate 
within the infected alveoli, lung specimens were processed for SEM as described in 
session 3.11.1 and colony morphology on Nutrient Agar.   
 
3.17.5 Statistical Analysis  
In the experimental animal study, statistical analysis was carried out using the 
Statistical Product and Service Solutions software (IBM SPSS statistics 20). Categorical 
data were compared by the χ2 test, while unpaired differences in continuous data were 
compared by both the Mann-Whitney U test and the analysis of variance (ANOVA) 
test. All values were reported as Standard Error Mean (S.E.M ±) and a probability value 
of p < 0.05 was considered to be statistically significant.  
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Table 3.4 Experimental design of animal model of chronic lung infection. 
 
a Intratracheal challenge was performed with 0.1 ml of P. aeruginosa 109 CFU/ml on day 1. 
b Duration of oral administration was daily for 14 days.   
 
 
 
3.18 Characterization of 139SI Active Compounds via HPLC 
The soil bacterial filtrate that exhibited in vitro antibiofilm activity was further 
identified by High Performance Liquid Chromatography (HPLC) which was blindly 
performed by the technical staff at the laboratories of Cancer Research Initiatives 
Foundation (CARIF). The active filtrate was processed for sterile filtration then 
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converted into powder by lyophilisation by dissolving 60 mg of crude extract in 5 ml of 
water in volumetric flask. Solution was then filtered by using SRP-4 membrane 0.45µm. 
Stock solution (12,000 ppm) was kept in fridge 4°C before it was injected into HPLC 
column (Agilent Zorbax XDB-C18 ,4.6 x 250 mm, 5.0 μm) at 100 μl injection volume 
with a flow rate of  1.2 ml/min. The standard solvent system used was Acetonitrile and 
Water (Ammonium formate 0.005M) at a pH of 3.55. Furthermore, the spectrum range 
was 200-500 nm with UV absorption of 200, 230, 254 and 320 nm and a data 
acquisition time of 0-32 min yielding a total of 32 fractions (compounds) were tested 
separately for their antibiofilm activity in vitro.    
 
 
3.19 Antibiofilm Activity of 139SI Active Compounds via MTP   
 To determine the antibiofilm activity of compounds obtained from the HPLC 
profiling of crude 139SI filtrate against biofilm-forming pathogens, MTP assay was 
performed as described in session 3.14.1 (Baldassarri et al., 2006; Nithya et al., 2010b). 
The selected concentration for each compound to be tested was the BIC (4500 µg/ml). 
Experiment was performed in triplicate and data was then averaged and standard 
deviation was calculated.  
 
 
3.20 Identification of 139SI Active Compounds via LC-MS  
Once the active fraction from HPLC was confirmed for its antibiofilm activity via 
MTP assay, further analysis was carried out to identify the chemical structure via Ultra 
Performance Liquid Chromatography-Diode Array Detection (UPLC–DAD) and Liquid 
Chromatography-Mass Spectrometry (LC-MS) which was blindly performed by the 
technical staff at the laboratories of CARIF. An Acquity UPLC system (Waters, Milford, 
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MA), equipped with a photo Diode Array Detection (DAD) detector was used for analysis 
and quantification under UPLC conditions.   
Data were processed with Empower 2 software (Waters). The Ultra Performance 
Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (UPLC–ESI-MS) 
peak identification was performed using the described UPLC system coupled with a LCQ 
DECA plus mass spectrometer equipped with an electrospray interface (Thermo-Finnigan 
Corp., San Jose., CA., USA). Instrument control and data acquisition were performed using 
Xcalibur 2.0 software. The quantification of UPLC–DAD was performed on a reversed-
phase column Acquity UPLC BEH C-18 (2.1 × 50 mm) with 1.7 μm spherical porous 
particles. A linear gradient elution of A (Water + 0.1% Formic acid) and B (Acetonitrile 
+ 0.1% Formic acid) was performed as follows: 0 min, 95% A, 5% B; 1 min, 85% A, 
15% B; 2 min 45% A, 55% B; 5 min, 95% A,5% B; v/v. The flow rate was 0.5 ml/min. 
Column temperature was set at 30°C. Injected volume was 5 μl (Chen et al., 2010). 
The diode array UV–vis detector (DAD) was used for the detection and the 
wavelength for quantification was set at 277 nm. UPLC–ESI-MS analysis was operated 
in positive ESI modes. The electrospray needle voltage was 4 kV, and the capillary 
temperature was 250°C. Typical background source pressure was 1.2 × 10−5 Torr as 
read by an ion gauge. The drying gas was nitrogen. Following ion trapping, ions were 
mass analyzed and detected in the electron multiplier at 880 V by time-of-flight (TOF). 
The LCQ mass analyzer was scanned to 2000 m/z in positive mode to confirm peak 
identity by observation of the corresponding ionized molecule ([M+H]+). Collision gas 
for MS–MS experiment is He. Normalized collision energy was 32.5% (Chen et al., 
2010).  
 
86 
 
4CHAPTER FOUR 
RESULTS 
            
4.1 Prevalence of Tonsillar Diseases  
The prevalence of tonsillar diseases among our selected patients varied and 
based on the clinical examination obtained prior to surgery, the clinical cases were 
classified into two main groups, and these include infection group and non-infection 
(obstruction) group. Infection group comprised of recurrent tonsillitis (RT) and chronic 
tonsillitis (CT) cases whereas obstruction group comprised of obstructive sleep apnea 
(OSA) cases. Our results showed that RT was the predominant clinical case showing the 
highest number with 49 (70%) patients followed by CT with 9 (12.85%) patients and 
OSA with 12 (17.14%) patients.         
Among the RT cases, there were 39 (55.71%) patients with Recurrent Tonsillitis, 
4 (5.71%) patients with Recurrent Tonsillitis with Bilateral Middle Ear Effusion (MEE), 
4 (5.71%) patients with Recurrent Tonsillitis with Snoring and 2 (2.85%) patients with 
Recurrent Adenotonsillitis. Whereas among the CT cases, there was 7 (10%) patients 
with Chronic Tonsillitis, 1 (1.42%) patient with Chronic Tonsillitis with Snoring and 1 
(1.42%) with patient Chronic Adenotonsillitis. Among the OSA cases, there were 3 
(4.28%) patients with Obstructive Sleep apnea, 3 (4.28%) patients with OSA Secondary 
to Tonsillar Hypertrophy, 3 (4.28%) patients with OSA Secondary to Recurrent 
Tonsillitis, 1 (1.42%) patient with OSA Secondary to Adenoid Hyperplasia, 1 (1.42%) 
patient with OSA with Primary Snoring (PS) and 1 (1.42%) patient with OSA 
Secondary to Recurrent Acute Tonsillitis.       
The prevalence of RT cases among the pediatric patients was 22 (31.42%) cases 
while in adult patients was 29 (41.42%) cases whereas the prevalence of CT cases 
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among pediatrics was 4 (5.71%) cases while in adults it was 5 (7.14%) cases. However, 
the prevalence of OSA cases among pediatrics was 9 (12.85%) cases while in adults 
was 3 (4.28%) cases. In the RT cases, it was noticed that the highest number of age 
group was 1.0-10 years old with 18 (25.71%) patients followed by 11.2-20 years old 
with 16 (22.85%) patients and 21-30 years old with 14 (20%) whereas the age group 31-
40 years old was among the lowest with 3 (4.28%) patients along with the age group 41-
50 years old with only 1 (1.42%) patient.  
In the CT cases, it was noticed that the highest number of age group was 11.0-20 
with 5 (7.14%) patients followed by the age group 1.0-10 years old with 3 (4.28%) 
patients and only 1 (1.42%) patient was within the age 21-30 years old. Whereas no 
patients were in the 31-40, 41-50 and 51-60 age groups. In the OSA cases, it was 
noticed that the predominant age group was 1.0-10 with 7 (10%) patients followed by 
the age group 11.0-20 years old with 2 (2.85%) patients whereas no patients fell in the 
rest of age groups.  
The distribution of patients among clinical cases based on their age groups is 
illustrated in (Figure 4.1). In terms of frequency and type of operative procedures 
performed on 70 clinical cases, 44 (62.85%) patients underwent tonsillectomy alone 
while 26 (37.14%) underwent Tonsillectomy & Adeonoidectomy (T&A). The detailed 
list of all clinical cases, type and date of operation can be found in (Appendix 8).     
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Figure 4.1 Distribution of patients among clinical cases based on age groups. 
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4.2  Histopathology of Tonsillar Specimens  
 Based on the gross pathology of collected tonsillar biopsies, our results showed 
that all patients had enlarged tonsils with various grading and an association with 
adenoids hypertrophy was detected in 26 (37.14%) patients. Patients presenting 
enlarged (hypertrophied) tonsils were classified into 4 groups according to size: grade I 
(1+) with 6 (8.57%) patients; grade II (2+) with 20 (28.57%) patients; grade III (3+) 
with 39 (55.71%) patients and grade IV (4+) with 5 (7.15%) patients.  
Based on the anatomic pathology report performed by the Department of 
Pathology, Faculty of Medicine, University of Malaya, the macroscopy (gross biopsy) 
evaluation of all the 140 tonsils described the specimens as nodular to tubular irregular 
brownish & soft surface tissue with an average measuring size of 2cm x 2cm x 1cm. 
However, the microscopy (histology section) evaluation described the tonsillar 
lymphoid tissue as being covered with benign stratified squamous epithelium with the 
stroma consisting of variably sized reactive lymphoid follicles where no cases of 
malignancies being found, a rate of crypt keratination was also reported.  
The overall pathological interpretation for the excised tonsils was stated as 
reactive (benign) lymphoid hyperplasia. The histopathology evaluation showed 
evidence of infection with Actinomyces sp. among 11 (15.71%) of our selected patients. 
These infections caused and an inflammatory lesion of the tonsillar crypts and led to 
tonsillar hypertrophy. However, it was noticed that there was no description for other 
microbial infections such biofilms. The gross pathology of excised palatine tonsils 
representing the 4 tonsillar grading is shown in (Figure 4.2).   
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Figure 4.2 Gross pathology of tonsils showing four tonsillar hypertrophy grading. A, 
grade I (+1) patient with recurrent tonsillitis. B, grade II (+2) patient with 
chronic tonsillitis. C, grade III (+3) patient with obstructive sleep apnea. 
D, grade IV (+4) patient with OSA secondary to tonsillar hypertrophy.   
 
 
4.3  Bacterial Isolates from Tonsillar Specimens    
 Based on our results, a total number of 464 bacterial isolates (302 Gram-positive 
and 162 Gram-negative) were recovered from all the tonsillar specimens. The most 
common isolate was Staphylococcus aureus (39.65%) followed by Haemophilus 
influenzae (18.53%) then Streptococcus agalactiae (12.06%). Differences in 
distribution between the surface (swab) and core (biopsy) were apparent at the species 
or group level. The number of recovered bacterial isolates from surface sites was 239 
(51.50%) in comparison with 225 (48.49%) isolates from core sites indicating no 
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significance in the recovery when considering the total number of isolates per site. All 
isolates usually were found to be present similarly at both sites of the tonsils except for 
Haemophilus parainfluenzae where it was most frequently isolated from core specimens 
10 (2.15%) more than the surface 21 (4.52%). Distribution of bacterial isolates among 
tonsillar specimens is shown (Table 4.1) and (Figure 4.3). 
 
 
Table 4.1 Distribution of bacterial isolates among tonsillar specimens. 
 
1 
Pyogenic streptococci group (Lancefield groups) / - hemolytic Streptococci,  
2 Pneumococci group / α- hemolytic Streptococci, 
3 
Viridans Group Streptococci (VGS) / Group F Streptococci (GFS), 
4
 Enterobacteriacea    
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Figure 4.3 Distribution of bacterial isolates among tonsillar specimens.  
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The weight of excised tonsils varied from 2.2 to 8.1 grams. However, there was 
no correlation between tonsillar weight (size) and the number or type of isolated 
microorganisms. However, there was a difference in the recovery rate of 
microorganisms among RT, CT and OSA cases where RT showed an average of 10.85 
isolates/gram tonsil while CT showed and average of 3.75 isolates/gram tonsil and OSA 
showed an average of 3 isolates/gram tonsil.  
The low recovered isolates varied in their distribution among clinical cases, for 
example Haemophilus parainfluenzae (HP) was present in 25 (5.38 %) RT cases 
followed by 3 (0.64%) CT cases then 2 (0.43%) OSA cases. Group G Streptococci 
(GGS) were present only in 18 (3.87 %) RT cases while absent in CT and OSA. Group 
G Streptococci (GCS) were present equally 4 (0.86 %) in both RT and OSA while 
absent in CT. Streptococcus pneumoniae (SPn) was present equally 1 (0.21 %) in CT 
and OSA while absent in RT. Pseudomonas aeruginosa (PA) was present in 5 (1.07 %) 
RT cases and 4 (0.86 %) OSA cases while absent in CT. Citrobacter sp. was only 
present in 4 (0.86 %) RT cases while absent in CT and OSA. Enterobacter cloacaea, 
Acinetobacter baumannii and Methicillin Resistant S. aureus as there was only one 
isolate from each was only recovered from RT respectively. There was no assessment of 
anaerobes, fungi and viruses to support their role in our study. The distribution of 
Gram-positive and Gram-negative bacterial isolates among both tonsillar infection and 
obstruction groups is shown (Figure 4.4) and (Figure 4.5).  
A polymicrobial flora of mixed organisms were recovered from different clinical 
groups except for Group A Beta-Haemolytic Streptococci (GABHS) where all the 14 
isolates has been recovered only from the group of Recurrent Tonsillitis cases among 
pediatric and young adults patients. The recovery rate of Group A Beta-Haemolytic 
Streptococci (GABHS) did not vary with patients’ age and the isolation of non-GABHS 
was two times higher in adults than in children.    
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The mean age in Streptococcal Tonsillitis (ST) group was 10 years old while in 
the Non-Streptococcal Tonsillitis (NST) group it was 13.34 years. The prevalence of ST 
group was significantly less than NST group which emphasizes the role of group B, C, 
G and F in the clinical presentation of pahryngotonsillitis (PT) infections.     
 An interesting finding includes the recovery of a group of pathogens called 
ESKAPE which includes Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species. It was emphasized that these pathogens pause a threat causing the majority of 
US hospital infections and effectively “escape” the effects of antibacterial drugs 
(Boucher et al., 2009). 225 (48.46%) ESKAPE pathogens were recovered from both 
tonsillar swab and specimens with 184 isolates (39.65%) of Staphylococcus aureus, 30 
(6.46%) of Klebsiella pneumoniae, 9 (1.93%) of Pseudomonas aeruginosa and 1 
(0.21%) isolate of Acinetobacter baumannii and Enterobacter cloacae, while there was 
no recovery for Enterococcus faecium isolates.  
 The only significant bacterial pathogen in acute pahryngotonsillitis is 
Streptococcus pyogenes or GABHS (Hoffmann, 1987). However, only 14 (3.01 %) 
isolates were recovered among patients with only recurrent tonsillitis (RT), while there 
were no isolates recovered from both CT and OSA. Detailed table for the distribution 
and mean of recovered bacterial isolates from tonsillar specimens is described 
(Appendix 9). 
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Figure 4.4 Distribution of bacterial isolates among patients with chronic and recurrent tonsillitis. 
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Figure 4.5 Distribution of bacterial isolates among patients with obstruction sleep apnea.  
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4.4 Antimicrobial Susceptibility of Bacterial Isolates 
Among the 184 isolates of Staphylococcus aureus, 169 (91.48%) were 
susceptible to all the selected antibiotics, 20 (10.87%) were resistant to fusidic acid 
only, whereas 1 (0.5%) isolate (MRSA) was resistant to both methicillin and fusidic 
acid (Alasil et al., 2011) (Appendix 3A). There was no significance in the difference of 
susceptibility between swab and biopsy specimens among adults and children and 
among male and female patients.   
The antibiotic co-trimoxazole (SXT) (trimethoprim-sulfamethoxazole) has 
shown the highest rate of resistance against various bacterial isolates including GABHS 
showing 11 (2.37%) resistant isolates and 3 (0.64%) susceptible, Group B 
Streptococcus showing 55 (11.85%) resistant isolates and 1 (0.21%) susceptible, Group 
G Streptococcus showing 14 (3.01%) resistant isolates and 11 (2.37%) susceptible, 
Streptococcus pneumoniae showing 3 (0.64%) resistant isolates, Haemophilus 
influenzae showing 27 (5.81%) resistant isolates and 59 (12.71%) susceptible and 
Haemophilus pararinfluenzae showing 10 (2.15%) resistant isolates and 21 (4.52%) 
susceptible.    
The number of Haemophilus influenzae (HI) isolates that were β-Lactamase 
Negative Ampicillin-Resistant (BLNAR) was 12 (2.58%) isolates were. A resistance to 
the penicillins class was detected including Streptococcus pneumoniae with 3 (0.64%) 
isolates resistant to penicillin, Haemophilus influenzae with 12 (2.58%) isolates 
resistant to ampicillin, Klebsiella pneumoniae with 30 (6.46%) isolates resistant to 
ampicillin, Pseudomonas aeruginosa with 7 (1.50%) isolates resistant to ampicillin, 
Acinetobacter baumannii with 1 (0.21%) isolate resistant to ampicillin, Citrobacter sp. 
with 4 (0.86%) isolates resistant to ampicillin and Enterobacter cloacae with 1 (0.21%) 
isolate resistant to ampicillin.  
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There was no significance in the number of Beta-Lactamase-Producing Bacteria 
(BLPB) with a total number of 5 isolates including 1 isolate of Acinetobacter baumannii 
against the antibiotic cefotaxime (CTX), 3 isolates of Haemophilus influenzae and 1 
isolate of Haemophilus parainfluenzae. A low rate in the number of isolates among 
infected tonsils that were multidrug resistant (MDR) was 10 (2.15%), while the number 
of isolates among non-infected tonsils that were multidrug resistant was 7 (1.50%) with 
a total of 17 (3.66%). The MDR isolates were represented by 7 isolates of Multidrug 
Resistant Gram-Negative Bacilli (MDR-GNB) Pseudomonas aeruginosa, 3 isolates of 
MDR Streptococcus pneumoniae, 1 isolate of multidrug resistant (MDR) Enterobacter 
cloacae whereas no MDR isolates of Klebsiella pneumoniae Carbapenemase (KPC) 
were identified. Interestingly, there was an increased number of H. influenzae isolates in 
association with GABHS which may be due to a synergistic relationship between these 
organisms. A summary of antimicrobial susceptibility among all Gram-Positive and 
Gram-Negative isolates against selected β-lactam and non-β-lactam agents is shown 
(Table 4.2) and illustrated (Figure 4.6) and (Figure 4.7). Detailed tables for the 
antimicrobial susceptibility results and antibiogram patterns of tonsillar isolates is 
described (Appendixes 12A, 12B, 12C, 12D, 12E, 12F, 12G, 12H, 12I, 12J, 12K, 12L, 
12M, 12N, 12O).  
 
 
  
 
 
 
 
 
 
99 
 
Table 4.2 Summary table of antimicrobial susceptibility percentage among tonsillar isolates.  
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Gram-Positive                         
MRSA 
a
                100 100 100  100 100 100  
S. aureus           100     100  100 100 89.13 100 100  
S. agalactiae (GBS)
 
 100       100 100 100  100    100  1.78 98.21    100 
Group F Streptococci    100       100 100 100  100    100  100 100    100 
Group C Streptococci    100       100 100 100  100    100  100 100    100 
Group G Streptococci    100       100 100 100  100    100  44 100    100 
S. pyogenes (GABHS)
 
 100       100 100 100  100    100  21.43 100    100 
S. pneumoniae        100               100 
Gram-Negative                        
A. baumannii
 
   100 100 100 100  100  100   100 100   100 100   100   
Citrobacter sp.
 
 100 100 100 100 100 100 100 100  100   100 100   100 100   100   
E. cloacae 
 
   100 100 100 100 100 100  100   100 100   100 100   100   
H. influenzae
 
 86.04 98.83     100 100       100   68.60      
H. parainfluenzae
 
 93.55 100     100 100       100   67.75      
K. pneumoniae
 
  100 100 100 100 100 100 100  100   100 100   100 100   100   
P. aeruginosa
 
 22.22 22.22 22.22 100 100 100 100 100  100   100 22.22   100 100   22.2
2 
  
TOTAL MEAN (%) 77  84  84  100  100  100  100  100   100 100  100  100  100  84  100  100  100  73  99 94 88  100  100  
 
1Penicillins class, 2β-lactamase inhibitor combinations class, 3Cephems (parenteral) class, 4Cephems (oral) class, 5Penems class, 6Aminoglycosides class, 7Ansamycins class, 8Quinolones class, 9Folate pathway inhibitors 
class, 10Glycopeptides class, 11Lincosamides class, 12Macrolides class, 13Fusidane class.  
() Drugs that has not been tested or indicated.     
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Figure 4.6 Antimicrobial susceptibility of tonsillar isolates against selected β-lactam agents.  
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Figure 4.7 Antimicrobial susceptibility of tonsillar isolates against selected non-β-lactam agents.  
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4.5  Microscopic Detection of Biofilm Presence  
4.5.1 Scanning Electron Microscopy 
Our results showed the presence of attached bacteria in the form of biofilms on 
the surface of tonsils in 42 (60%) of selected patients. Among the tonsillar infection 
group, the presence of bacterial biofilm was detected in 30 out of 49 patients with 
recurrent tonsillitis and 5 out of 9 patients with chronic tonsillitis. However, among 
obstructive (non-infected) group, biofilms were present in 7 out of 12 patients with 
obstructive sleep apnea. The microscopic analysis of various tonsillar specimens via 
SEM showed the network-like biofilm glycocalyx embedding the bacterial 
microcolonies (Figure 4.8 A). Attached bacteria were present on the surface of the 
specimen and could be clearly distinguished from smaller materials or irregularities of 
the tonsillar epithelium nearby. The low magnification images showed the tonsillar 
mucosa comprising of small debris covered with a network-like glycocalyx and blood 
cells (Figure 4.8 B). The number of attached bacteria was variable among specimens. 
The cells were not evenly distributed over the entire surface of the specimen but rather 
were clustered and formed microcolonies. These microcolonies were mostly located in 
small depressions between epithelial cells. Using higher magnification, the location of 
these microcolonies was confirmed to be at the junction of the epithelial cells in small 
crypts. Bacterial cells were visualized as being connected by an extracellular material 
which could represent the glycocalyx matrix and they were seemed to be organized in a 
scaffolding network located in small crypts. The adherent biofilms had a varying 
number of attached bacteria, ranging from a few cells to a mass. However, some of the 
dividing bacterial cells were observed within microcolonies (Figure 4.8 B). The 
appearance of the biofilm was inconsistent among our specimens. Some areas were 
covered completely with attached bacteria whereas others had few attached microbes, as 
evidenced by the presence of areas of normal mucosa.  
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Figure 4.8  Microscopic evidence of bacterial biofilms on the tonsillar surface via SEM. A, Overall image of biofilm from a patient with 
recurrent tonsillitis showing the layers of network-like glycocalyx (Low magnification 1500x). B, Representative image of biofilm 
from a patient with chronic tonsillitis showing bacterial cells attached to the surface of tonsillar cells and embedded in a network-
like glycocalyx (High magnification 25000x). Arrows indicate the biofilm structures.  
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4.5.2 Confocal Laser Scanning Microscopy 
The results of viewing biofilms using CLSM were consistent with the results 
shown using SEM. We have demonstrated the presence of 3-dimensional structures of 
biofilms in the tonsils of 42 (60%) patients for which 30 out of 49 patients were 
diagnosed with recurrent tonsillitis, 5 out of 9 patients were diagnosed with chronic 
tonsillitis. And 7 out of 12 patients with diagnosed with obstructive sleep apnea. To 
visualize bacterial cells and their surrounding glycocalyx matrix, which indicates the 
presence of a biofilm, double staining was performed using Propidium iodide and 
Concanavalin A (Con A). Bacterial cells and nuclei of tonsillar cells were stained red, 
whereas binding of Con A resulted in a fluorescent green staining indicated the presence 
of the biofilm’s glycocalyx. Inter-connected bacteria were encased in a scaffolding 
network composed of extracellular matrix, suggesting a 3-D structure of biofilm (Figure 
4.9 A). Higher magnification on CLSM shows the biofilm with its glycocalyx in green 
embedding the bacterial cells in red and covering the space between tonsillar nuclei in 
red  (Figure 4.9 B). Most of the bacteria were cocci shaped arranged in clusters and it 
noticed that ConA stained the biofilm’s matrix exclusively. One of the important 
features of using CLSM in visualizing biofilms is that it allows for a quantitative co-
localization analysis to examine antigens of interest in immunofluorescence images; in 
our case is the biofilm’s glycocalyx. The histometric measurement of the biofilm’s 
fluorescent-labeled structures showed green glycocalyx tagged with Con A and red 
bacterial cells tagged with Propidium iodide (Figure 4.10 A and B). The co-localized 
areas of detected biofilms were measured where single tagged pixels of the two 
channels are located in quadrant 1 and 2 respectively while pixels having intensity 
above the background (co-localized pixels) are located in quadrant 3 (Figure 4.11 A). 
The magnified 2.5-D image of biofilms were also measured (Figure 4.11 B). 
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Figure 4.9 Microscopic evidence of bacterial biofilms within the tonsillar crypts via CLSM. A, Representative image of biofilm from a 
patient with obstructive sleep apnea showing bacterial cells (red) embedded with glycocalyx (green) surrounding the tonsillar 
nuclei (red). B, Three-dimensional image of a biofilm showing bacterial aggregates (cells) embedded in a glycocalyx matrix 
(100x). Arrows indicate the biofilm structures and tissue sections were stained with Propidium iodide & Concanavalin A. 
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Figure 4.10 Evidence of fluorescent-labeled structures from a representative biofilm image via CLSM. A, Histometric measurement of the 
detected biofilm indicating absolute frequency of glycocalyx (green) in comparison with intensity of bacterial cells (red). B, 
Frequency of the detected glycocalyx (green) within the tonsillar crypt surrounded by tonsillar nuclei (red). Arrows indicate the 
biofilm structures and tissue sections were stained with Propidium iodide & Concanavalin A.  
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Figure 4.11 Evidence of co-localization areas from a representative biofilm image via CLSM. A, Co-localized areas of a biofilm within the 
space of tonsillar crypt (10x). B, Magnified 2.5-D image of a co-localized biofilm showing the depth of the structure. Arrows 
indicate the biofilm structures and tissue sections were stained with Propidium iodide & Concanavalin A. 
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Based on the data obtained from clinical examination for each patient, tonsillar 
hypertrophy was the most frequent symptom presented by adults and children. A 
significantly higher percentage of patients presented infection manifestation (sore 
throat) rather than obstruction (snore, nasal obstruction, tonsillar hypertrophy, adenoids 
hypertrophy and apnea). Interestingly, the symptoms presented by each of the patients 
were associated with the presence of biofilms in the tonsils as examined 
microscopically via CLSM. An association between the most frequent clinical 
symptoms of and biofilm presence is shown (Table 4.3). Detailed table for the evidence 
of bacterial biofilms detected via CLSM among clinical cases is described (Appendix 
10).  
 
 
Table 4.3 Association between clinical symptoms and biofilm presence in the 
tonsils.  
 
* Percentage was calculated based on the total number of patients which was 70   
 
 
4.6 Biofilm Formation Ability  
4.6.1 Microtiter Plate Assay 
The MTP assay allowed us to quantify the rate of adherence and subsequent 
biofilm formation of tested bacteria. The ability of biofilm formation appeared to be 
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related to the type of isolate rather than the site of isolation, in this case, a significant 
increase in the adherence index was detected spectrophotometrically among 
Staphylococcus aureus, Haemophilus influenzae, GABHS, Pseudomonas aeruginosa 
and Streptococcus pneumoniae  strains considering them as strong biofilm formers. 
However, a weak biofilm formation abilitiy indicated by a decrease in the value of 
adherence index was detetcd among Streptococcus agalacticae, Haemophilus 
parainfluenzae, Klebsiella pneumoniae, Group C Streptococci and Acinetobacter 
baumannii. Whereas no biofilm formation abilitiy was detected among Group C 
Streptococci, Citrobacter and Enterobacter cloacae.   
Among our 464 tonsillar isolates, the number and percentages of biofilm 
formers were 78 (42.39%) isolates of S. aureus, 55 (63.95%) isolates of H. influenzae, 
19 (33.92%) isolates of Streptococcus agalactiae (Group B Streptococci), 16 (51.61%) 
isolates of H. parainfluenzae, 15 (50%) isolates of K. pneumoniae, 6 (24%) isolates of 
Group G Streptococci (GGS), 12 (85.71%) isolates of GABHS, 7 (77.77%) isolates of 
P. aeruginosa, 2 (25%) isolates of Group C Streptococci (GCS) and 2 (66.66%) isolates 
of S. pneumoniae. Quantification of biofilm formation based on the adherence index 
among all the tonsillar clinical isolates is illustrated in (Figure 4.12). Moreover, there 
was a strong correlation between the presence of biofilms as detected microscopically in 
tonsillar tissue sections and the ability of tonsillar clinical isolates to form biofilm via 
MPT assay.  
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Figure 4.12 Biofilm formation ability among tonsillar clinical isolates via MTP assay. Positive result indicates a strong biofilm formation ability 
whereas negative result indicates no biofilm formation.   
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4.6.2 Congo Red Agar Method 
By examining the morphology of colonies on Congo Red Agar for each of our 
bacterial isolates, it was possible to define eight major morphological variations 
(colonial morphotypes) as shown in (Figure 4.13). The biofilm formation morphotypes 
had 4 variations including very black (VB) colonies (Figure 4.13 [1]) indicating strong 
slime production, Bright Black (BB) colonies (Figure 4.13 [2]) indicating strong slime 
production, Almost Black (AB) colonies (Figure 4.13 [3]) indicating moderate slime 
production and Dry Black (DB) colonies indicating weak slime production (Figure 4.13 
[4]). However, the non-biofilm forming morphotypes had also 4 variations where all 
indicated no virulence or no production of slime. These include the Orange (OR) 
colonies (Figure 4.13 [5]), Pinkish Red (PR) colonies (Figure 4.13 [6]), Bordeaux (BR) 
colonies (Figure 4.13 [7]) and Very Red (VR) colonies (Figure 4.13 [8]).   
  Although it was possible to classify most variants as one of the major 
morphotypes, there were some intermediate forms which were difficult to categorize. 
For example in the Bordeaux (BR) phenotype had a great tendency to undergo colonial 
variation more than the rest. Moreover, dryness of the agar or heavy inoculation of 
plates sometimes resulted in altered morphology. Another type of colonial variation was 
sometimes observed when CRA plates remained at room temperature for several days 
beyond the standard 2 day incubation period. Variants appeared as crops of tiny pink 
colonies imposed on the primary inoculum. However, subculture of these forms yielded 
normal sized colonies belonging to the original morphotype. It should be noted that 
CRA was used in this study to facilitate the detection of variant forms in correlation 
with the results obtained from MPT assay.  
Based on CRA results, out of the 464 isolates, three main categories can be 
determined. Firstly, invasive bacteria comprising of 5 types that were regarded as strong 
biofilm formers including Haemophilus influenzae with the highest mean of slime 
112 
 
production followed by Pseudomonas aeruginosa, GABHS, Staphylococcus aureus 
then Streptococcus pneumoniae. Secondly, colonizing bacteria were comprised of 6 
types that were regarded as weak biofilm formers including Streptococcus agalactiae 
with a moderate mean of slime production followed by Klebsiella pneumoniae, 
Haemophilus parainfluenzae and Group C Streptococci. Thirdly, commensal bacteria 
comprising of 4 types that were regarded as non-biofilm formers including Group G 
Streptococci, Group F Streptococci, Citrobacter sp. and Enterobacter cloacae.   
The CRA method allows the formation of colonies on the plate to be directly 
monitored for morphological variations. This is particularly significant because there is 
evidence to suggest that the phase variability itself should be regarded as an important 
virulence marker. The results of CRA were strongly associated with the results of MTP 
assay and there was no significance difference between the biofilm formation ability 
among tonsillar isolates (Table 4.4). Detailed tables for biofilm formation abilities 
among all clinical isolates using MPT assay, CRA method and microscopic 
observations is described (Appendixes 11A, 11B, 11C, 11D, 11E, 11F, 11G, 11H, 11I, 
11J, 11K, 11L, 11M, 11N, 11O). 
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Figure 4.13 Morphological variations of bacterial colonies via CRA method. 1-4, 
Indicates biofilm forming strains. 5-8, Indicates non-biofilm forming 
strains. The “√” sign represent positive results (slime production) 
whereas “x” sign represent negative result (no slime production).   
114 
 
Table 4.4 Comparison of biofilm formation abilities among clinical isolates by MTP 
assay and CRA method. 
 
 
 
 
4.7 Morphology Confirmation of Paenibacillus haemolyticus strain 139SI 
 The morphological confirmation to identify our isolate as Paenibacillus 
haemolyticus strain 139SI showed that cells of the strains were Gram-positive rod-
shaped with bipolar end terminal spores (Figure 4.13). Moreover, colonies of the isolate 
when grown on Colombia agar supplemented with 5% sheep blood were grey, large, 
rough and irregular edged with a size of 2–3 mm in diameter exhibiting a strong 
haemolytic activity after 16 h incubation at 37◦C (Figure 4.14). Conformation of the 
cellular morphology via SEM showed all cells regular rods with a size of 0.4–0.5 μm × 
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2.0–2.5 μm (Figure 4.15). Our report to discover the first haemolytic Paenibacillus 
haemolyticus with growth promoting activities of this work was published at Biologia 
(Appendix 3B). The strain was deposited with the American Type Culture Collection 
(ATCC) (Appendix 6) and its 16SrRNA sequence was assigned an accession number at 
GenBank (Appendix 7).  
 
 
Figure 4.14  Light Microscopy image showing Gram-positive bacilli cells of 
Paenibacillus haemolyticus strain 139SI when grown on BHI broth after 48 h 
incubation at 37
o
C. Image viewed under LM (100x).  
 
 
Figure 4.15  Colony morphology of the novel soil bacteria Paenibacillus haemolyticus 
strain 139SI grown on Columbia agar supplemented with 5% sheep 
blood. A, Cells after 24 h incubation at 37
o
C. B, Cells after 48 h 
incubation at 37
o
C. Arrows indicate the complete hemolysis of blood in 
the medium (β-hemolysis).   
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Figure 4.16 Cellular morphology of Paenibacillus haemolyticus strain 139SI as 
viewed by SEM. The image shows the strain when grown on BHI broth 
after 48 h incubation at 37
o
C. A, Single regular bacilli cells with a size of 
0.4–0.8 × 2–5 μm. (16000x). B, Two multiplying cells (13000x). Arrows 
indicates cells.      
 
 
4.8 In vitro Antibiofilm Activity of 139SI Culture Filtrate 
4.8.1 MPT Assay 
The results of MTP showed significant inhibition of biofilm formation among 
selected Gram-positive tonsillar isolates represented by Staphylococcus aureus, 
Streptococcus agalactiae, Group G Streptococci, Streptococcus pyogenes and 
Streptococcus pneumoniae. In addition to the Gram-negative isolates represented by 
Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, 
Citrobacter sp. and Pseudomonas aeruginosa. The most effective concentration was 
4500 µg/ml that resulted in a decreased adherence index when quantified 
spectrophotometrically (Table 4.5 and Table 4.6). There was a significant decrease in 
the adherence index among all the isolates tested with variations in the degree of 
adherence to the surface.   
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 Table 4.5 Antibiofilm activity of 139SI filtrate against Gram-negative isolates. The lowest most active concentration is highlighted.   
 
 
OD = Optical Density, SD = Standard Deviation, BHI = Brain Heart Infusion   
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Table 4.6 Antibiofilm activity of 139SI filtrate against Gram-positive isolates. The lowest most active concentration is highlighted.  
 
OD = Optical Density, SD = Standard Deviation, BHI = Brain Heart Infusion   
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4.8.2 BIC Test 
The BIC test was performed against selected Pseudomonas aerugniosa isolates 
as this species will be used later in the biofilm model of chronic lung infection. 
The139SI filtrate inhibited the bacterial attachment of P. aeruginosa when grown on the 
bottom of 6-well microtiter plate (Figures 4.17). The lowest and most effective 
concentration to achieve this inhibition was found to be 4500 µg/ml and the biofilms 
were inhibited up to 80% when visualized microscopically via LM and SEM (Figure 
4.18) and (Figure 4.19) respectively.  
Microscopic observation of Biofilm Inhibitory Concentration test via SEM 
showed that the biofilm of P. aeruginosa isolate coating the plastic surface of 
microtitter plate was disrupted after exposure to our soil bacterial culture filtrate at 
concentration of 4500 µg/ml. (Figure 4.19) The remains of biofilm showing scattered 
bacterial cells and aggregations of bacterial cells with no extracellular matrix 
connecting them. However, exposure to the 139SI filtrate at a lower consternation, i.e. 
3000 µg/ml, did not completely inhibit the biofilm of P. aeruginosa as indicated by the 
visualization of bacterial cells embedded in the remains of an amorphous extracellular 
matrix.  
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Figure 4.17  Biofilm Inhibitory Concentration (BIC) test of 139SI filtrate against P. aeruginosa biofilms that are attached to the surface of square 
cover slip placed inside the wells (1-6) of microtiter plate. The BIC of 139SI filtrate (4500 µg/ml) is highlighted and “x” sign indicates 
no or partial biofilm inhibition whereas “√”  sign indicates complete biofilm inhibition.  
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Figure 4.18  Microscopic observation of Biofilm Inhibitory Concentration via LM against biofilms of P. aeruginosa coating the glass cover slip and 
stained with Crystal violate. A, Complete inhibition of biofilm after exposure to 139SI filtrate at BIC (4500 µg/ml). B, Partial inhibition 
of biofilm after exposure to 139SI filtrate at non-BIC (4000 µg/ml). Arrows indicate the sites of biofilm inhibition.  
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Figure 4.19 Microscopic observation of Biofilm Inhibitory Concentration of via SEM against P. aeruginosa biofilms coating the 6-well of microtiter 
plate. A, Complete biofilm inhibition after exposure to 139SI filtrate at BIC concentration (4500 µg/ml). D, Partial biofilm inhibition after 
exposure to 139SI filtrate at non-BIC concentration (4000 µg/ml). Arrows indicates sites of biofilm inhibition.  
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4.9 Acute Toxicity Test of 139SI Culture Filtrate 
4.9.1 Gross General Observations  
 The rats were treated with low and high dose of 139SI filtrate while the control 
group was treated with 0.9% normal saline. Gross general observations indicated that all 
experimental rats showed no signs of tremor, convulsions and reflex abnormalities. No 
muscular numbness, salivation and diarrhea were observed. The food intake per day was 
also being found normal. The average and individual body weights of all rats were 
increased after the oral administration of 139SI filtrate which was statistically 
insignificant. From these observations we can conclude that the isolated compound has 
no adverse effect on normal growth of SD rats.   
   
4.9.2 Biochemical Parameters and Haematological Profiles  
The biochemical parameters changed slightly however remained within the 
normal range for both males and females except for few slight abnormalities as shown 
in Tables 4.7, 4.8, 4.9 and 4.10. All analyte values were expressed as the mean ± S.E.M. 
with p<0.05 as the significant value. There are no statistically significant differences 
between experimental groups which indicates the non-toxic nature of 139SI filtrate on 
both kidney and liver functions. The haematological profile was studied and the oral 
administrations of 139SI filtrate to check the haematological disorders. No 
abnormalities were found in the total count of white blood cells (WBCs), red blood cells 
(RBCs), platelet count and haemoglobin percentage of both low dose (2 gm/kg) and low 
does (4 gm/kg) in comparison with the control (vehicle) group. These data indicates 
that139SI filtrate has no substantial effect on the haematological structure. 
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 Table 4.7 Renal function test results among male rats. 
 
 
mmol/L = millimole per Liter, µmol/L = micromole per Liter  
* indicates values that are above or below the reference range   
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Table 4.8 Renal function test results among female rats. 
 
 
mmol/L = millimole per Liter, µmol/L = micromole per Liter  
* indicates values that are above or below the reference range   
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Table 4.9 Liver function test results among male rats. 
 
 
µmol/L = micromole per Liter, g/L = gram per Liter, IU/L = International Unit per Liter  
* indicates values that are above or below the reference range   
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Table 4.10 Liver function test results among female rats. 
 
µmol/L = micromole per Liter, g/L = gram per Liter, IU/L = International Unit per Liter  
* indicates values that are above or below the reference range 
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4.9.3 Histopathological Evaluation  
An evaluation of the histopathological (toxicological) effects of our 139SI 
bacterial culture filtrate was carried out by examining the liver and kidney of all 
experimental groups both males and females. No significant differences were detected 
in the histopathology of these organs whether among high or low doses groups as well 
the vehicle group. These findings indicate that the compound from 139SI filtrate that 
contains secondary metabolites have no effects on cellular structures meaning that they 
do not cause degeneration of the cells of these organs (Figure 4.20).  
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Figure 4.20 Gross and histopathology evaluation of liver and kidney in experimental 
groups based on acute toxicity test. A, Normal liver gross among vehicle 
(control) group. B, Normal liver histology among low dose group. C, 
Normal liver histology among high dose group. D, Normal kidney gross 
among vehicle (control) group. E, Normal kidney histology among low 
dose group. F, Normal kideny histology among high dose group. Tissue 
sections were stained with H&E.   
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4.10 In vivo Antibiofilm Activity of 139SI Culture Filtrate 
 Based on our results, we examined the therapeutic (treatment) effects of 139SI 
bacterial culture filtrate on the biofilm infection caused by a resistant strain of P. 
aeruginosa clinical isolate. The therapeutic effects were evaluated based on the daily 
oral administration of a low dose (25 gm/kg) culture filtrate that is believed to contain 
bioactive metabolites produced from a novel soil bacterial species, Paenibacillus 
haemolyticus strain 139SI. These effects included the survival time of rats, clearance of 
bacteria from the lungs, macroscopic and microscopic lung pathology. There was no 
mortality among rats from the negative group. However, it was noticed that all rats 
belonging to positive group (infection group) died before completing the course of 
experiment. The mortality among that group was noticed on various days, some died 
from a severe infection on day 2 post inoculation whereas others died on days 3 and 5. 
On the other hand, the survival time for the other groups particularly treatment group 
was noticed to be longer although few mortalities still occurred 2 (16.6%) on day 3 and 
7; however it was statistically insignificant. The comparative group had its share of 
mortalities with 3 (25%) rats dying on days 6 and 7.  
 
4.10.1 Lung Index of Macroscopic Pathology   
 To calculate the LIMP, which was used as an indicator of the severity of the 
lung pathology, we measured the area of the lungs exhibiting pathological changes. The 
major pathological changes observed were lung consolidation, abscesses and 
haemorrhage. On day 7 after challenge with P. aeruginosa, 4 rats were randomly 
selected for histopathology examination. On days 7, lung adhesion was rarely found, 
while lung consolidation with haemorrhage and abscesses were the main pathological 
changes. However, from day 14 on lung abscesses and haemorrhage became 
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predominant particularly in the positive control group, The LIMP for the four groups is 
shown in (Figure 4.21). 
 The 139SI filtrate exhibited promising activity in disrupting the biofilm P. 
aeruginosa in the lungs of both comparative control and treatment group which resulted 
in bacterial clearance from the lung and reduction of the severity of lung pathology. 
Treatment with the 139SI metabolite filtrate significantly prolonged survival times in 
the treatment group which was similar to the results found in comparative control 
group. It was noticed that areas with pathologic changes in the treatment group were 
smaller than that in the positive control group. The number of rats with chronic 
inflammation in both the treatment group 6 (12.5%) and comparative control group 6 
(12.5%) was significantly lower than that in the positive control group 12 (25%) as 
shown in (Table 4.11). the severity of chronic inflammation was reduced to half when 
both 139SI filtrate and 2(5H)-Furanone were administered.  
 
Table 4.11 Microscopic pathology of rat lungs 14 days after challenge with 
Pseudomonas aeruginosa.  
 
NA = Not Available   
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Figure 4.21 Gross pathology of lungs among experimental rats based on the lung 
index of macroscopic pathology. A, Normal lung showing no signs of 
haemorrhage. B, Infected lung with large haemorrhage and abscess (>40 
mm
2
). C, Swollen lungs with hyperemia, small atelectasis and moderate 
haemorrhage (10 mm
2 
- 40 mm
2
). D, Recovered lungs with hyperemia, 
atelectasis and moderate to small haemorrhage (<10 mm
2
).  
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4.10.2 Histopathology Scoring of the Lungs  
Upon random sacrifice of rats on day 3, the histopathology of lungs showed 
acute inflammation with an infiltration in which Polymorphonuclear leukocytes (PMNs) 
were predominant. Normal lungs were found in the negative control group with a score 
of I (Figure 4.22A) whereas chronic inflammation was found in positive (infection) 
control group showing severe inflammation to necrosis with a score of IV (Figure 
4.22B). The treatment (139SI) group showed signs of recovery with a score of II 
(Figure 4.23A) whereas comparative control group showed moderate to severe focal 
inflammation with a score of III (Figure 4.23B). Furthermore, on day 14 the 
inflammation in positive control was significantly more severe compared to those of 
comparative and treatment groups. A score of IV in positive control group and a score 
of III in the treatment group was found on day 3. Areas in which the biofilm’s alginate 
is attached and occupying the lung alveolar spaces are shown in (Figure 4.24). 
Moreover, to increase accuracy in detecting the therapeutic effects of 139SI filtrate, 
lung tissue sections were processed for immunohistochemistry and viewed under CLSM 
(Figure 4.25). The biofilm’s glycocalyx was stained in green with Concanavalin A 
whereas the lung epithelium (alveolar cells) and the infecting bacteria were stained red 
with Propidium iodide. Comparative control tissue showed significant infiltration of 
PMNs in the lung whereas the infection control was surrounded by numerous PMNs. In 
the treatment group, inflammation was much milder and the infiltration was 
predominantly with mononuclear cells (MNs). The area with pathological changes in 
the treatment group were smaller than in comparative group. The incidence of acute 
inflammation in treatment group was lower than comparative control, but the difference 
was not statistically significant. Evidence of P. aeruginosa embedded in alginate and 
covering the lung’s alveolar space are shown in (Figure 4.24 C and D).  
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Figure 4.22  Histopathological scoring of lungs according to the severity of inflammation (Scores I and IV). A, Score I: with normal histology of the 
lung (negative control). B, Score IV with severe inflammation to necrosis throughout the lung (positive control) Low magnification 4x 
Arrows indicate the score of tissue and sections were stained with H&E.  
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Figure 4.23 Histopathological scoring of lungs according to the severity of inflammation. (Scores II and III). A, Score II with mild focal 
inflammation of the lung (treatment group). B, Score III with moderate to severe focal inflammation of the lung (comparative control). 
Low magnification 4x. Arrows indicate the score of tissue and sections were stained with H&E. 
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Figure 4.24 Microscopic evidence of Pseudomonas aeruginosa biofilms embedded with alginate solution inside the alveolar space of infected 
lungs. A, Biofilm occupying the alveolar space (Low magnification 40x). B, Biofilm occupying the alveolar space (high magnification 
100x). C and D, Representative images of lung alveoli occupied with biofilms comprising of bacteria and alginate (high magnification 
100x). Arrows indicate the biofilm structures, A and B tissue sections were stained with H&E stain whereas C and D sections were 
stained with PAS stain.   
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Figure 4.25 Microscopic evaluation of the lung pathology via CLSM according to the severity of inflammation. A and B, Representative images of 
positive (infection) control were dense layers of biofilm’s alginate (green) are occupying the alveolar space and the P. aeruginosa and 
alveolar cells are shown (red). C and D, Representative images of treatment (139SI) group showing the therapeutic effects of 139SI 
filtrate in disrupting the biofilm’s alginate leading to clear alveolar spaces and a minimized chronic infection. Arrows indicate the 
biofilm structures and tissue sections were stained with Propidium iodide & Concanavalin A. 
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4.11 Determination of 139SI Potential Compounds  
 The results of profiling the 139SI filtrate via HPLC revealed 32 fractions in 
which four exhibited antibiofilm activity (bioactive secondary metabolites) while the 
rest were non-active metabolites against biofilm formation. The HPLC chromatogram 
of 139SI filtrate with all its 32 fractions is shown in (Figure 4.26) whereas the four 
potential chemical compounds (FR4, FR5, FR8 and FR13) are shown in Figure 4.27 
which were later further assessed and characterized.  
 
 
4.12 Antibiofilm Activity of 139SI Potential Compounds  
 Among all the purified 32 fractions, only four showed significant inhibition of 
biofilm via MTP assay against Gram-negative isolates (Table 4.12) and Gram-positive 
isolates (Table 4.13). All the four fractions with their BIC exhibited antibiofilm activity 
when quantified spectrophotometrically. However, compound 5 (FR5) was the most 
active one with significant decreased in the adherence index compared to the rest of 
compounds.  
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Figure 4.26 HPLC profiling chromatogram of 139SI filtrate showing all the obtained 32 compounds.  
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Figure 4.27 HPLC profiling chromatogram of 139SI filtrate showing the four potential compounds (FR4, FR5, FR8 and FR13). 
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Table 4.10.2 Antibiofilm activity of 139SI potential compounds against Gram-negative isolates. The most active compound (FR5) is 
highlighted. 
 
 
OD = Optical Density, SD = Standard Deviation 
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Table 4.10.2  Antibiofilm activity of 139SI potential compounds against Gram-positive isolates. The most active compound (FR5) is 
highlighted. 
 
 
OD = Optical Density, SD = Standard Deviation 
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4.13 Identification of 139SI Potential Compounds  
The compound identification was performed by UPLC–MS experiment in 
positive mode. A total number of six compounds were detected from the three active 
fractions obtained previously from HPLC in which they exhibited in vitro antibiofilm 
activity. Two compounds were detected from Fraction 4 (FR4), three compounds were 
detected from fraction 5 (FR5) and one compound was detected from fraction 13 
(FR13). All detected compounds were identified on the basis of the UV spectra and MS 
fragmentation patterns in comparison with literature or by searching the dictionary of 
natural products on DVD, Version 20:2 (2011) (CRC Press, Taylor & Francis Group, 
London, UK). Table 4.14 shows the identification of all the peaks detected with their 
retention time, UV max, observed m/z and the m/z of fragment ions. Typical HPLC-
TOF/MS peaks and UV diode array chromatograms of fractions 4, 5 and 13 are shown 
in (Figure 4.28, 4.30 and 4.32) respectively. Moreover, Mass Spectrum (TOF MS ES+), 
chemical structure and UV max spectra of the identified (peak No. 1) fractions 4, 5 and 
13 are shown in (Figure 4.29, 4.31 and 4.33) respectively. The ssuggested elemental 
composition of the active compound FR5 using LC-MS in the positive mode is shown 
in (Figure 4.34).  
 In the negative mode: The chemical compound was with the synonym 
SF2415A2 with a molecular weight of 450.533 and a molecular formula of C26H30N2O5 
described as a naphthoquinone related-antibiotic with an activity against Gram positive 
bacteria. However, in the positive mode: The first chemical compound was with 
synonym Leucine 2-(hydroxymethoxyphosphinyl)-2-methylhydrazide with a molecular 
weight of 253.237 and a molecular formula of C8H20N3O4P described as an amino acid 
antibiotic with an activity against Gram positive and Gram negative bacteria. The 
second chemical compound was with the synonym 4-Hydroxy-5-(Hydroxymethyl)-3-
(14-methylpentadecanoyl) tetronicacid-2(5H)-Furanone with a molecular weight of 
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368.512 and a molecular formula of C21H36O5 described as a phospholipase A2 
inhibitor. The third chemical compound was with synonym 6-(hydroxymethyl)-1-
phenazinecarboxyamide with a molecular weight of 253.260 and a molecular formula of 
C14H11N3O2 described as an antibacterial agent. All detected compounds were identified 
on the basis of the UV spectra and MS fragmentation patterns in comparison with 
literature by searching the dictionary of natural products on DVD, Version 20:2 (2011) 
(CRC Press, Taylor & Francis Group, London, UK).  
 
Table 4.10.24   Identified peaks of the 139SI filtrate filtrate detected with their 
retention time, UV max and m/z fragment ion.  
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Figure 4.28  HPLC-TOF/MS and UV diode array chromatograms of 139SI fraction 4 (FR4) showing the peak in positive mode ionization. A, Diode 
array detection UV spectra at 280 nm. B, Diode array detection UV spectra at range between 190 and 800 nm.   
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Figure 4.29 Mass Spectrum (TOF MS ES+) of peak No. 1 from fraction 4 (FR4) with its suggested elemental composition. 
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Figure 4.30 HPLC-TOF/MS and UV diode array chromatograms of 139SI fraction 5 (FR5) showing the peak in positive mode ionization. A, Diode 
array detection UV spectra at 280 nm. B, Diode array detection UV spectra at range between 190 and 800 nm.   
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Figure 4.31 Mass Spectrum (TOF MS ES+) of peak No1 from fraction 5 (FR5) with its suggested elemental composition. 
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Figure 4.32 HPLC-TOF/MS and UV diode array chromatograms of 139SI fraction 13 (FR13) showing the peak in positive mode ionization. A, 
Diode array detection UV spectra at 280 nm. B, Diode array detection UV spectra at range between 190 and 800 nm.   
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Figure 4.33 Mass Spectrum (TOF MS ES+) of peak No. 1 from fraction 13 (FR13) with its suggested elemental composition.  
151 
 
 
 
Figure 4.34 Suggested elemental composition of the active compound FR5 using LC-MS in the positive mode. A, Diode array detection UV 
spectra at 280 nm. B, Mass Spectrum (TOF MS ES+) of 2 peaks showing two chemical compounds, Leucine 2-
(hydroxymethoxyphosphinyl)-2-methylhydrazide (MW = 253.237) (C8H20N3O4P). The second chemical compound is 4-Hydroxy-5-
(Hydroxymethyl)-3-(14-methylpentadecanoyl) tetronic acid-2(5H)-Furanone (MW = 368.512) and formula (C21H36O5).  
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5CHAPTER FIVE 
DISCUSSION AND CONCLUSION 
5.1  Overview   
Diseases of the ear, nose and throat (ENT) are one of the most frequent health 
problems especially in children that usually require surgical intervention. Among them, 
is tonsillitis which represents a real challenge due to its resistance to common therapies 
(Nixon and Bingham, 2006; Vlastarakos et al., 2007). Despite the widespread use of 
antibiotics against tonsillar diseases, therapy is often insufficient and infections still 
occur and become chronic causing enlargement (hypertrophy) of the tonsils (Rehl et al., 
2007). Chronic tonsillar infections and hypertrophy are frequently caused by multiple 
and, sometimes, resistant bacteria. Many of these bacteria have the ability to form 
biofilms that are matrix-encased communities attached to a surface (Diaz et al., 2011). 
One of the suitable surfaces that bacteria usually attach and form biofilms are the tonsils 
(Al-Mazrou and Al-Khattaf, 2008). In our study, we reported the presence of biofilms in 
60% of selected patients and we established a clear relation between biofilms and some 
clinical symptoms of tonsillar diseases.   
The failure of antibiotic treatments in tonsillitis might be due to the presence of 
biofilms that can be considered as an etiological factor for tonsillar diseases whether 
due to infection and/or obstruction. The knowledge about biofilms is crucial in 
explaining the chronic nature of bacterial infections including those associated with the 
ear, nose and throat (Vlastarakos et al., 2007). In addition to detection of the presence of 
biofilms in the tonsils, we have isolated and identified the microorganisms from 
tonsillar specimens and assessed their ability to form biofilms in correlation with their 
antimicrobial susceptibility. Despite the fact that majority of our recovered tonsillar 
isolates were susceptible to a wide range of selected antibiotics, they exhibited a strong 
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ability to form biofilms. All of these results suggest that biofilms represent a new 
concept in ENT-related chronic infections, and are probably involved in their 
pathophysiology and in the antibiotic resistance which requires immediate attention to 
search for novel and effective therapeutic treatments. 
Among the promising approaches to combat biofilm infections is the use of 
microbial natural products from microorganisms inhabiting natural environments. In our 
study, a taxonomically novel bacterial species that belongs to the genus Paenibacillus 
was isolated from agricultural soil and investigated for its ability to synthesize and 
secret bioactive metabolites that can disrupt the biofilm formation of clinically 
important pathogens. Due to the remarkable haemolytic ability of our novel bacterial 
isolate, it was designated the name Paenibacillus haemolyticus strain 139SI. We have 
prepared a culture filtrate from this strain and tested it against a wide range of bacterial 
isolates previously recovered from tonsils. The culture filtrate of strain 139SI was tested 
for its in vitro antibiofilm activity, gross and histopathological toxicity, and therapeutic 
effects against biofilm-forming pathogens. Our findings suggest that the 139SI culture 
filtrate exhibited potent antibiofilm activity with no signs of toxicity and had 
significantly reduced a chronic biofilm infection in the lungs of experimental animals.     
Profiling of the crude culture filtrate of strain 139SI via high performance liquid 
chromatography (HPLC) has yielded a total number of 32 compounds (fractions). Each 
fraction was then tested for its in vitro antibiofilm activity via MTP assay and results 
revealed three potential fractions designated FR4, FR5 and FR13, These fractions were 
selected based on reducing bacterial adherence on the surface of microtitter plate and 
thus inhibiting the formation of biofilm. Each fraction with their respective 
concentrations were tested again to determine their in vitro antibiofilm activity. Among 
the three fractions, FR5 was selected as the most active fraction against Gram-positive 
and Gram-negative pathogens and it was further characterized to identify its molecular 
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weight, chemical formula and chemical structure via liquid chromatography-mass 
spectrometry (LC-MS). Three potential chemical compounds were identified from FR5; 
where the first compound was Leucine 2-(hydroxymethoxyphosphinyl)-2-
methylhydrazide (MW = 253.237) and (C8H20N3O4P) described as an amino acid 
antibiotic with an activity against Gram-positive and Gram-negative bacteria. The 
second compound was 4-Hydroxy-5-(Hydroxymethyl)-3-(14-methylpentadecanoyl) 
tetronicacid-2(5H)-Furanone (MW = 368.512) and (C21H36O5) described as a 
phospholipase A2 inhibitor. The third compound was 6-(hydroxymethyl)-1-
phenazinecarboxyamide (MW = 253.260) (C14H11N3O2) described as an antibacterial 
agent. 
 The FR5 fraction (compound) is readily soluble in water and exhibited 
antibiofilm activities against Gram-positive bacteria (Staphylococcus aureus and 
Streptococcus pneumonia) and Gram-negative bacteria (Haemophilus influenzae and 
Pseudomonas aeruginosa). However, other characteristics like mechanism of action and 
stability properties need to be elucidated in future work with the hope for therapeutic 
applications in medicine especially against ENT-biofilm associated infections.  
 
 
5.2 Pathology of Tonsillar Diseases  
The gross pathology of our tonsillar biopsy specimens showed that the highest 
rate of tonsillar grading was found among grade III (3+) with 39 (55.71%) patients 
followed by grade II (2+) with 20 (28.57%) patients then grade I (1+) with 6 (8.57%) 
patients and grade IV (4+) with 5 (7.15%) patients. This was similar to the finding made 
by Dell'Aringa et al. where they reported the highest grade III (3+) with 160 (64%) 
patients followed by grade II (2+) with 45 (18%) patients, grade IV (4+) with 26 
(10.4%) patients and grade I (1+) with 9 (3.6%) patients (Dell'Aringa et al., 2005). 
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There was no malignant neoplasia in all tonsillar specimens, this could be due to the 
low percentage of patients under the age of 18 years submitted to surgery, resulting in 
low incidence of these lesions. This was consistent with Dell'Aringa et al. where they 
reported the absence of malignancy from their tonsillar specimens (Dell'Aringa et al., 
2005). 
In our study we haven’t evaluated the influence of tonsil size on obstructive 
sleep apnea patients and the influence of oropharyngeal anatomy, body mass index and 
age on actual tonsil volume. This was due to the fact we emphasized on the 
microbiology and histopathology aspects of tonsillar diseases rather than physiological 
and anatomic aspects. Therefore, no correlation between oropharyngeal examination 
and the volume and size of palatine tonsils of snoring patients was assessed. However, a 
prospective study by Cahali et al. where they studied 130 patients with obstructive sleep 
apnea or primary snoring who underwent pharyngeal surgery with intraoperative 
measurement of tonsil volume demonstrated a strong correlation between clinical tonsil 
grade and the objective volume of tonsils in snoring adult patients, and this correlation 
existed regardless of the presence or severity of obstructive sleep apnea (Cahali et al., 
2011).   
According to the histopathological examination in our study, only 11 (15.71%) 
patients presented infections by Actinomyces sp. colonies in their tonsils leading to an 
enlargement of tonsils (hypertrophy) and an inflammatory lesion of the tonsillar crypts. 
This was consistent with the report by Sánchez et al. where they observed the presence 
of Actinomycosis in 8.5% of the patients with obstructive tonsillar hypertrophy and 
recurrent tonsillitis (Pransky et al., 1991). However, it was in contrast with the results 
obtained by Dell'Aringa et al. (2005) where they reported only 2 patients (0.8%) with 
infections by Actinomyces sp. that led to tonsil hypertrophy (Dell'Aringa et al., 2005) 
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Despite the presence of Actinomyces in our examined tonsillar tissue, the rate of 
these infections among clinical cases was considered low suggesting no relation 
between the presence of Actinomyces might cause hypertrophy of palatine and 
pharyngeal tonsils in these patients or, as Actinomyces is a common agent in the 
tonsillar tissue, it may not be routinely analyzed in the pathological specimens.  
 
 
5.3 Microbiology of Tonsillar Diseases  
Swabbing of tonsillar surface represents the routine method for bacteriological 
investigation of the tonsils. In our results, we have not been able to demonstrate a 
significant quantitative differences between surface (swab) and core (biopsy) cultures in 
regard to the recovery rate and type of aerobic bacteria. In fact, the microorganisms 
isolated from the tonsillar core could be also isolated from the surface. Therefore, the 
surface tonsillar swabs seem quite accurate in identifying the potential pathogens in 
chronic and recurrent tonsillitis as well as obstructive sleep apnea. This was similar to 
the investigation made by Alamadori et al. (1988) for which they have reported no 
significance qualitative difference between tonsillar surface and core cultures. However, 
it was in contrast with previous studies where they have demonstrated that the isolated 
microorganisms from tonsillar surface may not always represent the real cause of 
recurrent tonsillitis (Brook et al., 1980; Rosen et al., 1977). A study by Kurien et al. 
illustrated the problem of using the results of surface culture to determine the 
microorganisms responsible for tonsillar infections which in turn may lead to poor 
response to medical therapy in chronic and recurrent tonsillitis (Kurien et al., 2000). 
Another study by Rosen et al. also reported that in 48% of the bacteria isolated from 
their swab cultures were different from those isolated from deep tissue culture (Rosen et 
al., 1977). In addition, Brodsky et al. reported that the tonsil core bacteria with the 
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highest bacterial concentrations were more likely to be present on the tonsillar surface, 
and the greater the bacterial concentration, the more likely the bacteria were to be found 
in most if not all areas of the tonsil core (Brodsky et al., 1991).  
The only microorganism that was found to have significant difference between 
the surface and core distribution was Haemophilus influenzae for which 10 isolates 
where recovered from the core whereas 21 were recovered from the surface. This was 
similar to the study by Gul et al. which reported a significant difference between surface 
and deep tissue cultures, especially for H. influenzae and S. aureus isolates despite 
being common in core cultures, H. influenzae was rarely present on surface cultures 
(Gul et al., 2007) indicating that the surface cultures commonly show commensal flora 
whereas the tonsil core cultures show pathogenic microorganisms. Despite the contrast 
with previous studies on the role of tonsillar surface to precisely reflect the type of 
microorganisms, we believe that the use of superficial swabs can still be reliable to 
recognize the presence of possible pathogens especially for patients who are not willing 
to undergo surgical management in spite of not responding to routine medical treatment.  
Although there was no assessment of the role of anaerobic bacteria, viruses and 
fungi among our clinical specimens due to technical difficulties in collecting, 
transporting and culturing them, an accurate microbiological investigation towards 
isolating such microorganisms seems necessary in order to assess an adequate 
antimicrobial therapy prior to the occurrence of irreversible changes in the tonsillar flora 
that might to lead to a persistent infection.    
Our assessment of the microbiology of tonsillar specimens showed that 
Staphylococcus aureus was the most common microorganism among Gram-positive 
isolates and Haemophilus influenzae the most common among Gram-negative isolates 
indicating that they might be an etiological factor for tonsillitis. This was similar to the 
findings by Forbes et al. (2002) and Kielmovitch et al. (1989) which showed 
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Staphylococcus aureus and Haemophilus influenzae as the main causes of tonsillitis. 
Similarly studies by Gunnarsson and coworkers (2001) and Le et al. (2007) where they 
reported Haemophilus influenzae and Staphylococcus aureus as pathogens that play a 
role in upper respiratory tract infections along with group C and G β-hemolytic 
streptococci. However, the low number of recovered Streptococcus pneumoniae and 
GABHS isolates from both infected and hypertrophied tonsils indicates a less likely role 
in the development of tonsillitis. This was in contrast to a similar study by Kielmovitch 
et al. (1989) where the authors reported GABHS, Streptococcus pneumoniae, 
Corynebacterium diphtheriae, and Neisseria gonorrhoeae as the main causes of 
tonsillitis.  
In recurrent tonsillitis, the goal of the treatment is to eradicate the bacteria that 
cause infection. Inappropriate antibiotic therapy against pathogens in deep tissue or 
inadequate antibiotic levels in the tonsillar tissue leads to the continuation of the 
infection and the re-inoculation of the surface (Surow et al., 1989). Because the tonsillar 
surface is coated with oropharyngeal secretions, it generally shows normal flora of the 
oropharynx such as α-hemolytic and non-hemolytic streptococci, coagulase negative 
staphylococci, Neisseria, Flavescens, Corynebacterium, Actinomyces, Leptotrichiae, 
and Fusobacterium species (Surow et al., 1989).  
Previous investigations showed that hypertrophied tonsils have increased 
numbers of pathogenic bacteria compared with non-hypertrophied ones (Kuhn et al., 
1995) However, in our study when comparing the microbial flora among infected and 
non-infected tonsillar cases there was no significant difference in the number of 
recovered bacterial isolates. This was similar findings made by Stewart and Costerton 
where the same microbial flora was found among the infected and hypertrophied tonsils 
(Stewart and Costerton, 2001) suggesting that hypertrophied tonsils even without a 
history of infection cannot be considered as control samples which added a limitation to 
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our study due to difficulties in obtaining tonsillar specimens from age-matched 
individuals who never had infection or obstruction in their upper airways.  
In the case of a tonsillar infection, bacteria that inhabit the crypts spread into the 
tonsil and leave their toxins and other products in it, eventually leading to 
polymorphonuclear leukocyte infiltration, necrosis and surface ulceration in tonsils. 
Consequently, after an acute infection, bacteria may invade the tonsillar core (Brodsky 
et al., 1988; Gross and Harrison, 2000; Uppal and Bais, 1989). However, the 
mechanism of activating such infection in recurrent tonsillitis is still poorly understood 
(Loganathan et al., 2006). Therefore, knowing the bacteriology of tonsils does not help 
to treat the disease, however it helps develop an understanding of whether the bacteria 
play a role in re-activating recurrent infections by forming a biofilm community.   
 
 
5.4  Antimicrobial Susceptibility of Tonsillar Diseases  
Selective reporting of antimicrobial agents should help improve the clinical 
relevance of test reports and may assist to minimize the selection of multi-resistant 
nosocomial strains by overuse of broad-spectrum agents (Clinical and Laboratory 
Standards Institute, CLSI, 2009a). The Clinical Diagnostic Laboratory at UMMC in 
consultation with the infectious disease practitioners have decided which agents to 
report routinely and which might be reported only selectively. Therefore, based on their 
decision we have chosen the agents to be tested on each of our clinical isolates.  
Antimicrobial dosage regimens often vary widely among practitioners and 
institutions. Isolates that are initially susceptible may become intermediate or resistant 
after initiation of therapy (Clinical and Laboratory Standards Institute, CLSI 2010). Our 
results from disk diffusion tests showed that there is a high percentage of sensitivity 
among majority of tonsillar isolates against the selected antibiotics. These findings are 
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similar to the results by Sadoh et al. where the authors reported 100% sensitivity to 
cefuroxine, azithromycin and ceftazidime among S. aureus and Beta Haemolytic 
Streptococci (Sadoh et al., 2008). In our study, ampicillin showed more resistance 
against P. aeruginosa and H. influenzae isolates. Although the reason for this resistance 
is not clear, it may be related to the inappropriate consumption of the ampicillin that 
will eventually develop resistance. This was consistent with findings by Sadoh et al. 
(2008) when they tested their throat swabs bacterial isolates against selected antibiotics.  
We have detected a noticeable percentage of resistance to trimethoprim-
sulfamethoxazole (co-trimoxazole). These include 21.43% resistance by GABHS, 
68.60% resistance by H. influenzae and 67.75% by H. parainfluenzae. This resistance 
was consistent with findings by Sadoh et al. (2008) when they tested the throat swabs 
samples against ampicillin and co-trimoxazole.  
 Although our antimicrobial susceptibility data cannot estimate the current status 
of antibacterial resistance in Malaysia, it highlights a number of potentially important 
issues regarding the antibacterial susceptibility and epidemiology of the key respiratory 
tract pathogens such as S. aureus, H. influenza and GABHS (Alasil et al., 2011). 
Despite our results that showed high antimicrobial susceptibility against majority of the 
selected antibiotics, there was a noticeable resistance to fusidic acid by the pathogen S. 
aureus. This finding was consistent with the study made by Brown and Thomas (2002) 
where they reported a 10.6% increased rate of resistance to fusidic acid among 
methicillin-susceptible S. aureus (MSSA) isolates make it a less potential drug of choice 
for patients with chronic and recurrent tonsillitis. This was similar to another study by 
Norazah et al. (2002) reporting an increased resistant to fusidic acid between 3 to 5% 
among Malaysian hospitals.   
The fact that 12 (2.58%) of our tonsillar Haemophilus influenzae isolates were 
found to be β-Lactamase Negative Ampicillin-Resistant (BLNAR) is a big concern. 
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Resistance of H. influenzae to ampicillin has been increasing steadily since its 
emergence in the 1970s. Until recently, β-lactamase production has been the primary 
mechanism of ampicillin resistance among H. influenzae. However, the prevalence of β-
Lactamase-Nonproducing Ampicillin-Resistant (BLNAR) strains of H. influenzae now 
also appears to be increasing (Clinical and Laboratory Standards Institute, CLSI, 2003). 
This is of clinical significance, since BLNAR H. influenzae are typically co-resistant to 
other commonly prescribed β-lactams, including Augmentin (i.e. amoxicillin-
clavulanate) and ampicillin-sulbactam, in addition to most cephalosporins  (Clinical and 
Laboratory Standards Institute, CLSI, 2003).  
Since ESKAPE pathogens are responsible for a high percentage of nosocomial 
infections, interestingly we have found that the ESKAPE pathogens recovered from our 
tonsillar specimens showed high susceptibility against selected antibiotics except for 
Pseudomonas aeruginosa with 22.22% resistance (Appendix 10L) which was in 
contrast with the resistant ESKAPE pathogens previously reported by Rice (2010).  
The difficulty of treating biofilm infections with antibiotics is a major clinical 
problem (Ciofu and Tolker-Nielsen, 2011). Bacterial interference has been shown to 
exist between Alpha-Haemolytic Streptococci (AHS) and Beta-Haemolytic Streptococci 
and between Gram Negative Bacilli (GNB) and AHS recovered from tonsillar regions 
(Holm and Grahn, 1983). Study by Yoshioka et al. (1982) they demonstrated that oral 
ampicillin, cephalothin, tetracycline and chloramphenicol have been shown to suppress 
the AHS and promote the emergence of GNB. The lack of interference strains may 
explain the increased susceptibility of certain individuals to β-haemolytic streptococci. 
Preservation of the normal flora has more advantages than their re-establishment by 
antibiotics (Brook, 2007). Since the administration of antimicrobial agents can affect the 
composition of the nasopharyngeal bacterial flora, including the reduction of interfering 
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organisms, a proper use of antimicrobial agents is important in the preservation of the 
normal interfering flora (Brook and Gober, 2005).  
The lack of a rapid and reproducible assays that provide accessible assessment 
of activity of antibiotics with efficacy against bacterial biofilms has become a problem 
in selecting alternative antibiotic regimes (Ceri et al., 1999; Olson et al., 2002). 
Therefore, antimicrobial susceptibility of bacteria in a biofilm should be assessed 
especially when dealing with chronic infections caused by microorganisms for which 
their MICs have not provided clinically relevant information. This will assist clinicians 
in the selection of more powerful antibiotics for their activity and efficacy against 
biofilms.        
 
 
5.5  Evidence of Biofilms in the Tonsils 
Tonsillar and adenotonsillar diseases such as adenotonsillar hypertrophy causing 
obstructive sleep apnea syndrome (OSA) and/or chronic adenotonsillitis present a major 
problem in children and are the most common indications for tonsillectomy and/or T&A 
(Al-Mazrou and Al-Khattaf, 2008). Many of these infections are thought to be caused 
by resistant bacteria that have the ability to form biofilms (Don et al., 2005). Therefore, 
proper detection of such biofilms is of great importance for better management of 
tonsillar and adenotonsillar diseases.  
Our results showed the presence of attached bacteria in the form of biofilms on 
the surface of the palatine tonsils in 42 (60%) of selected patients via SEM and CLSM. 
The distribution of biofilms was 30 out of 49 patients with recurrent tonsillitis, 5 out of 
9 patients with chronic tonsillitis and 7 out of 12 patients with obstructive sleep apnea. 
This was similar to results published by Kania et al. (2007) who detected the presence 
of bacterial biofilms on human tonsillar mucosal tissue in (70.8%) patients with 
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tonsillitis via CLSM and SEM. Another similar study by Chole and Faddis (2003) 
demonstrated the presence of bacterial biofilms as acellular deposits among the crypts 
of 11 of 15 infected tonsils and 3 of 4 hypertrophied tonsils.  
Recovery of clinical isolates from infected and hypertrophied tonsils is 
important. However, the detection of biofilm formation by these isolates is thought to be 
of great impact to overcome therapeutic failures. Our study showed the presence of 
bacterial biofilms in infected and hypertrophied tonsils from patients with a history of 
infection and obstruction which suggest the role of biofilms in the pathogenesis of these 
clinical conditions and raise the possibility that bacterial biofilms are part of tonsillar 
microbial flora among clinically diseased tonsils which may explain the recalcitrant 
nature of some cases of recurrent tonsillitis (Chole and Faddis, 2003).  
Moreover, the fact that biofilms were observed in 7 out of 12 of the hypertrophic 
tonsils confirm the hypothesis that not only tonsillar infections but tonsillar hypertrophy 
is one of the important symptoms associated with the presence of biofilms. This was 
similar to the findings described by Chole and Faddis (2003) who reported that bacteria 
in biofilms are sequestered from host defenses and antibiotics which may explain the 
recalcitrant nature of some cases of chronic and recurrent tonsillitis.  
Based on the histological characteristics of tonsillar specimens, the number of 
lymphatic follicles was related to the presence of biofilms in infected more than non-
infected tonsils similar to the results obtained previously by Diaz et al. which might be 
related to the fact that most of the patients were diagnosed with infection-related 
symptoms rather than obstruction (Diaz et al., 2011). Despite the low prevalence of 
symptoms like apnea and nasal obstruction in comparison with tonsillar and adenoid 
hypertrophy among our selected patients, a direct correlation between apnea and nasal 
obstruction was found with the presence of biofilms in 7 out of 12 hypertrophied tonsils. 
This finding is consistent with previous investigations (Diaz et al., 2011).  
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Failure of patients with tonsillitis to respond to antimicrobial therapy leaves no 
choice but tonsillectomy. However, despite the role of tonsillectomy in relieving the 
symptoms of tonsillar diseases, the more likely explanation for its effectiveness is the 
elimination of a possible microbial biofilm infection. This is suggested by previous 
observations of bacterial resistance within a biofilm which confirms the hypothesis that 
chronic and recurrent tonsillitis are biofilm-related (Richardson et al., 1980; Stewart and 
Costerton, 2001).   
The fundamental knowledge and rapid detection of biofilms can lead to a better 
therapeutic management of tonsillar diseases to become more effective and less invasive 
(Suh et al., 2010). However, the demonstration of biofilms in human tissues is 
technically challenging and has so far relied mostly on the use of scanning electron 
microscopy and transmission electron microscopy (Kania et al., 2007). During sample 
preparation for SEM, the biofilm structure can be damaged which will add a limitation 
to clearly visualize biofilms (Akiyama et al., 2003). Despite the fact that image 
acquisition of biofilms obtained from SEM were correlated with the image acquisition 
obtained from CLSM, presence of biofilms via SEM in some of our samples was 
hampered by cell clots and mucus on the surface of the tissue leading to mask the 
bacteria from being properly visualized. This finding was similar to a study by Kania et 
al. where they reported that the images obtained by SEM are largely affected by the 
specimen’s dehydration (Kania et al., 2007) which can lead according to their report for 
false positive biofilm-like artifacts. Therefore, we conclude that detecting the bacteria 
and its glycocalyx is crucial for a fundamental understanding of the presence of biofilms 
in clinical specimens which can be largely supported through the use of CLSM.  
Our results indicates that the prevalence of bacterial biofilms among the 5 
clinical cases of Streptococcal Tonsillitis (ST) was 100% while among the 30 clinical 
cases of Non-Streptococcal Tonsillitis (NST) was 53% indicating a role of both 
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GABHS and non-GABHS isolates in the pathogenesis of biofilm-associated infection 
and obstruction tonsillar diseases among both children and adults. This was similar to 
findings made by Diaz et al. (2011) during a study which investigated the correlation 
between chronic inflammation of the tonsils, clinical features and the presence of 
biofilms in the crypts in 36 patients undergoing tonsillectomy for obstructive sleep 
apnea and recurrent upper airway pathology (Diaz et al., 2011). Their results showed 
that symptoms like harsh raucous sound, tonsillar and adenoids hypertrophy, apnea, and 
cervical adenopathies are clearly related to the presence of biofilm in tonsils allowing 
them to conclude that biofilms are involved in the pathogenesis of tonsils and adenoids 
hypertrophy. Therefore, the prevention of biofilms formation should be focused in the 
early stages, attempting to restrain bacterial attachment to the respiratory mucosa. 
The absence in reporting a biofilm infection via routine clinical pathology 
examination is maybe due to the conventional techniques that are still being used in 
most histopathology labs such as light microscope coupled with routine staining such as 
H&E which might hamper the ability to precisely detect a source of infection as 
important as a biofilm. Therefore, for a fundamental understanding and proper 
examination of bacterial biofilms in tissue sections, detection must include both the 
bacteria and its glycocalyx matrix (Kania et al., 2007). This can be achieved by using 
Confocal Laser Scanning Microscopy (CLSM) (Oliveira and Cunha Mde, 2010) 
coupled with a double staining technique which will allow to visualize microbial 
biofilms and observe their 3-dimensional structure in a way that routine histology 
methods cannot, thus providing a more realistic image of the biofilm in situ. This 
observation was similar to previous reports (Kania et al., 2007; Oliveira and Cunha 
Mde, 2010; Rumbaugh and Carty, 2011) where they emphasized on the role using novel 
visualization approaches such as CLSM to examine biofilms in single sections of 
human mucosal tissue such as the tonsils.  
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The use of confocal laser scanning microscopy allows a better examination of 
biofilms, and this is mainly achieved by the use of certain fluorescent dyes such as 
Concanavalin A that binds to mannose residues specific to the bacteria’s glycocalyx 
(Zur et al., 2004). Moreover, the use of various software functions within the CLSM 
have a big impact on analyzing important parameters within the biofilm such as the 
degree of co-localization of certain labeled structures (Kania et al., 2007). However, 
despite the importance of using CLSM to visualize biofilms, it has the limitation of not 
identifying the type of microorganisms causing that biofilm in addition of being costly 
and time-consuming in terms of sample processing and analysis. This finding was 
similar to what was reported previously (Kania et al., 2007).  
Our results demonstrated that clinical symptoms like snoring, apnea, nasal 
obstruction, tonsillar and adenoid hypertrophy are found to be related to the presence of 
bacterial biofilms in the tonsils. This finding was largely implicated by the study of 
Diaz et al. (2011) where they found that tonsillar tissue sections obtained from patients 
with chronic and recurrent tonsillitis with evidence of bacterial biofilms showed 
increased number of lymphatic follicles in comparison to sections from patients with 
OSA. Therefore, prevention of a biofilm infection should be focused on in the early 
stages, having in mind the connection with clinical symptoms demonstrated here. 
 
 
5.6 Biofilm Formation Ability of Clinical Isolates   
The association between biofilm formation and persistence was accomplished by 
quantitative assays like the CRA method and MTP assay. The biofilm formation ability 
of all of our 464 isolates was found to be significantly associated with bacterial 
persistence. The isolates having biofilm formation ability were more likely to persist in 
the nasopharynx than non-biofilm formers showing a clonal distribution of strains 
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within the population. These findings provide evidence indicating the relationship 
between biofilm formation and the persistence of bacteria. Our results emphasize the 
need to evaluate the potential for biofilm formation before designing preventive and 
therapeutic strategies. 
Among all our tonsillar bacterial isolates obtained from both tonsillar swabs and 
biopsies, 232 (50%) isolates were showed to be strong to moderate biofilm formers via 
MTP assay. This was further confirmed by the biofilm formation ability via CRA 
method where 207 (44.6%) isolates where biofilms formers as assessed by the CRA 
method indicating a correlation between the two methods. This was similar to results by 
Drago et al. (2012) were they evaluated the ability of bacterial isolates recovered from 
tonsillar biopsies and swabs to form biofilms in vitro. Their results showed that 44.7% 
of the intraoperative collected samples were either moderate or strong biofilm producers 
compared with 27% of isolates at 6 months after surgery concluding that the ability to 
form biofilm decreased in bacteria isolated after tonsillectomy which suggests a role for 
biofilm in pathogenesis of recurrent and chronic pharyngeal diseases such as tonsillitis 
(Drago et al., 2012). However, our findings were in contrast to the study by Lizcano et 
al. were they tested the ability of 30 invasive and 22 non-invasive clinical isolates of S. 
pneumoniae serotype 6A and 6B to form early biofilms in polystyrene microtiter plates 
(Lizcano et al., 2010). They suggested that the ability to form early biofilms in vitro 
does not reflect virulence potential. 
The recovery of important pathogens like Staphylococcus aureus, Haemophilus 
influenzae and GABHS and their strong ability to form biofilms in vitro does suggest 
the existence of polymicrobial infections in tonsillar diseases and emphasize the role of 
bacterial load in the core of tonsils as important new concepts in understanding the 
development of chronic infections in otolaryngology. 
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The failure of conventional culture techniques to detect the antimicrobial 
susceptibility of bacteria in biofilms part of the failure to eradicate biofilm-associated 
infections. Many investigators have used the MTP assay to examine the mechanisms 
that contribute to biofilm formation and bacterial attachment to abiotic surfaces among 
pneumococcal isolates (Allegrucci and Sauer, 2007; Trappetti et al., 2009). Advantages 
of this assay include simplicity, high-throughput screening and visualization of biofilm 
structures. Based on existing evidence supporting a role for biofilm formation during 
middle ear infection and nasopharyngeal colonization, we conclude that the ability to 
form biofilms in vitro might also contribute towards the ability to cause invasive 
biofilm-associated infections in vivo. Our results indicate that the MTP assay can serve 
as a reliable quantitative tool for comparing the adherences of different pathogenic 
strains which helps to confirm the pathogenic significance of adherence among 
clinically important isolates.   
On CRA, biofilm producers or virulent strains produce black to almost black 
color colonies and non-producers from pink to bordeaux colored colonies on CRA. It is 
known that Congo red can directly interact with certain polysaccharide forming 
chromatic complexes. However, it appears more likely that some metabolic changes of 
the dye to form a secondary product could play a more important part in the formation 
of dark colonies (Aricola et al., 2001).   
The CRA method is rather easy to perform, taking less time and it is sensitive 
and specific. Moreover it allows the formation of the colonies on the plate to be directly 
monitored for the appearance of phase variant bacteria, which can eventually be 
evidenced as pink spikes on the surface of dark colonies (Ziebuhar et al., 1997). This is 
particularly significant because there is evidence suggesting that the phase variability 
itself should be regarded as an important virulence marker. Our results showed that 
CRA method was both sensitive and specific for biofilm detection in all bacterial 
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isolates including the most common isolate Staphylococcus aureus. This was similar to 
a study by Jain and Agarwal (2009) were the authors concluded the specificity of CRA 
when applied to S. aureus isolates. We conclude that CRA method can still be used to 
determine whether an isolate has the potential for biofilm production or not despite 
previous reports suggesting CRA as being slightly imprecise in the identification of 
positive isolates when compared to molecular analysis of the genes involved in biofilm 
production (Oliveira and Cunha Mde, 2010).   
Since an early detection of biofilms from potentially pathogenic microorganisms 
can be essential towards prevention and management of biofilm-associated nosocomial 
infections (Jain and Agarwal, 2009), we believe that clinical microbiology laboratories 
implement CRA method and MTP assays as qualitative and quantitative screening 
techniques when dealing with clinical isolates suspected to be potential biofilm formers. 
 
 
5.7 Discovery of Antibiofilm Activity from Paenibacillus Strain 139SI  
 A novel bacterial strain used in this study was originally discovered, isolated and 
characterized from agricultural soil. We proposed the name Paenibacillus haemolyticus 
based on the strong haemolytic activity and the results of 16S rRNA gene sequencing 
(Salmah et al., 2012).  
The bacterial cells were characterized as Gram-positive, facultatively anaerobic, 
endospore-forming bacteria with remarkable haemolytic activity when grown on 
Columbia agar supplemented with 5% sheep blood. Culturing the bacteria on blood agar 
is often considered as a screening method for the ability of those microorganisms to 
produce biosurfactants on hydrophilic media (Plaza et al., 2006; Schulz et al., 1991; 
Youssef et al., 2004). Although the method has some limitations, i.e. poor specificity 
and diffusion restriction of the surfactant compound that may inhibit formation of 
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clearing zones (Jain et al., 1991; Schulz et al., 1991), it is still regarded as a preliminary 
screening method that should be supported by other identification techniques (Mulligan 
et al., 1984). The use of enrichment media is important in providing favourable growth 
conditions for the organisms of interest and unfavourable for the competing organisms 
(Bento et al., 2005; Sen, 2010; Willumsen and Karlson, 1997). In addition, sequencing 
of 16S rRNA gene is considered the method of choice for the accurate identification of 
microorganisms (Sintchenko, 2010) because it allows the study of slow-growing and 
uncultivable bacteria which in turn paves the way for the discovery of new bacterial 
species. We are in the process of obtaining the bacteriological code validation for our 
Paenibacillus haemolyticus.  
In recent years, many researchers have focused on acute toxicity study on 
antimicrobial metabolites isolated from different soil microorganisms such as 
Streptomyces species (Bari et al., 2006; Khondkar et al., 1997) for the purpose of 
identifying new sources of bioactive natural products. Our results of acute toxicity 
showed that the metabolite compound isolated from novel species of Paenibacillus 
haemolyticus strain 139SI is not a toxic compound with no substantial effect on the 
biochemical parameters and haematological profiles of SD rats in addition to not 
showing any effects on cellular structures which makes us conclude that the compound 
can be considered potential candidate to establish new therapeutics. These findings were 
similar to another study made by Akhand et al. (2010) where they assessed the effect of 
a new compound from a new soil Streptomyces species. Their finding demonstrated that 
their compound did not show any effect on Long Evan’s rats at a dose of 300 
μg/rat/day. Thus the findings of this investigation would give valuable support to further 
studies and clinical trials of isolated compounds and thus new compounds with 
biological activity (Clarridge, 2004; Hall et al., 2003; Woo et al., 2008).    
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In our study, Paenibacillus possessed antibiofilm activity against clinical 
bacterial isolates. However, this novel species was not virulence in mice (Mahsa, 2013). 
Whether this bacterium can also be found in animal gut or whether there is symbiosis 
with its host remains to be seen. Our findings suggest that extracts from 139SI bacterial 
strain exhibit potent antibiofilm activity against clinically important pathogens and that 
treatment with this extract significantly prolonged the survival time of the experimental 
animal groups with no detected toxicity. 
The great potential of soil microbial resource can only be truly utilize through 
the combination of the innovative techniques of both biology and chemistry. Therefore, 
we have applied HPLC profiling couples with LC-MS to identify to purified bioactive 
compounds from a microbial origin. This was similar to the approach applied by Mitova 
et al., where they used HPLC bioactivity profiling/microtiter technique in conjunction 
with capillary NMR instrumentation in addition to AntiMarin database for the isolation 
and characterization of new bioactive metabolites from New Zealand fungi particularly 
the strain Sepedonium chrysospermum (Mitova et al., 2008).   
 
 
5.8 Therapeutic Effects of Paenibacillus Strain 139SI against Biofilms   
In our animal model, treatment with the crude culture filtrate of Paenibacillus 
haemolyticus strain 139SI along with the synthetic furanones as a control drug 
significantly increased the survival time of infected rats, assisted bacterial clearance by 
the host and reduced the lung pathology. The rats were infected with Pseudomonas 
aeruginosa containing a large amount of an endotoxin which has been shown 
previously to enhanced oxidative burst response (Kharazmi et al., 1991). It is likely that 
the metabolites produced by novel Paenibacillus haemolyticus strain 139SI may 
activate the endotoxin-primed neutrophils. 
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This was similar to the study made by Wu et al., where they tested synthetic 
furanones for their ability to attenuate bacterial virulence in the mouse models of 
chronic lung infection by targeting bacterial quorum-sensing without directly killing 
bacteria or inhibiting their growth  (Wu et al., 2004). They reported that furanones 
successfully interfered with N-acyl homoserine lactone and suppressed bacterial 
quorum-sensing in lungs, which resulted in an accelerated lung bacterial clearance, and 
a reduced severity of lung pathology.  
Inhibition of the alginate barrier produced by P. aeruginosa using nontoxic 
compounds targeted against alginate biosynthetic may be useful in eliminating P. 
aeruginosa biofilms from chronically infected tissues such as the lungs of CF patients 
(May et al., 1991). It was noticed that the areas with pathologic changes in treatment 
group was smaller than that in the positive control group. The incidence of chronic 
inflammation in treatment group including 6 (12.5%) rats was lower than that in control 
group 12 (25%) (Table 4.7). This was similar to the findings made by Song et al., when 
they evaluated the effect of ginseng treatment on the oxidative burst response of 
peripheral blood neutrophils and alveolar macrophages in a rat model of chronic mucoid 
P. aeruginosa lung infection (Song et al., 1998).  
The fact that majority of rats classified under Score II, i.e. mild focal 
inflammation of the lung, were belonging to the comparative control group 5 (10.4%) 
and the treatment group 6 (12.5%) whereas majority of rats under Score IV, i.e. severe 
inflammation to necrosis of the lung, belong to the positive control group 10 (20.83%) 
indicates the therapeutic effect of 139SI filtrate and 2(5H)-Furanone in attenuating the 
biofilm infection of Pseudomonas aeruginosa in the lungs of SD male and female rats.  
PMNs are among the blood cells that are important for the host defense against 
bacterial infections. However, in CF patients the infiltration of numerous PMNs in the 
lung tissues affected with chronic P. aeruginosa infection does not clear the bacteria 
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effectively. Instead, the PMNs become an important cause of tissue damage of the lung 
parenchyma because of the release of lysosomal enzymes, particularly leukocyte 
elastase (Høiby, 1995). It has been shown that the extracellular products of P. 
aeruginosa, alkaline protease and elastase, can inhibit the myeloperoxidase- mediated 
chemiluminescence which is one of the major antimicrobial systems manifested by 
PMNs (Kharazmi et al., 1984) This might be among the reasons that PMN infiltration 
into lungs affected by CF does not eliminate the P. aeruginosa infection effectively. 
Another reason is the weak response of PMNs to the biofilm mode of growth of P. 
aeruginosa in the lungs of CF patients  (Høiby et al., 1995).  
Our finding suggests that culture filtrate from novel bacterial species of 
Paenibacillus haemolyticus strain 139SI bacterial strain exhibited antibiofilm activity 
against clinically important pathogens and that treatment with this extract significantly 
prolonged the survival time of the experimental animal and was able to clear the 
artificial alginate that mimics the biofilm environment. However, the identified 
compounds were not further evaluated to identify their chemical structure and 
antibiofilm activity. The mechanism of antibiofilm activity for Paenibacillus 
haemolyticus strain 193SI are yet to be explored.  
 
 
5.9 Conclusions  
This study contributes important findings that have not been reported by others 
where compounds derived from the novel bacterial species of Paenibacillus 
haemolyticus strain 193SI showed remarkable antibiofilm activity against clinically 
important pathogens and was capable of inhibiting the biofilm formation of a broad 
range of bacterial isolates recovered from chronically infected tonsils which adds an 
important new dimension to the search for potent drugs against bacterial biofilm 
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infections. Other findings conclude that ENT infections such as chronic and recurrent 
tonsillitis are biofilm-related and the strong ability of clinical bacterial isolates that are 
susceptible to antibiotics to being strongly associated with biofilm formation. In 
addition to the ability in establishing an animal model of chronic lung infection that is 
treated with crude filtrate of metabolites produced by the novel Paenibacillus 
haemolyticus strain 139SI.  
More studies are needed to identify the mechanism(s) of action of these 
antibiofilm agents and characterize the diversity of the genus Paenibacillus and their 
adaptation to the soil environment secondary metabolite production will create a better 
understanding of the potential utility of these bacteria as a source of useful products for 
medicine particularly against biofilm infections. 
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5.10 Limitations of the Study 
1. No control group due to difficulty in obtaining tonsils from age-matched individuals 
who never had infection or obstruction in the upper airways (Kania et al., 2007).   
2. No assessment on the role of anaerobic bacteria, viruses and fungi in tonsillar 
diseases due to the difficulties in collecting, transporting and culturing them.    
3. No pre and post tonsillectomy assessment of infant’s development and body weight 
(Greenfeld et al., 2003).   
4. No post-tonsillectomy evaluation of patients’ quality of life (QOL) (Witsell et al., 
2008). 
5. No evaluation between biofilm in tonsillar diseases among ethnic groups (no racial 
comparison study). 
  
6. It was not possible to establish a rat model for tonsillitis because rodents have a 
different pharyngeal anatomy than humans and they lack both the palatine and 
nasopharyngeal tonsils (Perry and Whyte, 1998). 
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5.11 Strengths of the Study 
 
1. The discovery of a secondary metabolite compound from a taxonomically novel 
species of Paenibacillus that exhibits antibiofilm activity against a wide range of 
clinically important pathogens.  
 
2. The use of Confocal Laser Scanning Microscopy as a standard tool to detect the 
presence of bacterial biofilm in the palatine tonsils.           
 
3. To avoid selection (sample) bias, patients were clinically assessed by the ENT 
specialists and medical officers at UMMC prior to inclusion to ensure adequate 
representation of the specimens.   
 
4. To avoid measurement bias, tonsillar specimens (i.e. swabs and biopsies) were 
referred to the Clinical Diagnostic Laboratories (CDL) at University Malaya Medical 
Centre (UMMC) for proper isolation and identification of bacterial isolates.      
 
5. To avoid information bias, characterization and identification of the antibiofilm 
compounds from 139SI filtrate were blindly assessed by a certified consultancy 
group using skilled technicians equipped with highly calibrated equipment.      
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5.12  Future Studies 
 
1. Evaluation of the immunopathology of tonsils with and without biofilms. 
2. A racial comparison study for the presence of biofilms among paediatric patients 
with OSA.    
3. Post-tonsillectomy quantification of the oropharyngeal microbial flora and their 
biofilm formation among larger sample size.  
4. Post-operative assessment of the effectiveness of tonsillectomy in eradicating 
biofilm infections.     
5. Establishment of a rational basis in the treatment of tonsillar diseases by comparing 
the pre-operative symptoms with the respective changes that took place post-
operatively.  
6. Administration of 139SI compound in rats as a goggle or spray rather than orally.      
7. Evaluation of the in vivo antibiofilm activity of the FR5 potential compound. 
8. Identify the mechanisms of action of all the potential 139SI antibiofilm compounds. 
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Appendix 8 List of Patients with their Clinical Cases, Type and Date of Surgery  
 
 
Patient 
No. 
Sex Age Clinical Case Type of Operation Date of 
Surgery 
1 F 7 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 26/10/2009 
2 M 11 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 26/10/2009 
3 M 23 Recurrent Tonsillitis Tonsillectomy 26/10/2009 
4 F 9 Recurrent Adenotonsillitis Tonsillectomy & Adenoidectomy 02/11/2009 
5 M 16 Recurrent Tonsillitis Tonsillectomy 04/11/2009 
6 M 31 Recurrent Tonsillitis Tonsillectomy 09/11/2009 
7 M 16 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 09/11/2009 
8 M 16 Chronic Tonsillitis Tonsillectomy 18/11/2009 
9 M 11 OSA Secondary to Recurrent Acute Tonsillitis Tonsillectomy & Adenoidectomy 30/11/2009 
10 F 11 Recurrent Tonsillitis Tonsillectomy 02/12/2009 
11 M 5 Recurrent Tonsillitis Tonsillectomy 07/12/2009 
12 F 9 Recurrent Tonsillitis Tonsillectomy 07/12/2009 
13 F 13 Recurrent Tonsillitis with Bilateral MEE Tonsillectomy & Adenoidectomy 09/12/2009 
14 M 9 Recurrent Tonsillitis with Bilateral MEE Tonsillectomy & Adenoidectomy 09/12/2009 
15 F 26 Recurrent Tonsillitis Tonsillectomy 14/12/2009 
16 F 24 Recurrent Tonsillitis Tonsillectomy 28/12/2009 
17 F 26 Recurrent Tonsillitis Tonsillectomy 13/01/2010 
18 F 17 Recurrent Tonsillitis with Bilateral MEE Tonsillectomy & Adenoidectomy 18/01/2010 
19 F 15 Recurrent Adenotonsillitis Tonsillectomy & Adenoidectomy 27/01/2010 
20 F 10 Recurrent Tonsillitis Tonsillectomy 03/02/2010 
21 M 8 Recurrent Tonsillitis Tonsillectomy 03/02/2010 
22 F 5 Recurrent Tonsillitis with Snoring Tonsillectomy & Adenoidectomy 10/02/2010 
23 F 5 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 10/02/2010 
24 M 6 Recurrent Tonsillitis Tonsillectomy 10/02/2010 
25 F 17 Chronic Tonsillitis Tonsillectomy 22/02/2010 
26 M 7 Obstructive Sleep Apnea Tonsillectomy & Adenoidectomy 01/03/2010 
27 F 28 Recurrent Tonsillitis Tonsillectomy 03/03/2010 
28 M 6 OSA Secondary to Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 08/03/2010 
29 F 18 Chronic Tonsillitis with Snoring Tonsillectomy 08/03/2010 
30 F 24 Chronic Tonsillitis Tonsillectomy 10/03/2010 
31 F 13 Recurrent Tonsillitis Tonsillectomy 15/03/2010 
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32 F 12 Recurrent Tonsillitis with Bilateral MEE Tonsillectomy 15/03/2010 
33 F 9 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 22/03/2010 
34 M 8 OSA Secondary to Tonsillar Hypertrophy Tonsillectomy 22/03/2010 
35 F 23 Recurrent Tonsillitis Tonsillectomy 22/03/2010 
36 F 24 Recurrent Tonsillitis Tonsillectomy 29/03/2010 
37 M 11 Chronic Tonsillitis Tonsillectomy 31/03/2010 
38 M 9 Recurrent Tonsillitis Tonsillectomy 31/03/2010 
39 F 10 Recurrent Tonsillitis Tonsillectomy 31/03/2010 
40 F 27 Recurrent Tonsillitis Tonsillectomy 12/04/2010 
41 F 16 Obstructive Sleep Apnea Tonsillectomy & Adenoidectomy 12/04/2010 
42 F 8 Obstructive Sleep Apnea Tonsillectomy & Adenoidectomy 14/04/2010 
43 M 10 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 14/04/2010 
44 M 8 Chronic Tonsillitis Tonsillectomy 19/04/2010 
45 M 4 OSA Secondary to Tonsillar Hypertrophy Tonsillectomy & Adenoidectomy 21/04/2010 
46 F 11 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 21/04/2010 
47 M 10 OSA Secondary to  Adenoid Hyperplasia Tonsillectomy & Adenoidectomy 26/04/2010 
48 F 25 Recurrent Tonsillitis Tonsillectomy 28/04/2010 
49 M 5 OSA Secondary to Tonsillar Hypertrophy Tonsillectomy 03/05/2010 
50 F 12 Recurrent Tonsillitis with Snoring Tonsillectomy & Adenoidectomy 12/05/2010 
51 F 6 OSA Secondary to Recurrent Tonsillitis Tonsillectomy 31/05/2010 
52 F 27 OSA secondary to Recurrent Tonsillitis Tonsillectomy 31/05/2010 
53 M 7 Chronic Tonsillitis Tonsillectomy 02/06/2010 
54 M 7 Recurrent Tonsillitis with Snoring Tonsillectomy 09/06/2010 
55 F 13 Recurrent Tonsillitis Tonsillectomy 14/06/2010 
56 M 38 Recurrent Tonsillitis with Snoring Tonsillectomy & Adenoidectomy 14/06/2010 
57 F 17 Recurrent Tonsillitis Tonsillectomy 16/06/2010 
58 F 8 Recurrent Tonsillitis Tonsillectomy 28/06/2010 
59 M 17 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 30/06/2010 
60 F 7 Recurrent Tonsillitis Tonsillectomy 30/06/2010 
61 M 16 Chronic Adenotonsillitis Tonsillectomy & Adenoidectomy 05/07/2010 
62 F 36 Recurrent Tonsillitis Tonsillectomy 05/07/2010 
63 M 22 Recurrent Tonsillitis Tonsillectomy 05/07/2010 
64 F 23 Recurrent Tonsillitis Tonsillectomy & Adenoidectomy 07/07/2010 
65 F 15 OSA Secondary to Primary Snoring Tonsillectomy & Adenoidectomy 07/07/2010 
66 M 3 Chronic Tonsillitis Tonsillectomy 14/07/2010 
67 F 48 Recurrent Tonsillitis Tonsillectomy 14/07/2010 
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68 M 27 Recurrent Tonsillitis Tonsillectomy 26/07/2010 
69 F 20 Recurrent Tonsillitis Tonsillectomy 26/07/2010 
70 F 30 Recurrent Tonsillitis Tonsillectomy 02/08/2010 
 
 
 
 Tonsillar Obstructive Group  
 Tonsillar Infection Group  
 Tonsillar Infection Group  
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Appendix 9  Distribution and Mean of the Recovered Bacterial Isolates from 
Tonsillar Specimens 
 
 
Patient 
No. 
Sex Age Clinical Case Tonsillar 
Specimen  
Recovered Bacterial Isolate  Mean of Isolates 
per specimen  
1 F 7 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 1 
Swab 
 
  
2 M 11 Recurrent Tonsillitis Biopsy Staphylococcus aureus 1 
Swab 
 
  
3 M 23 Recurrent Tonsillitis Biopsy 
 
Enterobacter cloacae 
Acinetobacter baumannii 
Pseudomonas aeruginosa 
Staphylococcus aureus 
4 
Swab 
 
  
4 F 9 Recurrent 
Adenotonsillitis 
Biopsy 
 
Staphylococcus aureus  
Haemophilus influenzae  
Staphylococcus aureus 
3 
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
5 M 16 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
Swab 
 
Staphylococcus aureus  
Haemophilus influenzae  
Staphylococcus aureus 
3 
6 M 31 Recurrent Tonsillitis Biopsy 
 
Group B Streptococci  
Group B Streptococci  
Group G Streptococci 
3 
Swab 
 
Group B Streptococci  
Group B Streptococci  
Methicillin-Resistant S. aureus 
3 
7 M 16 Recurrent Tonsillitis Biopsy 
 
Klebsiella pneumoniae  
Staphylococcus aureus  
Klebsiella pneumoniae 
3 
Swab 
 
Klebsiella pneumoniae 
Klebsiella pneumoniae 
2 
8 M 16 Chronic Tonsillitis Biopsy 
 
 
Staphylococcus aureus 
Haemophilus influenzae  
Group B Streptococci  
Staphylococcus aureus 
Haemophilus parainfluenzae  
Group B Streptococci  
6 
Swab 
 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Group F Streptococci  
Haemophilus parainfluenzae 
4 
9 M 11 Recurrent Acute 
Tonsillitis with OSA 
Biopsy 
 
 
Staphylococcus aureus 
Haemophilus influenzae  
Staphylococcus aureus 
Group G Streptococci 
Haemophilus parainfluenzae 
5 
Swab 
 
Staphylococcus aureus 
Group G Streptococci 
Haemophilus influenzae 
Group G Streptococci 
Haemophilus parainfluenzae 
5 
10 F 11 Recurrent Tonsillitis Biopsy 
 
 
Staphylococcus aureus 
Staphylococcus aureus 
Haemophilus influenzae 
6 
Swab 
 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
 
11 M 5 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
6 
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 Group B Streptococci 
Staphylococcus aureus 
Haemophilus influenzae 
Group B Streptococci 
Swab 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
12 F 9 Recurrent Tonsillitis Biopsy 
Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Haemophilus influenzae 
Staphylococcus aureus 
4 
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus 
Haemophilus influenzae 
Haemophilus influenzae 
4 
13 F 13 Recurrent Tonsillitis  
with Bilateral MEE 
Biopsy 
 
Staphylococcus aureus 
Group G Streptococci 
Group G Streptococci 
Haemophilus influenzae 
Staphylococcus aureus 
5 
Swab 
 
Group G Streptococci 
Group G Streptococci 
2 
14 M 9 Recurrent Tonsillitis 
 with Bilateral MEE 
Biopsy 
 
Staphylococcus aureus 
Group G Streptococci 
Haemophilus influenzae 
Staphylococcus aureus 
Group G Streptococci 
Haemophilus influenzae 
6 
Swab 
 
Group G Streptococci 
Haemophilus influenzae 
Staphylococcus aureus 
Group G Streptococci 
Haemophilus influenzae 
Staphylococcus aureus 
6 
15 F 26 Recurrent Tonsillitis Biopsy 
 
Klebsiella pneumoniae 
Staphylococcus aureus 
Group B Streptococci 
Klebsiella pneumoniae 
Staphylococcus aureus 
Group B Streptococci  
6 
Swab 
 
Klebsiella pneumoniae 
Group B Streptococci 
Klebsiella pneumoniae 
Staphylococcus aureus 
Group B Streptococci 
5 
16 F 24 Recurrent Tonsillitis Biopsy 
 
Klebsiella pneumoniae 
Staphylococcus aureus 
Group B Streptococci 
Klebsiella pneumoniae 
Staphylococcus aureus 
Group B Streptococci 
6 
Swab 
 
Klebsiella pneumoniae 
Staphylococcus aureus 
Klebsiella pneumoniae 
3 
17 F 26 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Staphylococcus aureus 
Haemophilus parainfluenzae 
3 
Swab 
 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
18 F 17 Recurrent Tonsillitis 
with Bilateral MEE 
Biopsy 
 
 
Haemophilus influenzae 
Haemophilus influenzae 
Group G Streptococci 
3 
Swab 
 
Haemophilus influenzae  
Haemophilus influenzae 
Haemophilus influenzae 
Group G Streptococci 
4 
19 F 15 Recurrent 
Adenotonsillitis 
Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
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Swab 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
20 F 10 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae  
Group G Streptococci 
Staphylococcus aureus 
3 
Swab 
 
Staphylococcus aureus 
Haemophilus influenzae  
Staphylococcus aureus 
Haemophilus influenzae  
4 
21 M 8 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae  
Group A Streptococci 
2 
Swab 
 
Haemophilus influenzae 
Group A Streptococci 
Haemophilus influenzae 
Group A Streptococci 
4 
22 F 5 Recurrent Tonsillitis 
with Snoring 
Biopsy 
 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
3 
Swab 
 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Haemophilus parainfluenzae 
3 
23 F 5 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
3 
Swab 
 
Haemophilus influenzae 
Staphylococcus aureus 
2 
24 M 6 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
Swab 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
3 
25 F 17 Chronic Tonsillitis Biopsy 
 
Group B Streptococci 
Staphylococcus aureus 
Group B Streptococci 
Haemophilus influenzae 
Staphylococcus aureus 
5 
Swab 
 
Group B Streptococci 
Haemophilus influenzae 
Klebsiella pneumonia  
3 
26 M 7 Obstructive Sleep 
Apnea 
Biopsy 
 
Group A Streptococci 
Staphylococcus aureus 
Klebsiella pneumoniae 
Group A Streptococci 
Staphylococcus aureus 
Klebsiella pneumoniae 
6 
Swab 
 
Group A Streptococci 
Staphylococcus aureus 
Klebsiella pneumoniae 
Group A Streptococci 
Staphylococcus aureus 
5 
27 F 28 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 1 
Swab 
 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
3 
28 M 6 Adenotonsillar 
Hypertrophy 
Biopsy 
 
Staphylococcus aureus  
Group B Streptococci 
Group B Streptococci 
Haemophilus parainfluenzae 
Staphylococcus aureus  
5 
Swab 
 
Staphylococcus aureus  
Haemophilus parainfluenzae 
Group B Streptococci 
Group B Streptococci 
Haemophilus influenzae 
Staphylococcus aureus 
6 
29 F 18 Chronic Tonsillitis  
with Snoring 
Biopsy 
 
Group G Streptococci 
Staphylococcus aureus 
Group G Streptococci 
5 
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Staphylococcus aureus 
Klebsiella pneumonia 
Swab 
 
 
Group G Streptococci 
Staphylococcus aureus 
Group G Streptococci 
Staphylococcus aureus 
4 
30 F 24 Chronic Tonsillitis Biopsy 
 
Staphylococcus aureus  
Group A Streptococci  
Staphylococcus aureus  
3 
Swab 
 
Group A Streptococci  
Staphylococcus aureus  
Staphylococcus aureus  
3 
31 F 13 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae 
Haemophilus influenzae 
2 
Swab 
 
Haemophilus influenzae 
Haemophilus influenzae 
2 
32 F 12 Recurrent Tonsillitis  
with Bilateral MEE 
Biopsy 
 
Haemophilus influenzae 
Staphylococcus aureus 
Staphylococcus aureus 
3 
Swab 
 
Haemophilus influenzae 
Staphylococcus aureus 
Staphylococcus aureus 
Streptococcus pneumoniae 
4 
33 F 9 Tonsillar Hypertrophy Biopsy 
 
Pseudomonas aeruginosa 
Pseudomonas aeruginosa 
2 
Swab 
 
Pseudomonas aeruginosa 
Haemophilus influenzae 
Pseudomonas aeruginosa 
3 
34 M 8 Tonsillar Hypertrophy  
with OSA 
Biopsy 
 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Group F Streptococci  
Staphylococcus aureus 
Group F Streptococci  
5 
Swab 
 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Staphylococcus aureus 
Group F Streptococci 
4 
35 F 23 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae 
Haemophilus influenzae 
Staphylococcus aureus 
3 
Swab 
 
Haemophilus influenzae 
Haemophilus influenzae 
Staphylococcus aureus 
3 
36 F 24 Recurrent Tonsillitis Biopsy 
 
Group B Streptococci 
Staphylococcus aureus  
Group B Streptococci 
Staphylococcus aureus 
Klebsiella pneumoniae 
5 
Swab 
 
Group B Streptococci 
Staphylococcus aureus  
Group B Streptococci 
Staphylococcus aureus 
Klebsiella pneumoniae 
5 
37 M 11 Chronic Tonsillitis Biopsy 
 
Haemophilus influenzae 1 
Swab 
 
Haemophilus influenzae 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
38 M 9 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 1 
Swab 
 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Staphylococcus aureus 
5 
39 F 10 Recurrent Tonsillitis Biopsy 
 
Klebsiella pneumoniae 
Klebsiella pneumoniae 
2 
Swab 
 
Klebsiella pneumoniae 
Klebsiella pneumoniae 
 
40 F 27 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Group F Streptococci 
Staphylococcus aureus 
4 
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Group B Streptococci 
Swab 
 
Staphylococcus aureus 
Group F Streptococci 
Staphylococcus aureus 
Group B Streptococci 
4 
41 F 16 Obstructive Sleep 
Apnea 
Biopsy 
 
Staphylococcus aureus 
Group B Streptococci 
Staphylococcus aureus 
Group B Streptococci 
4 
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
42 F 8 Obstructive Sleep 
Apnea 
Biopsy 
 
Haemophilus influenzae 
Staphylococcus aureus  
Group B Streptococci 
Haemophilus influenzae 
Staphylococcus aureus  
Group B Streptococci 
6 
Swab 
 
Haemophilus influenzae 
Staphylococcus aureus  
Haemophilus influenzae 
Staphylococcus aureus  
4 
43 M 10 Recurrent Tonsillitis Biopsy 
 
Group B Streptococci 
Staphylococcus aureus  
2 
Swab 
 
Group G Streptococci 
Haemophilus parainfluenzae 
Group G Streptococci 
Haemophilus parainfluenzae 
Group G Streptococci 
5 
44 M 8 Chronic Tonsillitis Biopsy 
 
Klebsiella pneumoniae 
Group C Streptococci 
Haemophilus influenzae 
Klebsiella pneumoniae 
Staphylococcus aureus  
Group C Streptococci 
Haemophilus influenzae 
7 
Swab 
 
 
Klebsiella pneumoniae 
Haemophilus influenzae 
 Group C Streptococci  
Klebsiella pneumoniae  
Group C Streptococci 
Staphylococcus aureus  
Group C Streptococci 
Group B Streptococci 
Haemophilus influenzae 
9 
45 M 4 Tonsillar Hypertrophy Biopsy 
 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
4 
Swab 
 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
4 
46 F 11 Tonsillar Hypertrophy Biopsy 
 
Haemophilus influenzae 
Staphylococcus aureus  
Group B Streptococci 
Staphylococcus aureus  
Group B Streptococci 
5 
Swab 
 
Haemophilus influenzae 
Staphylococcus aureus  
Group B Streptococci 
Staphylococcus aureus  
Group B Streptococci 
5 
47 M 10 Adenoid Hyperplasia  
with OSA 
Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
Swab 
 
Staphylococcus aureus 
Klebsiella pneumoniae 
Staphylococcus aureus 
Haemophilus influenzae 
4 
48 F 25 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Pseudomonas aeruginosa 
4 
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Staphylococcus aureus 
Pseudomonas aeruginosa 
Swab 
 
Staphylococcus aureus 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Pseudomonas aeruginosa 
Haemophilus parainfluenzae 
5 
49 M 5 Tonsillar Hypertrophy 
with OSA 
Biopsy 
 
Haemophilus parainfluenzae 1 
Swab 
 
Haemophilus influenzae 
Haemophilus parainfluenzae 
2 
50 F 12 Recurrent Tonsillitis  
with Snoring  
Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Group G Streptococci 
Staphylococcus aureus 
Haemophilus influenzae 
5 
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
51 F 6 Recurrent Tonsillitis  
with OSA 
Biopsy 
 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
3 
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus 
Haemophilus influenzae 
3 
52 F 27 Recurrent Tonsillitis  
with OSA 
Biopsy 
 
Group B Streptococci 
Staphylococcus aureus 
Group B Streptococci 
Staphylococcus aureus 
4 
Swab 
 
Group B Streptococci 
Group F Streptococci 
Staphylococcus aureus 
Group B Streptococci 
Staphylococcus aureus 
5 
53 M 7 Chronic Tonsillitis Biopsy 
 
Citrobacter sp.  
Citrobacter sp. 
2 
Swab 
 
Citrobacter sp.  
Citrobacter sp. 
2 
54 M 7 Recurrent Tonsillitis  
with Snoring  
Biopsy 
 
Haemophilus influenzae 
Haemophilus influenzae 
2 
Swab 
 
Haemophilus influenzae 
Streptococcus pneumoniae 
Haemophilus influenzae 
3 
55 F 13 Recurrent Tonsillitis Biopsy 
 
Group A Streptococci 
Group A Streptococci 
2 
Swab 
 Swab 
 
Haemophilus influenzae 
 Group A Streptococci 
Group A Streptococci 
3 
56 M 38 Recurrent Tonsillitis  
with Snoring  
Biopsy 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
57 F 17 Recurrent Tonsillitis Biopsy 
 
Klebsiella pneumoniae 
Group B Streptococci 
2 
Swab 
 
Staphylococcus aureus 
Klebsiella pneumoniae 
Staphylococcus aureus 
3 
58 F 8 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus 
Staphylococcus aureus 
2 
Swab 
 
Staphylococcus aureus 
Group A Streptococci  
Staphylococcus aureus 
3 
59 M 17 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae 
Staphylococcus aureus 
Haemophilus influenzae 
Staphylococcus aureus 
4 
Swab 
 
Haemophilus influenzae 
Haemophilus influenzae 
Haemophilus parainfluenzae 
Staphylococcus aureus 
4 
60 F 7 Recurrent Tonsillitis Biopsy 
 
Group C Streptococci 
Staphylococcus aureus 
Group C Streptococci 
4 
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Staphylococcus aureus 
Swab 
 
Group C Streptococci 
Staphylococcus aureus 
Group C Streptococci 
Staphylococcus aureus 
4 
61 M 16 Nasopharyngeal 
Lymphoid Hypertrophy  
Biopsy 
 
  
Swab 
 
Staphylococcus aureus 
Staphylococcus aureus  
Group B Streptococci  
Group F Streptococci 
4 
62 F 36 Recurrent Tonsillitis Biopsy 
 
Group G Streptococci 
Staphylococcus aureus 
Group G Streptococci 
Staphylococcus aureus 
4 
Swab 
 
Group G Streptococci 
Staphylococcus aureus 
Group G Streptococci 
Staphylococcus aureus 
4 
63 M 22 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae 1 
Swab 
 
Haemophilus parainfluenzae 1 
64 F 23 Recurrent Tonsillitis Biopsy 
 
Haemophilus influenzae 
Haemophilus influenzae 
Group F Streptococci  
Group B Streptococci  
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Group F Streptococci  
Group B Streptococci 
9 
Swab 
 
Haemophilus influenzae 
Haemophilus influenzae 
Group F Streptococci  
Group B Streptococci 
Staphylococcus aureus 
Haemophilus parainfluenzae 
Staphylococcus aureus 
Group B Streptococci 
8 
65 F 15 Primary Snoring   Biopsy 
 
Staphylococcus aureus  
Group C Streptococci  
Group B Streptococci 
Staphylococcus aureus  
Group C Streptococci  
Group B Streptococci 
Streptococcus pneumoniae 
7 
Swab 
 
Staphylococcus aureus  
Group C Streptococci  
Haemophilus influenzae 
Staphylococcus aureus  
Haemophilus parainfluenzae 
Group C Streptococci 
6 
66 M 3 Chronic Tonsillitis Biopsy 
 
Staphylococcus aureus  
Group B Streptococci 
Haemophilus parainfluenzae 
Staphylococcus aureus 
4 
Swab 
 
Staphylococcus aureus  
Group B Streptococci 
Staphylococcus aureus 
3 
67 F 48 Recurrent Tonsillitis Biopsy 
 
Klebsiella pneumoniae 1 
Swab 
 
  
68 M 27 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus  
Staphylococcus aureus 
2 
Swab 
 
Staphylococcus aureus  
Staphylococcus aureus 
2 
69 F 20 Recurrent Tonsillitis Biopsy 
 
  
Swab 
 
  
242 
 
70 F 30 Recurrent Tonsillitis Biopsy 
 
Staphylococcus aureus  
Group B Streptococci 
Klebsiella pneumonia 
Staphylococcus aureus  
Klebsiella pneumonia  
Group B Streptococci 
6 
Swab 
 
Staphylococcus aureus  
Group B Streptococci 
Klebsiella pneumoniae 
Staphylococcus aureus  
Group B Streptococci 
5 
 
The Mean Average of bacterial isolates is 3.67 isolate / tonsillar biopsy and 3.72 isolate / tonsillar swab  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Tonsillar Biopsy  
 Tonsillar Swab 
 Cases with biofilms   
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Appendix 10  Evidence of Bacterial Biofilms Detected via CLSM among Clinical 
Cases  
 
Patient 
No. 
Sex Age Clinical Case Biofilm 
Presence   
 
1 F 7 Recurrent Tonsillitis - 
2 M 11 Recurrent Tonsillitis + 
3 M 23 Recurrent Tonsillitis - 
4 F 9 Recurrent Adenotonsillitis - 
5 M 16 Recurrent Tonsillitis + 
6 M 31 Recurrent Tonsillitis + 
7 M 16 Recurrent Tonsillitis + 
8 M 16 Chronic Tonsillitis - 
9 M 11 Recurrent Acute Tonsillitis with OSA + 
10 F 11 Recurrent Tonsillitis - 
11 M 5 Recurrent Tonsillitis + 
12 F 9 Recurrent Tonsillitis + 
13 F 13 Recurrent Tonsillitis with Bilateral MEE + 
14 M 9 Recurrent Tonsillitis with Bilateral MEE - 
15 F 26 Recurrent Tonsillitis - 
16 F 24 Recurrent Tonsillitis + 
17 F 26 Recurrent Tonsillitis - 
18 F 17 Recurrent Tonsillitis with Bilateral MEE + 
19 F 15 Recurrent Adenotonsillitis + 
20 F 10 Recurrent Tonsillitis + 
21 M 8 Recurrent Tonsillitis - 
22 F 5 Recurrent Tonsillitis with Snoring + 
23 F 5 Recurrent Tonsillitis - 
24 M 6 Recurrent Tonsillitis + 
25 F 17 Chronic Tonsillitis + 
26 M 7 Obstructive Sleep Apnea - 
27 F 28 Recurrent Tonsillitis + 
28 M 6 Adenotonsillar Hypertrophy - 
29 F 18 Chronic Tonsillitis with Snoring + 
30 F 24 Chronic Tonsillitis + 
31 F 13 Recurrent Tonsillitis + 
32 F 12 Recurrent Tonsillitis with Bilateral MEE + 
33 F 9 Tonsillar Hypertrophy + 
34 M 8 Tonsillar Hypertrophy with OSA + 
35 F 23 Recurrent Tonsillitis - 
36 F 24 Recurrent Tonsillitis + 
37 M 11 Chronic Tonsillitis - 
38 M 9 Recurrent Tonsillitis - 
39 F 10 Recurrent Tonsillitis + 
40 F 27 Recurrent Tonsillitis - 
41 F 16 Obstructive Sleep Apnea + 
42 F 8 Obstructive Sleep Apnea - 
43 M 10 Recurrent Tonsillitis + 
44 M 8 Chronic Tonsillitis - 
45 M 4 Tonsillar Hypertrophy + 
46 F 11 Tonsillar Hypertrophy - 
47 M 10 Adenoid Hyperplasia with OSA + 
48 F 25 Recurrent Tonsillitis + 
49 M 5 Tonsillar Hypertrophy with OSA - 
50 F 12 Recurrent Tonsillitis with Snoring  - 
51 F 6 Recurrent Tonsillitis with OSA + 
52 F 27 Recurrent Tonsillitis with OSA + 
53 M 7 Chronic Tonsillitis + 
54 M 7 Recurrent Tonsillitis with Snoring  + 
55 F 13 Recurrent Tonsillitis - 
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56 M 38 Recurrent Tonsillitis with Snoring  - 
57 F 17 Recurrent Tonsillitis - 
58 F 8 Recurrent Tonsillitis + 
59 M 17 Recurrent Tonsillitis + 
60 F 7 Recurrent Tonsillitis - 
61 M 16 Nasopharyngeal Lymphoid Hypertrophy  + 
62 F 36 Recurrent Tonsillitis - 
63 M 22 Recurrent Tonsillitis + 
64 F 23 Recurrent Tonsillitis + 
65 F 15 Primary Snoring   - 
66 M 3 Chronic Tonsillitis + 
67 F 48 Recurrent Tonsillitis + 
68 M 27 Recurrent Tonsillitis + 
69 F 20 Recurrent Tonsillitis - 
70 F 30 Recurrent Tonsillitis + 
 
 Presence of biofilm in the tonsil 
 
Biofilm was present in 42 (60%) patients whereas it was absent in 28 (40%) patients  
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Appendix 11 Distribution of Bacterial Isolates among Clinical Cases and their Biofilm Formation Abilities  
 
11A  Staphylococcus aureus (SA) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm 
Formation 
High Weak High Weak 
1 Recurrent Tonsillitis F 7 SA001  +  + - 
2 Recurrent Tonsillitis M 11 SA002  +  + - 
3 Recurrent Tonsillitis M 23 SA003 +  +  + 
4 Recurrent Adenotonsillitis F 9 SA004  +  + - 
    SA005    + - 
    SA006  + +  - 
    SA007  +  + - 
5 Recurrent Tonsillitis M 16 SA008 +  +  + 
    SA009  +  + + 
    SA010 +  +  + 
    SA011  +  + - 
7 Recurrent Tonsillitis M 16 SA012 +  +  + 
8 Chronic Tonsillitis M 16 SA013  +  + - 
    SA014  +  + - 
    SA015  +  + - 
9 Recurrent Acute Tonsillitis with OSA M 11 SA016 +  +  + 
    SA017 +  +  + 
    SA018  + +  + 
10 Recurrent Tonsillitis F 11 SA019  +  + - 
    SA020  +  + - 
    SA021  +  + - 
    SA022  +  + - 
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11 Recurrent Tonsillitis M 5 SA023  +  + - 
    SA024  +  + - 
    SA025  + +  - 
    SA026 +  +  - 
12 Recurrent Tonsillitis F 9 SA027  +  + - 
    SA028  +  + - 
    SA029  +  + - 
    SA030  +  + - 
13 Recurrent Tonsillitis with Bilateral 
MEE 
F 13 SA031 +  +  + 
    SA032 +  +  + 
14 Recurrent Tonsillitis with Bilateral 
MEE 
M 9 SA033 +  +  + 
    SA034  + +  - 
    SA035 +  +  - 
    SA036 +  +  - 
15 Recurrent Tonsillitis F 26 SA037  +  + - 
    SA038  +  + - 
    SA039  +  + - 
16 Recurrent Tonsillitis F 24 SA040 +  +  + 
    SA041 +  +  + 
    SA042 +  +  + 
17 Recurrent Tonsillitis F 26 SA043  +  + - 
    SA044  +  + - 
    SA045  +  + - 
    SA046  +  + - 
19 Recurrent Adenotonsillitis F 15 SA047 +  +  + 
    SA048 +  +  + 
    SA049 +  +  + 
    SA050 +  +  + 
21 Recurrent Tonsillitis M 8 SA051  +  + - 
    SA052  +  + - 
    SA053  +  + - 
22 Recurrent Tonsillitis F 5 SA054  +  + - 
    SA055  +  + - 
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    SA056  +  + - 
24 Recurrent Tonsillitis M 6 SA057 +  +  + 
    SA058 +  +  + 
    SA059 +  +  + 
25 Chronic Tonsillitis F 17 SA060  +  + + 
    SA061  +  + + 
    SA062 +  +  + 
    SA063 +  +  + 
26 Obstructive Sleep Apnea M 7 SA064  +  + - 
    SA065  +  + - 
27 Recurrent Tonsillitis F 28 SA066 +  +  + 
    SA067 +  +  + 
    SA068 +  +  + 
    SA069  + +  - 
28 Adenotonsillar Hypertrophy M 6 SA070  +  + - 
    SA071  +  + - 
    SA072  +  + - 
29 Chronic Tonsillitis with Snoring F 18 SA073 +  +  + 
    SA074 +  +  + 
    SA075 +  +  + 
    SA076  + +  + 
30 Chronic Tonsillitis F 24 SA077 +  +  + 
    SA078 +   + - 
    SA079 +  +  + 
    SA080  +  + - 
31 Recurrent Tonsillitis F 13 SA081 +  +  + 
    SA082  +  + - 
    SA083 +  +  + 
    SA084  +  + - 
33 Tonsillar Hypertrophy F 9 SA085 +  +  + 
    SA086 +  +  + 
    SA087  + +  - 
    SA088 +  +  + 
35 Recurrent Tonsillitis F 23 SA089  +  + - 
    SA090  +  + - 
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    SA091 +  +  + 
    SA092  +  + - 
36 Recurrent Tonsillitis F 24 SA093  + +  + 
    SA094 +   + + 
37 Chronic Tonsillitis M 11 SA095  +  + + 
    SA096  +  + + 
    SA097  + +  - 
    SA098  +  + - 
38 Recurrent Tonsillitis M 9 SA099 +   + - 
39 Recurrent Tonsillitis F 10 SA100 +  +  + 
    SA101  +  + - 
    SA102 +  +  + 
    SA103  +  + - 
41 Obstructive Sleep Apnea F 16 SA104 +  +  + 
    SA105 +  +  + 
    SA106 +  +  + 
    SA107 +  +  + 
42 Obstructive Sleep Apnea F 8 SA112  +  + - 
    SA113 +  +  + 
    SA114  +  + - 
    SA115 +  +  + 
43 Recurrent Tonsillitis M 10 SA108  +  + + 
    SA109  +  + + 
    SA110  +  + + 
    SA111  +  + + 
44 Chronic Tonsillitis M 8 SA116  +  + - 
    SA117  +  + - 
45 Tonsillar Hypertrophy M 4 SA118 +  +  + 
    SA119 +  +  + 
    SA120 +  +  + 
    SA121  + +  + 
46 Tonsillar Hypertrophy F 11 SA122  +  + - 
    SA123  +  + - 
    SA124  +  + - 
    SA125 +   + - 
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47 Adenoid Hyperplasia with OSA M 10 SA126 +  +  + 
    SA127 +  +  + 
    SA128 +  +  + 
    SA129 +  +  + 
48 Recurrent Tonsillitis F 25 SA130  +  + - 
    SA131  +  + - 
    SA132  +  + - 
    SA133  +  + - 
50 Recurrent Tonsillitis with Snoring F 12 SA134  +  + - 
    SA135  +  + - 
    SA136 +   + - 
    SA137  +  + - 
51 Recurrent Tonsillitis  with OSA F 6 SA138 +  +  + 
    SA139 +  +  + 
    SA140 +  +  + 
    SA141 +  +  + 
55 Recurrent Tonsillitis F 13 SA142  +  + - 
    SA143  +  + - 
    SA144  +  + - 
    SA145  +  + - 
56 Recurrent Tonsillitis with Snoring M 38 SA146 +   + - 
    SA147 +   + - 
57 Recurrent Tonsillitis F 17 SA148  +  + - 
    SA149  +  + - 
    SA150  + +  - 
    SA151  +  + - 
58 Recurrent Tonsillitis F 8 SA152 +  +  + 
    SA153 +  +  + 
    SA154 +  +  + 
59 Recurrent Tonsillitis M 17 SA159  +  + - 
    SA160  +  + - 
60 Recurrent Tonsillitis F 7 SA155  +  + - 
    SA156  +  + - 
    SA157  +  - - 
    SA158  +  + - 
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61 Nasopharyngeal Lymphoid 
Hypertrophy 
M 16 SA165 +  +  + 
    SA166 +  +  + 
    SA167 +  +  + 
    SA168 +  +  + 
62 Recurrent Tonsillitis F 36 SA161  +  + - 
    SA162  +  + - 
    SA163  +  + - 
    SA164 +  +  - 
64 Recurrent Tonsillitis F 23 SA173  +  + - 
    SA174  +  + - 
    SA175  + +  - 
    SA176 +   + - 
65 Primary Snoring F 15 SA169  +  + - 
    SA170  +  + - 
    SA171  +  + - 
    SA172 +  +  + 
68 Recurrent Tonsillitis M 27 SA177  +  + - 
    SA178  +  + - 
    SA179  +  + - 
    SA180  +  + - 
70 Recurrent Tonsillitis F 30 SA181 +  +  + 
    SA182  + +  - 
    SA183 +  +  - 
    SA184 +  +  + 
 
 
 Biofilm presence in the tonsils detected via CLSM 
 Biofilm formation in vitro detected via LM 
 Antibiotic resistant isolate 
 
(+) indicates biofilm inhibition, (−) indicates biofilm formation 
Number of S. aureus that are BIOFILM FORMERS = 78 (42.39%), Number of S. aureus that are NON-BIOFILM FORMERS = 106 (57.60%) 
 
251 
 
11B  Haemophilus influenzae (HI) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
4 Recurrent Adenotonsillitis F 9 HI001  +  + - 
5 Recurrent Tonsillitis M 16 HI002 +  +  + 
7 Chronic Tonsillitis M 16 HI003  + +  + 
9 Recurrent Acute Tonsillitis with OSA M 11 HI004 +  +  + 
    HI005 +  +  + 
10 Recurrent Tonsillitis F 11 HI006  +  + - 
11 Recurrent Tonsillitis M 5 HI007 +  +  + 
    HI008 +  +  + 
    HI009  + +  + 
    HI010 +  +  + 
12 Recurrent Tonsillitis F 9 HI011 +  +  + 
    HI012 +  +  + 
    HI013 +  +  + 
13 Recurrent Tonsillitis with Bilateral MEE F 13 HI014 +  +  + 
14 Recurrent Tonsillitis with Bilateral MEE M 9 HI015  +  + - 
    HI016  +  + - 
    HI017  +  + - 
    HI018  +  + - 
15 Recurrent Tonsillitis F 26 HI019 +  +  + 
18 Recurrent Tonsillitis with Bilateral MEE F 17 HI020 +  +  + 
    HI021 +  +  + 
    HI022  +  + + 
    HI023 +  +  + 
19 Recurrent Adenotonsillitis F 15 HI024 +   + + 
    HI025  + +  + 
    HI026 +  +  + 
    HI027  +  + + 
21 Recurrent Tonsillitis M 8 HI028 +  +  + 
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    HI029  +  + - 
    HI030 +  +   
22 Recurrent Tonsillitis with Snoring F 5 HI031  + +  + 
    HI032  + + + - 
    HI033  +  + - 
24 Recurrent Tonsillitis M 6 HI034 +  +  + 
    HI035  +  + - 
25 Chronic Tonsillitis F 17 HI036 +  +  + 
    HI037 +  +  + 
    HI038 +  +  + 
26 Obstructive Sleep Apnea M 7 HI039  +  + - 
    HI040  +  + - 
29 Chronic Tonsillitis with Snoring F 18 HI041  + +  + 
32 Recurrent Tonsillitis with Bilateral MEE F 12 HI042 +  +  + 
    HI043  + +  + 
    HI044  + +  + 
    HI045 +  +  + 
33 Tonsillar Hypertrophy F 9 HI046  +  + - 
    HI047  +  + - 
34 Tonsillar Hypertrophy with OSA M 8 HI048 +  +  + 
36 Recurrent Tonsillitis F 24 HI049  + +  + 
    HI050 +  +  + 
    HI051 +  +  + 
    HI052  +  + - 
38 Recurrent Tonsillitis M 9 HI053  + +  - 
    HI054  +  + - 
    HI055 +  +  - 
    HI056  +  + - 
42 Obstructive Sleep Apnea F 8 HI057 +   + - 
    HI058  +  + - 
    HI059  +  + - 
    HI060  +  + - 
45 Tonsillar Hypertrophy M 4 HI061 +  +  + 
    HI062 +  +  + 
    HI063 +  +  + 
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46 Tonsillar Hypertrophy F 11 HI064 +  +  + 
    HI065  +  + - 
47 Adenoid Hyperplasia with OSA M 10 HI066  +  + - 
    HI067 +  +  + 
    HI068 +  +  + 
49 Tonsillar Hypertrophy with OSA M 5 HI069  +  + - 
50 Recurrent Tonsillitis with Snoring F 12 HI070  +  + - 
    HI071 +  +  + 
53 Chronic Tonsillitis M 7 HI072  +  + + 
    HI073  + +  + 
    HI074  +  + + 
    HI075 +  +  + 
54 Recurrent Tonsillitis with Snoring M 7 HI076  +  + - 
58 Recurrent Tonsillitis F 8 HI077 +  +  + 
    HI078 +  +  + 
    HI079  +  + + 
    HI080 +  +  + 
61 Nasopharyngeal Lymphoid Hypertrophy M 16 HI081 +  +  + 
    HI082 +  +  + 
    HI083 +  +  + 
    HI084 +  +  + 
63 Recurrent Tonsillitis M 22 HI085 +  +  + 
65 Recurrent Tonsillitis F 15 HI086  +  + - 
 
 
Number of H. influenzae that are BIOFILM FORMERS = 55 (63.95%), Number of H. influenzae that are NON-BIOFILM FORMERS = 31 (36.04%) 
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11C  Streptococcus agalactiae (GBS) 
 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate 
No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
6 Recurrent Tonsillitis M 31 STB01  +  + - 
    STB02  +  + - 
    STB03  +  + - 
    STB04  +  + - 
7 Chronic Tonsillitis M 16 STB05 +  +  + 
    STB06 +  +  + 
11 Recurrent Tonsillitis M 5 STB07 +  +  + 
    STB08 +   + + 
15 Recurrent Tonsillitis F 26 STB09  +  + - 
    STB10  +  + - 
    STB11  + +  - 
    STB12  +  + - 
16 Recurrent Tonsillitis F 24 STB13  + +  - 
    STB14  +  + - 
    STB15  +  + - 
26 Obstructive Sleep Apnea M 7 STB16  +  + - 
    STB17  +  + - 
    STB18  +  + - 
29 Chronic Tonsillitis with Snoring F 18 STB19  +  + - 
    STB20 +  +  + 
    STB21  + +  + 
    STB22 +  +  + 
37 Chronic Tonsillitis M 11 STB23  +  + - 
    STB24  +  + - 
    STB25  +  + - 
    STB26 +  +  - 
41 Obstructive Sleep Apnea F 16 STB27  +  + - 
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    STB28 +  +  - 
42 Obstructive Sleep Apnea F 8 STB31  +  + - 
    STB32  +  + - 
43 Recurrent Tonsillitis M 10 STB29  + +  + 
    STB30 +  +  + 
44 Chronic Tonsillitis M 8 STB33  +  + - 
46 Tonsillar Hypertrophy F 11 STB34  +  + - 
    STB35 +  +  - 
    STB36  +  + - 
    STB37 +  +  - 
51 Recurrent Tonsillitis  with OSA F 6 STB38 +  +  + 
    STB39 +  +  + 
    STB40 +  +  + 
    STB41 +  +  + 
56 Recurrent Tonsillitis with Snoring M 38 STB42  +  + - 
59 Recurrent Tonsillitis M 17 STB43  +  + - 
61 Nasopharyngeal Lymphoid 
Hypertrophy 
M 16 STB44 +  +  + 
    STB45 +  +  + 
    STB46  + +  + 
    STB47 +  +  + 
64 Recurrent Tonsillitis F 23 STB50  +  + - 
    STB51  +  + - 
65 Primary Snoring F 15 STB48  +  + - 
    STB49 +   + - 
68 Recurrent Tonsillitis M 27 STB52  +  + - 
70 Recurrent Tonsillitis F 30 STB53 +  +  + 
    STB54  +  + - 
    STB55 +  +  + 
    STB56  + +  + 
 
 
Number of Streptococcus agalactiae that are BIOFILM FORMERS = 19 (33.92%), Number of Streptococcus agalactiae that are NON-BIOFILM FORMERS = 37 (66.07%) 
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11D  Haemophilus parainfluenzae (HP) 
 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
8 Chronic Tonsillitis M 16 HP001 +  +  - 
    HP002  +  + - 
    HP003  +  + - 
9 Recurrent Acute Tonsillitis with OSA M 11 HP004 +  +  + 
    HP005  + +  + 
10 Recurrent Tonsillitis F 11 HP006  +  + - 
12 Recurrent Tonsillitis F 9 HP007 +  +  + 
15 Recurrent Tonsillitis F 26 HP008  +  + - 
    HP009  +  + - 
23 Recurrent Tonsillitis F 5 HP010  + +  - 
    HP011  +  + - 
    HP012 +   + - 
28 Adenotonsillar Hypertrophy M 6 HP013  +  + - 
29 Chronic Tonsillitis with Snoring F 18 HP014 +  +  + 
    HP015 +  +  + 
35 Recurrent Tonsillitis F 23 HP016  +  + - 
    HP017 +   + - 
39 Recurrent Tonsillitis F 10 HP018 +  +  + 
    HP019 +  +  + 
44 Chronic Tonsillitis M 8 HP020  + +  + 
    HP021 +  +  + 
45 Tonsillar Hypertrophy M 4 HP022 +  +  + 
48 Recurrent Tonsillitis F 25 HP023  + +  + 
49 Tonsillar Hypertrophy with OSA M 5 HP024  +  + - 
    HP025  +  + - 
58 Recurrent Tonsillitis F 8 HP026 +  +  + 
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61 Nasopharyngeal Lymphoid 
Hypertrophy 
M 16 HP027 +  +  + 
    HP028  + +  + 
63 Recurrent Tonsillitis M 22 HP029 +  +  + 
64 Recurrent Tonsillitis F 23 HP030  +  + + 
65 Primary Snoring F 15 HP031  + +  - 
 
 
Number of H. parainfluenzae that are BIOFILM FORMERS = 16 (51.61%), Number of H. parainfluenzae that are NON-BIOFILM FORMERS = 15 (48.38%) 
 
 
 
 
 
 
 
 
 
11E  Klebsiella pneumoniae (KP) 
 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
5 Recurrent Tonsillitis M 16 KP001 +  +  + 
    KP002  +  + - 
    KP003 +  +  + 
    KP004 +  +  + 
15 Recurrent Tonsillitis F 26 KP005  +  + - 
    KP006  +  + - 
    KP007 +   + - 
    KP008  +  + - 
16 Recurrent Tonsillitis F 24 KP009 +  +  + 
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    KP010  + +  + 
    KP011 +  +  + 
    KP012 +  +  + 
26 Obstructive Sleep Apnea M 7 KP013  +  + - 
27 Recurrent Tonsillitis F 28 KP014 +  +  + 
    KP015 +  +  + 
    KP016  + +  + 
30 Chronic Tonsillitis F 24 KP017 +  +  + 
37 Chronic Tonsillitis M 11 KP018  +  + - 
    KP019 +  +  - 
47 Adenoid Hyperplasia with OSA M 10 KP020  +  + - 
52 Recurrent Tonsillitis with OSA F 27 KP021 +  +  + 
    KP022  + +  + 
    KP023 +  +  + 
    KP024 +  +  + 
56 Recurrent Tonsillitis with Snoring M 38 KP025  +  + - 
    KP026  +  + - 
67 Recurrent Tonsillitis F 48 KP027  +  + - 
70 Recurrent Tonsillitis F 30 KP028  + +  - 
    KP029  +  + - 
    KP030 +   + - 
 
 
Number of K. pneumoniae that are BIOFILM FORMERS = 15(50%), Number of K. pneumoniae that are NON-BIOFILM FORMERS = 15(50%) 
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11F  Group F Streptococci (GFS) 
 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate 
No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
8 Chronic Tonsillitis M 16 STF01  +  + - 
35 Recurrent Tonsillitis F 23 STF02 +   + - 
    STF03  +  + - 
    STF04  +  + - 
41 Obstructive Sleep Apnea F 16 STF05  +  + - 
    STF06  + +  - 
51 Recurrent Tonsillitis  with OSA F 6 STF07 +  +  + 
59 Recurrent Tonsillitis M 17 STF08 +  +  - 
61 Nasopharyngeal Lymphoid 
Hypertrophy 
M 16 STF09  +  + - 
    STF10  +  + - 
    STF11 +  +  + 
 
 
Number of Group F Streptococci (GFS) that are BIOFILM FORMERS = 2 (18.18%), Number of Group F Streptococci (GFS) that are NON-BIOFILM FORMERS = 9 (81.81%) 
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11G  Group G Streptococci (GGS) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
6 Recurrent Tonsillitis M 31 STG01  +  + - 
9 Recurrent Acute Tonsillitis with OSA M 11 STG02 +  +  - 
    STG03  +  + - 
    STG04  +  + - 
13 Recurrent Tonsillitis with Bilateral MEE F 13 STG05 +  +  + 
    STG06  + +  + 
    STG07  +  + - 
    STG08 +  +  + 
14 Recurrent Tonsillitis with Bilateral MEE M 9 STG09  +  + - 
    STG10  +  + - 
    STG11 +  +  - 
    STG12  +  + - 
18 Recurrent Tonsillitis with Bilateral MEE F 17 STG13 +   + - 
30 Chronic Tonsillitis F 24 STG14 +  +  + 
    STG15  + +  + 
    STG16 +   + - 
    STG17  + +  + 
44 Chronic Tonsillitis M 8 STG18  +  + - 
    STG19  + +  - 
    STG20  +  + - 
50 Recurrent Tonsillitis with Snoring F 12 STG21 +   + - 
62 Recurrent Tonsillitis F 36 STG22  +  + - 
    STG23 +  +  - 
    STG24  +  + - 
    STG25  +  + - 
 
Number of Group G Streptococci (GGS) that are BIOFILM FORMERS = 6(24%), Number of Group G Streptococci (GGS) that are NON-BIOFILM FORMERS = 19 (76%) 
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11H  Streptococcus pyogenes (GABHS) 
 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
22 Recurrent Tonsillitis with Snoring F 5 STA01 +  +  + 
    STA02  +  + - 
    STA03 +  +  + 
31 Recurrent Tonsillitis F 13 STA04 +  +  + 
    STA05  + +  + 
54 Recurrent Tonsillitis with Snoring M 7 STA06 +  +  + 
    STA07 +  +  + 
    STA08  +  + - 
    STA09 +  +  + 
57 Recurrent Tonsillitis F 17 STA10  +  + + 
58 Recurrent Tonsillitis F 8 STA11 +  +  + 
    STA12 +  +  + 
    STA13  + +  + 
    STA14 +  +  + 
 
 
GABHS = Group A Beta-Haemolytic Streptococci  
Number of S. pyogenes (GABHS) that are BIOFILM FORMERS = 12(85.71%), Number of S. pyogenes (GABHS) that are NON-BIOFILM FORMERS = 2 (14.28%) 
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11I  Pseudomonas aeruginosa (PA) 
 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
3 Recurrent Tonsillitis M 23 PA001  +  + - 
34 Tonsillar Hypertrophy with OSA M 8 PA002 +  +  + 
    PA003  +  + - 
    PA004 +  +  + 
    PA005 +  +  + 
48 Recurrent Tonsillitis F 25 PA006 +  +  + 
    PA007 +  +  + 
    PA008 +  +  + 
    PA009 +  +  + 
 
 
Number of P. aeruginosa that are BIOFILM FORMERS = 7 (77.77%), Number of P. aeruginosa that are NON-BIOFILM FORMERS = 2 (22.22%) 
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11J  Group C Streptococci (GCS) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
1 Recurrent Tonsillitis F 7 STC01  +  + - 
    STC02 +  +  + 
    STC03  +  + - 
    STC04 +  +  + 
65 Primary Snoring F 15 STC05  +  + - 
    STC06  +  + - 
    STC07  + +  - 
    STC08  +  + - 
 
 
Number of Group C Streptococci (GCS) that are BIOFILM FORMERS = 2 (25%), Number of Group C Streptococci (GCS) that are NON-BIOFILM FORMERS = 6 (75%) 
 
 
 
11K  Methicillin Resistant S. aureus (MRSA) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
6 Recurrent Tonsillitis M 31 MRS01 +  +  + 
 
 
Number of MRSA that are BIOFILM FORMERS = 1 (100%), Number of MRSA that are NON-BIOFILM FORMERS = 0 
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11L  Citrobacter sp. 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
52 Recurrent Tonsillitis  with OSA F 27 CBF01  +  + - 
    CBF02 +   + - 
    CBF03  +  + - 
    CBF04  +  + - 
 
Number of Citrobacter sp. that are BIOFILM FORMERS = 0, Number of Citrobacter sp. that are NON-BIOFILM FORMERS = 4 (100%) 
 
 
 
11M  Streptococcus pneumoniae (SPn) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
33 Tonsillar Hypertrophy F 9 STP01  +  + + 
53 Chronic Tonsillitis M 7 STP02 +  +  + 
65 Primary Snoring F 15 STP03  +  + - 
 
Number of S. pneumoniae (SPn) that are BIOFILM FORMERS = 2 (66.66%), Number of S. pneumoniae (SPn) that are NON-BIOFILM FORMERS = 1 (33.33%) 
265 
 
11N  Enterobacter cloacae (EC) 
 
Patient 
No. 
Clinical Case Sex Age Clinical 
Isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
3 Recurrent Tonsillitis M 23 EBC01  +  + - 
 
 
Number of Enterobacter cloacae that are BIOFILM FORMERS = 0, Number of Enterobacter cloacae that are NON-BIOFILM FORMERS = 1 (100%) 
 
 
 
 
 
 
 
11O  Acinetobacter baumannii (AB) 
 
Patie
nt 
No. 
Clinical Case Sex Age Clinical 
isolate No. 
Biofilm Formation 
Congo Red Agar 
method (CRA) 
Microtitter Plate 
assay (MTP) 
Microscopic 
Observation of 
Biofilm Formation High Weak High Weak 
3 Recurrent Tonsillitis M 23 ABB01 +   + - 
 
 
Number of Acinetobacter baumannii (AB) that are BIOFILM FORMERS = 0, Number of Acinetobacter baumannii (AB) that are NON-BIOFILM FORMERS = 1(100%) 
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Appendix 12 Antimicrobial Susceptibility Results and Antibiogram Patterns of Tonsillar Isolates  
12A   Staphylococcus aureus (SA) 
 
Antimicrobial Class Penicillins
1
 Aminoglycosides
2
 Macrolides
2
 Folate pathway 
inhibitors
2
 
Lincosamides
2
 Fusidane
2
  
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Methicillin 
(ME) 
Gentamycin 
(GM) 
Erythromycin 
(EM) 
Co-trimoxazole 
(SXT) 
a
 
Clindamycin 
(CM) 
Fusidic Acid 
(FA)
3
 
Disk Content 
 
5 μg 10 μg 15 μg 1.25/23.75 μg 2 μg 10 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 14 – R ≤ 9 S ≥ 15 – R ≤ 12 S ≥ 23 – R ≤ 13 S ≥ 16 – R ≤ 10 S ≥ 21 – R ≤ 14 S ≥22 – R ≤19 
Clinical Isolate 
 
      
SA001 S S S S S S SSSSSS 
SA002 S S S S S S SSSSSS 
SA003 S S S S S S SSSSSS 
SA004 S S S S S S SSSSSS 
SA005 S S S S S S SSSSSS 
SA006 S S S S S S SSSSSS 
SA007 S S S S S S SSSSSS 
SA008 S S S S S R SSSSSR 
SA009 S S S S S R SSSSSR 
SA010 S S S S S R SSSSSR 
SA011 S S S S S R SSSSSR 
SA012 S S S S S S SSSSSS 
SA013 S S S S S S SSSSSS 
SA014 S S S S S S SSSSSS 
SA015 S S S S S S SSSSSS 
SA016 S S S S S R SSSSSR 
SA017 S S S S S R SSSSSR 
SA018 S S S S S R SSSSSR 
SA019 S S S S S S SSSSSS 
SA020 S S S S S S SSSSSS 
SA021 S S S S S S SSSSSS 
SA022 S S S S S S SSSSSS 
SA023 S S S S S S SSSSSS 
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SA024 S S S S S S SSSSSS 
SA025 S S S S S S SSSSSS 
SA026 S S S S S S SSSSSS 
SA027 S S S S S S SSSSSS 
SA028 S S S S S S SSSSSS 
SA029 S S S S S S SSSSSS 
SA030 S S S S S S SSSSSS 
SA031 S S S S S S SSSSSS 
SA032 S S S S S S SSSSSS 
SA033 S S S S S S SSSSSS 
SA034 S S S S S S SSSSSS 
SA035 S S S S S S SSSSSS 
SA036 S S S S S S SSSSSS 
SA037 S S S S S S SSSSSS 
SA038 S S S S S S SSSSSS 
SA039 S S S S S S SSSSSS 
SA040 S S S S S S SSSSSS 
SA041 S S S S S S SSSSSS 
SA042 S S S S S S SSSSSS 
SA043 S S S S S S SSSSSS 
SA044 S S S S S S SSSSSS 
SA045 S S S S S S SSSSSS 
SA046 S S S S S S SSSSSS 
SA047 S S S S S S SSSSSS 
SA048 S S S S S S SSSSSS 
SA049 S S S S S S SSSSSS 
SA050 S S S S S S SSSSSS 
SA051 S S S S S S SSSSSS 
SA052 S S S S S S SSSSSS 
SA053 S S S S S S SSSSSS 
SA054 S S S S S S SSSSSS 
SA055 S S S S S S SSSSSS 
SA056 S S S S S S SSSSSS 
SA057 S S S S S S SSSSSS 
SA058 S S S S S S SSSSSS 
SA059 S S S S S S SSSSSS 
SA060 S S S S S S SSSSSS 
SA061 S S S S S S SSSSSS 
SA062 S S S S S S SSSSSS 
SA063 S S S S S S SSSSSS 
SA064 S S S S S R SSSSSR 
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SA065 S S S S S R SSSSSR 
SA066 S S S S S S SSSSSS 
SA067 S S S S S S SSSSSS 
SA068 S S S S S S SSSSSS 
SA069 S S S S S S SSSSSS 
SA070 S S S S S S SSSSSS 
SA071 S S S S S S SSSSSS 
SA072 S S S S S S SSSSSS 
SA073 S S S S S S SSSSSS 
SA074 S S S S S S SSSSSS 
SA075 S S S S S S SSSSSS 
SA076 S S S S S S SSSSSS 
SA077 S S S S S S SSSSSS 
SA078 S S S S S S SSSSSS 
SA079 S S S S S S SSSSSS 
SA080 S S S S S S SSSSSS 
SA081 S S S S S S SSSSSS 
SA082 S S S S S S SSSSSS 
SA083 S S S S S S SSSSSS 
SA084 S S S S S S SSSSSS 
SA085 S S S S S S SSSSSS 
SA086 S S S S S S SSSSSS 
SA087 S S S S S S SSSSSS 
SA088 S S S S S S SSSSSS 
SA089 S S S S S S SSSSSS 
SA090 S S S S S S SSSSSS 
SA091 S S S S S S SSSSSS 
SA092 S S S S S S SSSSSS 
SA093 S S S S S S SSSSSS 
SA094 S S S S S S SSSSSS 
SA095 S S S S S S SSSSSS 
SA096 S S S S S S SSSSSS 
SA097 S S S S S S SSSSSS 
SA098 S S S S S S SSSSSS 
SA099 S S S S S S SSSSSS 
SA100 S S S S S S SSSSSS 
SA101 S S S S S S SSSSSS 
SA102 S S S S S S SSSSSS 
SA103 S S S S S S SSSSSS 
SA104 S S S S S S SSSSSS 
SA105 S S S S S S SSSSSS 
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SA106 S S S S S S SSSSSS 
SA107 S S S S S S SSSSSS 
SA108 S S S S S S SSSSSS 
SA109 S S S S S S SSSSSS 
SA110 S S S S S S SSSSSS 
SA111 S S S S S S SSSSSS 
SA112 S S S S S S SSSSSS 
SA113 S S S S S R SSSSSR 
SA114 S S S S S R SSSSSR 
SA115 S S S S S R SSSSSR 
SA116 S S S S S S SSSSSS 
SA117 S S S S S S SSSSSS 
SA118 S S S S S S SSSSSS 
SA119 S S S S S S SSSSSS 
SA120 S S S S S S SSSSSS 
SA121 S S S S S S SSSSSS 
SA122 S S S S S S SSSSSS 
SA123 S S S S S S SSSSSS 
SA124 S S S S S S SSSSSS 
SA125 S S S S S S SSSSSS 
SA126 S S S S S S SSSSSS 
SA127 S S S S S S SSSSSS 
SA128 S S S S S S SSSSSS 
SA129 S S S S S S SSSSSS 
SA130 S S S S S S SSSSSS 
SA131 S S S S S S SSSSSS 
SA132 S S S S S S SSSSSS 
SA133 S S S S S S SSSSSS 
SA134 S S S S S S SSSSSS 
SA135 S S S S S S SSSSSS 
SA136 S S S S S S SSSSSS 
SA137 S S S S S S SSSSSS 
SA138 S S S S S R SSSSSR 
SA139 S S S S S R SSSSSR 
SA140 S S S S S R SSSSSR 
SA141 S S S S S R SSSSSR 
SA142 S S S S S S SSSSSS 
SA143 S S S S S S SSSSSS 
SA144 S S S S S S SSSSSS 
SA145 S S S S S S SSSSSS 
SA146 S S S S S S SSSSSS 
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SA147 S S S S S S SSSSSS 
SA148 S S S S S S SSSSSS 
SA149 S S S S S S SSSSSS 
SA150 S S S S S S SSSSSS 
SA151 S S S S S S SSSSSS 
SA152 S S S S S S SSSSSS 
SA153 S S S S S S SSSSSS 
SA154 S S S S S S SSSSSS 
SA155 S S S S S S SSSSSS 
SA156 S S S S S S SSSSSS 
SA157 S S S S S S SSSSSS 
SA158 S S S S S S SSSSSS 
SA159 S S S S S S SSSSSS 
SA160 S S S S S S SSSSSS 
SA161 S S S S S R SSSSSR 
SA162 S S S S S R SSSSSR 
SA163 S S S S S R SSSSSR 
SA164 S S S S S R SSSSSR 
SA165 S S S S S S SSSSSS 
SA166 S S S S S S SSSSSS 
SA167 S S S S S S SSSSSS 
SA168 S S S S S S SSSSSS 
SA169 S S S S S S SSSSSS 
SA170 S S S S S S SSSSSS 
SA171 S S S S S S SSSSSS 
SA172 S S S S S S SSSSSS 
SA173 S S S S S S SSSSSS 
SA174 S S S S S S SSSSSS 
SA175 S S S S S S SSSSSS 
SA176 S S S S S S SSSSSS 
SA177 S S S S S S SSSSSS 
SA178 S S S S S S SSSSSS 
SA179 S S S S S S SSSSSS 
SA180 S S S S S S SSSSSS 
SA181 S S S S S S SSSSSS 
SA182 S S S S S S SSSSSS 
SA183 S S S S S S SSSSSS 
SA184 S S S S S S SSSSSS 
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a
 Co-trimoxazole = Trimethoprim-sulfamethoxazole 
1
β-Lactam antibiotic, 
2
Non–β-Lactam antibiotic,   
3
Results are based on the zone diameter proposed interpretive breakpoints for fusidic acid against Staphylococcus aureus (Jones et al 2010).  
 
Data were generated from clinical isolates of patients’ specimens submitted to the microbiology referral laboratory at University Malaya Medical Centre (UMMC).      
 
Results are based on the zone diameter interpretive standards for Staphylococcus aureus from the CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement M100-S20 Vol. 30 
No. 1, Page 60-68, 2010.  
 Antibiotic resistant isolate 
 
 
 
 
 
 
 
 
 
 
 
 
12B   Methicillin Resistant S. aureus (MRSA)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Class Penicillins
1
 Macrolides
2
 Folate pathway 
inhibitors
2
 
Fusidane
2
 Aminoglycosides
2
 Lincosamides
2
 Ansamycins Quinolones
2
  
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Methicillin 
(ME) 
Erythromycin 
(EM) 
Co-trimoxazole 
(SXT) 
a
 
Fusidic Acid 
(FA)
3
 
Gentamycin 
(GM) 
Clindamycin 
(CM) 
Rifampin 
(RA) 
Ciprofloxacin 
(CIP) 
Disk Content 
 
5μg 15μg 1.25/23.75μg 10μg 10μg 2μg 5μg 5μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 14 – R ≤ 9 S ≥ 23 – R ≤ 13 S ≥ 16 – R ≤ 10 S ≥22 – R ≤19 S ≥ 15 – R ≤ 12 S ≥ 21 – R ≤ 14 S ≥ 20 – R ≤ 16 S ≥ 21 – R ≤ 15 
Clinical Isolate 
 
        
SA001 R R S S R S S R RRSSRSSR 
Susceptibility Testing Conditions:  
Test method: Disk diffusion.  
Medium: Mueller-Hinton Agar (MHA). 
Inoculum: Direct colony suspension, equivalent to a 0.5 McFarland standard. 
Incubation conditions: 35 ± 2 °C; ambient air.  
Incubation length:16 to 18 hours.   
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12C   Streptococcus pyogenes (GABHS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GABHS = Group A Beta-Haemolytic Streptococci  
 
 
 
 
Antimicrobial Class Penicillins
1
 Macrolides
2
 Glycopeptides
2
 Penicillins
1
 Penems
1
 Folate pathway 
inhibitors
2
 
Cephems 
(oral)
1
 
Lincosamides
2
 Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Penicillin 
(PEN) 
Erythromycin 
(EM) 
Vancomycin 
(VA) 
Ampicillin 
(AM) 
Imipenem 
(IPM) 
Co-trimoxazole 
(SXT) 
a
 
Cephalexin 
(LEX) 
Clindamycin 
(CM) 
Cefuroxime 
(CXM)
4
 
Disk Content 
 
10 μg 15 μg 30 μg 10 μg 10 μg 1.25/23.75 μg 30 μg 2 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 24 – R ≤ S ≥ 21 – R ≤ 15 S ≥ 17 – R ≤ – S ≥ 24 – R ≤ S ≥ – – R ≤ S ≥ 19 – R ≤ 15 S ≥ –  – R ≤ S ≥ 19 – R ≤ 15 S ≥ 24 – R ≤ – 
Clinical Isolate 
 
         
STA01 S S S S S S S S S SSSSSSSSS 
STA02 S S S S S R S S S SSSSSRSSS 
STA03 S S S S S R S S S SSSSSRSSS 
STA04 S S S S S R S S S SSSSSRSSS 
STA05 S S S S S R S S S SSSSSRSSS 
STA06 S S S S S R S S S SSSSSRSSS 
STA07 S S S S S R S S S SSSSSRSSS 
STA08 S S S S S R S S S SSSSSRSSS 
STA09 S S S S S S S S S SSSSSSSSS 
STA10 S S S S S R S S S SSSSSRSSS 
STA11 S S S S S S S S S SSSSSSSSS 
STA12 S S S S S R S S S SSSSSRSSS 
STA13 S S S S S R S S S SSSSSRSSS 
STA14 S S S S S R S S S SSSSSRSSS 
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12D   Streptococcus agalactiae (GBS)  
 
Antimicrobial Class Penicillins
1
 Macrolides
2
 Glycopeptides
2
 Penicillins
1
 Penems
1
 Folate pathway 
inhibitors
2
 
Cephems 
(oral)
1
 
Lincosamides
2
 Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Penicillin 
(PEN) 
Erythromycin 
(EM) 
Vancomycin 
(VA) 
Ampicillin 
(AM) 
Imipenem 
(IPM) 
Co-trimoxazole 
(SXT) 
a
 
Cephalexin 
(LEX)
 b
 
Clindamycin 
(CM) 
Cefuroxime 
(CXM)
4
 
Disk Content 
 
10 μg 15 μg 30 μg 10 μg 10 μg 1.25/23.75 μg 30 μg 2 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 24 – R ≤ S ≥ 21 – R ≤ 15 S ≥ 17 – R ≤ – S ≥ 24 – R ≤ S ≥ – – R ≤ S ≥ 19 – R ≤ 15 S ≥ –  – R ≤ S ≥ 19 – R ≤ 15 S ≥ 24 – R ≤ – 
Clinical Isolate 
 
         
STB01 S S S S S R S S S SSSSSRSSS 
STB02 S S S S S R S S S SSSSSRSSS 
STB03 S S S S S R S S S SSSSSRSSS 
STB04 S S S S S R S S S SSSSSRSSS 
STB05 S S S S S R S S S SSSSSRSSS 
STB06 S S S S S R S S S SSSSSRSSS 
STB07 S S S S S R S S S SSSSSRSSS 
STB08 S S S S S R S S S SSSSSRSSS 
STB09 S S S S S R S S S SSSSSRSSS 
STB10 S S S S S R S S S SSSSSRSSS 
STB11 S S S S S R S S S SSSSSRSSS 
STB12 S S S S S R S S S SSSSSRSSS 
STB13 S S S S S R S S S SSSSSRSSS 
STB14 S S S S S R S S S SSSSSRSSS 
STB15 S S S S S R S S S SSSSSRSSS 
STB16 S S S S S R S S S SSSSSRSSS 
STB17 S S S S S R S S S SSSSSRSSS 
STB18 S S S S S R S S S SSSSSRSSS 
STB19 S S S S S R S S S SSSSSRSSS 
STB20 S S S S S R S S S SSSSSRSSS 
STB21 S S S S S R S S S SSSSSRSSS 
STB22 S S S S S R S S S SSSSSRSSS 
STB23 S S S S S R S S S SSSSSRSSS 
STB24 S S S S S R S S S SSSSSRSSS 
STB25 S S S S S R S S S SSSSSRSSS 
STB26 S S S S S R S S S SSSSSRSSS 
STB27 S S S S S R S S S SSSSSRSSS 
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For the Streptococcus spp. β-Hemolytic Group, an organism that is susceptible to penicillin can be considered susceptible to the listed antimicrobial agents when used for approved indications and need not be tested against 
those agents. For β-hemolytic streptococci (Groups A, B, C, G): ampicillin, amoxicillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, cefazolin, cefepime, cephradine, cephalothin, cefotaxime, ceftriaxone, ceftizoxime, 
imipenem, ertapenem, and meropenem. In addition, for group A streptococci only: cefaclor, cefdinir, cefprozil, ceftibuten, cefuroxime, cefpodoxime, and cephapirin (CLSI document M100-S20 Vol. 30 No. 1, Page 92-94, 
2010). Results are based on the zone diameter interpretive standards for Streptococcus spp. β-Hemolytic Group from the CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational 
Supplement M100-S20 Vol. 30 No. 1, Page 92-94, 2010.  
 
 
STB28 S S S S S R S S S SSSSSRSSS 
STB29 S S S S S R S S S SSSSSRSSS 
STB30 S S S S S R S S S SSSSSRSSS 
STB31 S S S S S R S S S SSSSSRSSS 
STB32 S S S S S R S S S SSSSSRSSS 
STB33 S S S S S S S S S SSSSSSSSS 
STB34 S S S S S R S S S SSSSSRSSS 
STB35 S S S S S R S S S SSSSSRSSS 
STB36 S S S S S R S S S SSSSSRSSS 
STB37 S S S S S R S S S SSSSSRSSS 
STB38 S S S S S R S S S SSSSSRSSS 
STB39 S S S S S R S S S SSSSSRSSS 
STB40 S S S S S R S S S SSSSSRSSS 
STB41 S S S S S R S S S SSSSSRSSS 
STB42 S S S S S R S S S SSSSSRSSS 
STB43 S S S S S R S S S SSSSSRSSS 
STB44 S S S S S R S S S SSSSSRSSS 
STB45 S S S S S R S S S SSSSSRSSS 
STB46 S S S S S R S S S SSSSSRSSS 
STB47 S S S S S R S S S SSSSSRSSS 
STB48 S S S S S R S S S SSSSSRSSS 
STB49 S S S S S R S S S SSSSSRSSS 
STB50 S S S S S R S S S SSSSSRSSS 
STB51 S S S S S R S S S SSSSSRSSS 
STB52 S S S S S R S S S SSSSSRSSS 
STB53 S S S S S R S S S SSSSSRSSS 
STB54 S S S S S R S S S SSSSSRSSS 
STB55 S S S S S R S S S SSSSSRSSS 
STB56 S S S S S R S S S SSSSSRSSS 
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12E  Group C Streptococci (GCS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Class Penicillins
1
 Macrolides
2
 Glycopeptides
2
 Penicillins
1
 Penems
1
 Folate pathway 
inhibitors
2
 
Cephems 
(oral)
1
 
Lincosamides
2
 Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Penicillin 
(PEN) 
Erythromycin 
(EM) 
Vancomycin 
(VA) 
Ampicillin 
(AM) 
Imipenem 
(IPM) 
Co-trimoxazole 
(SXT) 
a
 
Cephalexin 
(LEX) 
Clindamycin 
(CM) 
Cefuroxime 
(CXM)
4
 
Disk Content 
 
10 μg 15 μg 30 μg 10 μg 10 μg 1.25/23.75 μg 30 μg 2 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 24 – R ≤ S ≥ 21 – R ≤ 15 S ≥ 17 – R ≤ – S ≥ 24 – R ≤ S ≥ – – R ≤ S ≥ 19 – R ≤ 15 S ≥ –  – R ≤ S ≥ 19 – R ≤ 15 S ≥ 24 – R ≤ 
Clinical Isolate 
 
         
STC01 S S S S S S S S S SSSSSSSSS 
STC02 S S S S S S S S S SSSSSSSSS 
STC03 S S S S S S S S S SSSSSSSSS 
STC04 S S S S S S S S S SSSSSSSSS 
STC05 S S S S S S S S S SSSSSSSSS 
STC06 S S S S S S S S S SSSSSSSSS 
STC07 S S S S S S S S S SSSSSSSSS 
STC08 S S S S S S S S S SSSSSSSSS 
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12F   Group F Streptococci (GFS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Viridans Group Streptococci (VGS) include the following five groups, with several species within each group: mutans group, salivarius group, bovis group, anginosus group (previously "S. milleri" group), and mitis group. 
The anginosus group includes small colony–forming β-hemolytic strains with groups A, C, F, and G antigens. For detailed information on the species within the groups, please refer to recent clinical microbiology literature 
(CLSI 2010).   
 
 
 
 
 
 
 
 
 
Antimicrobial Class Penicillins
1
 Macrolides
2
 Glycopeptides
2
 Penicillins
1
 Penems
1
 Folate pathway 
inhibitors
2
 
Cephems 
(oral)
1
 
Lincosamides
2
 Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Penicillin 
(PEN) 
Erythromycin 
(EM) 
Vancomycin 
(VA) 
Ampicillin 
(AM) 
Imipenem 
(IPM) 
Co-trimoxazole 
(SXT) 
a
 
Cephalexin 
(LEX) 
Clindamycin 
(CM) 
Cefuroxime 
(CXM)
4
 
Disk Content 
 
10 μg 15 μg 30 μg 10 μg 10 μg 1.25/23.75 μg 30 μg 2 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 24 – R ≤ S ≥ 21 – R ≤ 15 S ≥ 17 – R ≤ – S ≥ 24 – R ≤ S ≥ – – R ≤ S ≥ 19 – R ≤ 15 S ≥ –  – R ≤ S ≥ 19 – R ≤ 15 S ≥ 24 – R ≤ – 
Clinical Isolate 
 
         
STF01 S S S S S S S S S SSSSSSSSS 
STF02 S S S S S S S S S SSSSSSSSS 
STF03 S S S S S S S S S SSSSSSSSS 
STF04 S S S S S S S S S SSSSSSSSS 
STF05 S S S S S S S S S SSSSSSSSS 
STF06 S S S S S S S S S SSSSSSSSS 
STF07 S S S S S S S S S SSSSSSSSS 
STF08 S S S S S S S S S SSSSSSSSS 
STF09 S S S S S S S S S SSSSSSSSS 
STF10 S S S S S S S S S SSSSSSSSS 
STF11 S S S S S S S S S SSSSSSSSS 
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12G   Group G Streptococci (GGS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Class Penicillins
1
 Macrolides
2
 Glycopeptides
2
 Penicillins
1
 Penems
1
 Folate pathway 
inhibitors
2
 
Cephems 
(oral)
1
 
Lincosamides
2
 Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Penicillin 
(PEN) 
Erythromycin 
(EM) 
Vancomycin 
(VA) 
Ampicillin 
(AM) 
Imipenem 
(IPM) 
Co-trimoxazole 
(SXT) 
a
 
Cephalexin 
(LEX) 
Clindamycin 
(CM) 
Cefuroxime 
(CXM)
4
 
Disk Content 
 
10 μg 15 μg 30 μg 10 μg 10 μg 1.25/23.75 μg 30 μg 2 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 24 – R ≤ S ≥ 21 – R ≤ 15 S ≥ 17 – R ≤ – S ≥ 24 – R ≤ S ≥ – – R ≤ S ≥ 19 – R ≤ 15 S ≥ –  – R ≤ S ≥ 19 – R ≤ 15 S ≥ 24 – R ≤ – 
Clinical Isolate 
 
         
STG01 S S S S S S S S S SSSSSSSSS 
STG02 S S S S S R S S S SSSSSRSSS 
STG03 S S S S S R S S S SSSSSRSSS 
STG04 S S S S S S S S S SSSSSSSSS 
STG05 S S S S S R S S S SSSSSRSSS 
STG06 S S S S S R S S S SSSSSRSSS 
STG07 S S S S S R S S S SSSSSRSSS 
STG08 S S S S S R S S S SSSSSRSSS 
STG09 S S S S S R S S S SSSSSRSSS 
STG10 S S S S S R S S S SSSSSRSSS 
STG11 S S S S S R S S S SSSSSRSSS 
STG12 S S S S S R S S S SSSSSRSSS 
STG13 S S S S S S S S S SSSSSSSSS 
STG14 S S S S S R S S S SSSSSRSSS 
STG15 S S S S S R S S S SSSSSRSSS 
STG16 S S S S S R S S S SSSSSRSSS 
STG17 S S S S S R S S S SSSSSRSSS 
STG18 S S S S S S S S S SSSSSSSSS 
STG19 S S S S S S S S S SSSSSSSSS 
STG20 S S S S S S S S S SSSSSSSSS 
STG21 S S S S S S S S S SSSSSSSSS 
STG22 S S S S S S S S S SSSSSSSSS 
STG23 S S S S S S S S S SSSSSSSSS 
STG24 S S S S S S S S S SSSSSSSSS 
STG25 S S S S S S S S S SSSSSSSSS 
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12H   Streptococcus pneumoniae (SPn)  
 
Antimicrobial Class Macrolides
2
 Folate pathway 
inhibitors
2
 
Cephems 
(oral)
1
 
Cephems 
(parenteral)
1
 
Penicillins
1
 Glycopeptides
2
  
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Erythromycin 
(EM) 
Co-trimoxazole 
( SXT) 
a
 
Cephalexin 
(LEX)
3
 
Cefuroxime 
(CXM)
4
 
Penicillin 
(PEN) 
Vancomycin 
(VA) 
Disk Content 
 
15 μg 1.25/23.75 μg 30 μg 30 μg 10 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 21 – R ≤ 15 S ≥ 19 – R ≤ 15 S ≥ –  – R ≤ S ≥ 24 – R ≤ S ≥ – – R ≤ S ≥ 17 – R ≤ 
Clinical Isolate 
 
      
STP01 R R R S R S RRRSRS 
STP02 R R R S R S RRRSRS 
STP03 R R R S R S RRRSRS 
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12I  Haemophilus influenzae (HI)  
 
Antimicrobial Class Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
Cephems 
(oral)
1
 
Cephems 
(parenteral)
1
 
Macrolides
2
  
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Ampicillin 
(AM) 
Co-trimoxazole 
(SXT) 
a
 
Amoxicillin- 
Clavulanic acid (AMC) 
Cefuroxime 
(CXM) 
Ceftriaxone 
(CTR)
b
 
Azithromycin 
(AZM) 
Disk Content 
 
10 μg 1.25/23.75μg 20/10 μg 30 μg 30 μg 15 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 22 – R ≤ 18 S ≥ 16 – R ≤ 10 S ≥ 20 – R ≤ 19 S ≥ 20 – R ≤ 16 S ≥ 26 – R  – S ≥ 12 – R  – 
Clinical Isolate 
 
      
HI001 S S S S S S SSSSSS 
HI002 S S S S S S SSSSSS 
HI003 S S S S S S SSSSSS 
HI004 S S S S S S SSSSSS 
HI005 S R S S S S SRSSSS 
HI006 S S S S S S SSSSSS 
HI007 R S S S S S RSSSSS 
HI008 R S S S S S RSSSSS 
HI009 S S S S S S SSSSSS 
HI010 S S S S S S SSSSSS 
HI011 S S S S S S SSSSSS 
HI012 S S S S S S SSSSSS 
HI013 S R S S S S SRSSSS 
HI014 S R S S S S SRSSSS 
HI015 S S S S S S SSSSSS 
HI016 S S S S S S SSSSSS 
HI017 S S S S S S SSSSSS 
HI018 S S S S S S SSSSSS 
HI019 S R S S S S SRSSSS 
HI020 S R S S S S SRSSSS 
HI021 S R S S S S SRSSSS 
HI022 S R S S S S SRSSSS 
HI023 S R S S S S SRSSSS 
HI024 S S S S S S SSSSSS 
HI025 S S S S S S SSSSSS 
HI026 S S S S S S SSSSSS 
HI027 S S S S S S SSSSSS 
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HI028 S R S S S S SRSSSS 
HI029 S R S S S S SRSSSS 
HI030 S R S S S S SRSSSS 
HI031 S S S S S S SSSSSS 
HI032 S S S S S S SSSSSS 
HI033 S S S S S S SSSSSS 
HI034 S R S S S S SRSSSS 
HI035 S S S S S S SSSSSS 
HI036 S S S S S S SSSSSS 
HI037 S S S S S S SSSSSS 
HI038 R S S S S S RSSSSS 
HI039 S S S S S S SSSSSS 
HI040 S S S S S S SSSSSS 
HI041 S R S S S S SRSSSS 
HI042 S S S S S S SSSSSS 
HI043 S S S S S S SSSSSS 
HI044 S S S S S S SSSSSS 
HI045 S S S S S S SSSSSS 
HI046 S S S S S S SSSSSS 
HI047 S S S S S S SSSSSS 
HI048 R R R S S S RRRSSS 
HI049 R R S S S S RRSSSS 
HI050 R R S S S S RRSSSS 
HI051 S S S S S S SSSSSS 
HI052 S S S S S S SSSSSS 
HI053 S S S S S S SSSSSS 
HI054 S S S S S S SSSSSS 
HI055 S S S S S S SSSSSS 
HI056 S S S S S S SSSSSS 
HI057 S S S S S S SSSSSS 
HI058 S S S S S S SSSSSS 
HI059 S S S S S S SSSSSS 
HI060 S S S S S S SSSSSS 
HI061 S R S S S S SRSSSS 
HI062 S R S S S S SRSSSS 
HI063 S R S S S S SRSSSS 
HI064 R S S S S S RSSSSS 
HI065 S S S S S S SSSSSS 
HI066 S S S S S S SSSSSS 
HI067 S R S S S S SRSSSS 
HI068 S R S S S S SRSSSS 
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HI069 S S S S S S SSSSSS 
HI070 S R S S S S SRSSSS 
HI071 S R S S S S SRSSSS 
HI072 S S S S S S SSSSSS 
HI073 S S S S S S SSSSSS 
HI074 S S S S S S SSSSSS 
HI075 S S S S S S SSSSSS 
HI076 S S S S S S SSSSSS 
HI077 S R S S S S SRSSSS 
HI078 S R S S S S SRSSSS 
HI079 S R S S S S SRSSSS 
HI080 S R S S S S SRSSSS 
HI081 R S S S S S RSSSSS 
HI082 R S S S S S RSSSSS 
HI083 R S S S S S RSSSSS 
HI084 R S S S S S RSSSSS 
HI085 R S S S S S RSSSSS 
HI086 S S S S S S SSSSSS 
 
 
Amoxicillin-clavulanic acid, azithromycin, clarithromycin, cefaclor, cefprozil, loracarbef, cefdinir, cefixime, cefpodoxime, cefuroxime, and telithromycin are oral agents that may be used as empiric therapy for respiratory 
tract infections due to Haemophilus spp. The results of susceptibility tests with these antimicrobial agents are often not useful for management of individual patients. However, susceptibility testing of Haemophilus spp. 
with these compounds may be appropriate for surveillance or epidemiological studies. 
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12J   Haemophilus parainfluenzae (HP) 
 
Antimicrobial Class Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
Cephems 
(oral)
1
 
Cephems 
(parenteral)
1
 
Macrolides
2
  
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Ampicillin 
(AM) 
Co-trimoxazole 
( SXT) 
a
 
Amoxicillin- 
Clavulanic acid (AMC) 
Cefuroxime 
(CXM) 
Ceftriaxone 
(CTR) 
Azithromycin 
(AZM) 
Disk Content 
 
10 μg 1.25/23.75 μg 20/10 μg 30 μg 30 μg 15 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 22 – R ≤ 18 S ≥ 16 – R ≤ 10 S ≥ 20 – R ≤ 19 S ≥ 20 – R ≤ 16 S ≥ 26 – R  – S ≥ 12 – R  – 
Clinical Isolate 
 
      
HP001 S R S S S S SRSSSS 
HP002 S S S S S S SSSSSS 
HP003 S S S S S S SSSSSS 
HP004 S S S S S S SSSSSS 
HP005 S S S S S S SSSSSS 
HP006 S R S S S S SRSSSS 
HP007 S S S S S S SSSSSS 
HP008 S R S S S S SRSSSS 
HP009 S R S S S S SRSSSS 
HP010 S R S S S S SRSSSS 
HP011 R R S S S S RRSSSS 
HP012 R S S S S S RSSSSS 
HP013 S R S S S S SRSSSS 
HP014 S S S S S S SSSSSS 
HP015 S R S S S S SRSSSS 
HP016 S S S S S S SSSSSS 
HP017 S S S S S S SSSSSS 
HP018 S S S S S S SSSSSS 
HP019 S S S S S S SSSSSS 
HP020 S S S S S S SSSSSS 
HP021 S S S S S S SSSSSS 
HP022 S S S S S S SSSSSS 
HP023 S S S S S S SSSSSS 
HP024 S S S S S S SSSSSS 
HP025 S R S S S S SRSSSS 
HP026 S S S S S S SSSSSS 
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HP027 S S S S S S SSSSSS 
HP028 S S S S S S SSSSSS 
HP029 S R S S S S SRSSSS 
HP030 S S S S S S SSSSSS 
HP031 S S S S S S SSSSSS 
  
 
 
 
12K   Klebsiella pneumoniae (KP) 
  
Antimicrobial Class Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
β-lactamase inhibitor  
combinations
1
 
Aminoglycosides
2
 Aminoglycosides
2
 Cephems 
(parenteral)
1
 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Ampicillin 
(AM) 
Co-trimoxazole 
(SXT) 
a
 
Ampicillin- 
Sulbactam (SAM) 
Amoxicillin- 
Clavulanic Acid (AMC) 
Gentamycin 
(GM) 
Amikacin 
(AMK) 
Cefuroxime 
(CXM) 
Disk Content 
 
10 μg 1.25/23.75 μg 10/10 μg 20/10 μg 10 μg 30 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 17 – R ≤ 13 S ≥ 19 – R ≤ 15 S ≥ 15 – R ≤ 11 S ≥ 18 – R ≤ 13 S ≥ 15 – R ≤ 12 S ≥ 17 – R ≤ 14 S ≥ 18 – R ≤ 14 
Clinical Isolate 
 
       
KP001 R S S S S S S 
KP002 R S S S S S S 
KP003 R S S S S S S 
KP004 R S S S S S S 
KP005 R S S S S S S 
KP006 R S S S S S S 
KP007 R S S S S S S 
KP008 R S S S S S S 
KP009 R S S S S S S 
KP010 R S S S S S S 
KP011 R S S S S S S 
KP012 R S S S S S S 
KP013 R S S S S S S 
KP014 R S S S S S S 
KP015 R S S S S S S 
KP016 R S S S S S S 
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KP017 R S S S S S S 
KP018 R S S S S S S 
KP019 R S S S S S S 
KP020 R S S S S S S 
KP021 R S S S S S S 
KP022 R S S S S S S 
KP023 R S S S S S S 
KP024 R S S S S S S 
KP025 R S S S S S S 
KP026 R S S S S S S 
KP027 R S S S S S S 
KP028 R S S S S S S 
KP029 R S S S S S S 
KP030 R S S S S S S 
 
Antimicrobial Class Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Quinolones
2
 Penems
1
 β-lactamase inhibitor  
combinations
1
 
Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Cefoperazone 
(CFP) 
Ceftazidime 
(CAZ)
b
 
Ceftriaxone 
(CTR) 
Ciprofloxacin 
(CIP) 
Imipenem 
(IPM) 
Piperacillin- 
Tazobactam (TZP) 
Cefotaxime 
(CTX) 
b
 
Disk Content 
 
75 μg 30 μg 30 μg 5μg 10 μg 100/10 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 21 – R ≤ 15 S ≥ 21 – R ≤ 17 S ≥ 23 – R ≤ 19 S ≥ 21 – R ≤ 15 S ≥ 16 – R ≤ 13 S ≥ 21 – R ≤ 17 S ≥ 26 – R ≤ 22 
Clinical Isolate 
 
       
KP001 S S S S S S S RSSSSSSSSSSSSS 
KP002 S S S S S S S RSSSSSSSSSSSSS 
KP003 S S S S S S S RSSSSSSSSSSSSS 
KP004 S S S S S S S RSSSSSSSSSSSSS 
KP005 S S S S S S S RSSSSSSSSSSSSS 
KP006 S S S S S S S RSSSSSSSSSSSSS 
KP007 S S S S S S S RSSSSSSSSSSSSS 
KP008 S S S S S S S RSSSSSSSSSSSSS 
KP009 S S S S S S S RSSSSSSSSSSSSS 
KP010 S S S S S S S RSSSSSSSSSSSSS 
KP011 S S S S S S S RSSSSSSSSSSSSS 
KP012 S S S S S S S RSSSSSSSSSSSSS 
KP013 S S S S S S S RSSSSSSSSSSSSS 
KP014 S S S S S S S RSSSSSSSSSSSSS 
KP015 S S S S S S S RSSSSSSSSSSSSS 
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KP016 S S S S S S S RSSSSSSSSSSSSS 
KP017 S S S S S S S RSSSSSSSSSSSSS 
KP018 S S S S S S S RSSSSSSSSSSSSS 
KP019 S S S S S S S RSSSSSSSSSSSSS 
KP020 S S S S S S S RSSSSSSSSSSSSS 
KP021 S S S S S S S RSSSSSSSSSSSSS 
KP022 S S S S S S S RSSSSSSSSSSSSS 
KP023 S S S S S S S RSSSSSSSSSSSSS 
KP024 S S S S S S S RSSSSSSSSSSSSS 
KP025 S S S S S S S RSSSSSSSSSSSSS 
KP026 S S S S S S S RSSSSSSSSSSSSS 
KP027 S S S S S S S RSSSSSSSSSSSSS 
KP028 S S S S S S S RSSSSSSSSSSSSS 
KP029 S S S S S S S RSSSSSSSSSSSSS 
KP030 S S S S S S S RSSSSSSSSSSSSS 
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12L   Pseudomonas aeruginosa (PA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Class Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
β-lactamase inhibitor  
combinations
1
 
Aminoglycosides
2
 Aminoglycosides
2
 Cephems 
(parenteral)
1
 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Ampicillin 
(AM) 
Co-trimoxazole 
(SXT) 
a
 
Ampicillin- 
Sulbactam (SAM) 
Amoxicillin- 
Clavulanic Acid (AMC) 
Gentamicin 
(GM) 
Amikacin 
(AMK) 
Cefuroxime 
(CXM) 
Disk Content 
 
10 μg 1.25/23.75 μg 10/10 μg 20/10 μg 10 μg 30 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 17 – R ≤ 13 S ≥ 19 – R ≤ 15 S ≥ 15 – R ≤ 11 S ≥ 18 – R ≤ 13 S ≥ 15 – R ≤ 12 S ≥ 17 – R ≤ 14 S ≥ 18 – R ≤ 14 
Clinical Isolate 
 
       
PA001 R S R R R R S 
PA002 R S R R R R S 
PA003 R S R R R R S 
PA004 R S R R R R S 
PA005 R S R R R R S 
PA006 R S R R R R S 
PA007 R S R R R R S 
PA008 S S S S S S S 
PA009 S S S S S S S 
Antimicrobial Class Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Quinolones
2
 Penems
1
 β-lactamase inhibitor  
combinations
1
 
Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Cefoperazone 
(CFP) 
Ceftazidime 
(CAZ) 
b
 
Ceftriaxone 
(CTR) 
Ciprofloxacin 
(CIP) 
Imipenem 
(IPM) 
Piperacillin-
Tazobactam (TZP) 
Cefotaxime 
(CTX) 
b
 
Disk Content 
 
75 μg 30 μg 30 μg 5μg 10 μg 100/10 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 21 – R ≤ 15 S ≥ 18 – R ≤ 14 S ≥ 21 – R ≤ 13 S ≥ 21 – R ≤ 15 S ≥ 16 – R ≤ 13 S ≥ 18 – R ≤ 17 S ≥ 23 – R ≤ 14 
Clinical Isolate 
 
       
PA001 S S S S S S S RSRRRRSSSSSSSS 
PA002 S S S S S S S RSRRRRSSSSSSSS 
PA003 S S S S S S S RSRRRRSSSSSSSS 
PA004 S S S S S S S RSRRRRSSSSSSSS 
PA005 S S S S S S S RSRRRRSSSSSSSS 
PA006 S S S S S S S RSRRRRSSSSSSSS 
PA007 S S S S S S S RSRRRRSSSSSSSS 
PA008 S S S S S S S SSSSSSSSSSSSSS 
PA009 S S S S S S S SSSSSSSSSSSSSS 
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12M   Citrobacter sp.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Antimicrobial Class Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
β-lactamase inhibitor  
combinations
1
 
Aminoglycosides
2
 Aminoglycosides
2
 Cephems 
(parenteral)
1
 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Ampicillin 
(AM) 
Co-trimoxazole 
(SXT) 
a
 
Ampicillin- 
Sulbactam (SAM) 
Amoxicillin- 
Clavulanic Acid (AMC) 
Gentamicin 
(GM) 
Amikacin 
(AMK) 
Cefuroxime 
(CXM) 
Disk Content 
 
10 μg 1.25/23.75 μg 10/10 μg 20/10 μg 10 μg 30 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 17 – R ≤ 13 S ≥ 19 – R ≤ 15 S ≥ 15 – R ≤ 11 S ≥ 18 – R ≤ 13 S ≥ 15 – R ≤ 12 S ≥ 17 – R ≤ 14 S ≥ 18 – R ≤ 14 
Clinical Isolate 
 
       
CBF01 R S S S S S S 
CBF02 R S S S S S S 
CBF03 R S S S S S S 
CBF04 R S S S S S S 
Antimicrobial Class Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Quinolones
2
 Penems
1
 β-lactamase inhibitor  
combinations
1
 
Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Cefoperazone 
(CFP) 
Ceftazidime 
(CAZ) 
b
 
Ceftriaxone 
(CTR) 
Ciprofloxacin 
(CIP) 
Imipenem 
(IPM) 
Piperacillin- 
Tazobactam(TZP) 
Cefotaxime 
(CTX) 
b
 
Disk Content 
 
75 μg 30 μg 30 μg 5μg 10 μg 100/10 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 21 – R ≤ 15 S ≥ 18 – R ≤ 14 S ≥ 21 – R ≤ 13 S ≥ 21 – R ≤ 15 S ≥ 16 – R ≤ 13 S ≥ 18 – R ≤ 17 S ≥ 23 – R ≤ 14 
Clinical Isolate 
 
       
CBF01 S S S S S S S RSSSSSSSSSSSSS 
CBF02 S S S S S S S RSSSSSSSSSSSSS 
CBF03 S S S S S S S RSSSSSSSSSSSSS 
CBF04 S S S S S S S RSSSSSSSSSSSSS 
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12N   Enterobacter cloacae (EC) 
 
Antimicrobial Class Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
β-lactamase inhibitor  
combinations
1
 
Aminoglycosides
2
 Aminoglycosides
2
 Cephems 
(parenteral)
1
 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Ampicillin 
(AM) 
Co-trimoxazole 
(SXT) 
a
 
Ampicillin- 
Sulbactam (SAM) 
Amoxicillin- 
Clavulanic Acid (AMC) 
Gentamycin 
(GM) 
Amikacin 
(AMK) 
Cefuroxime 
(CXM) 
Disk Content 
 
10 μg 1.25/23.75 μg 10/10 μg 20/10 μg 10 μg 30 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 17 – R ≤ 13 S ≥ 19 – R ≤ 15 S ≥ 15 – R ≤ 11 S ≥ 18 – R ≤ 13 S ≥ 15 – R ≤ 12 S ≥ 17 – R ≤ 14 S ≥ 18 – R ≤ 14 
Clinical Isolate 
 
       
EBC01 R S S R S S S 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Antimicrobial Class Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Quinolones
2
 Penems
1
 β-lactamase inhibitor  
combinations
1
 
Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial Agent Generic 
Name (Abbreviation) 
Cefoperazone 
(CFP) 
Ceftazidime 
(CAZ) 
b
 
Ceftriaxone 
(CTR) 
Ciprofloxacin 
(CIP) 
Imipenem 
(IPM) 
Piperacillin- 
Tazobactam (TZP) 
Cefotaxime 
(CTX) 
b
 
Disk Content 
 
75 μg 30 μg 30 μg 5μg 10 μg 100/10 μg 30 μg 
Zone Diameter Breakpoints, 
nearest whole mm 
S ≥ 21 – R ≤ 15 S ≥ 18 – R ≤ 14 S ≥ 21 – R ≤ 13 S ≥ 21 – R ≤ 15 S ≥ 16 – R ≤ 13 S ≥ 18 – R ≤ 17 S ≥ 23 – R ≤ 14 
Clinical Isolate 
 
       
EBC01 S S S S S S S RSSRSSSSSSSSSS 
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12O   Acinetobacter baumannii (AB)   
 
Antimicrobial  
Class 
Penicillins
1
 Folate pathway 
inhibitors
2
 
β-lactamase inhibitor  
combinations
1
 
β-lactamase inhibitor  
combinations
1
 
Aminoglycosides
2
 Aminoglycosides
2
 Cephems 
(parenteral)
1
 
Antimicrobial  
Generic Name  
Ampicillin  
(AM) 
Co-trimoxazole 
(SXT) 
a
 
Ampicillin- 
Sulbactam (SAM) 
Amoxicillin- 
Clavulanic Acid (AMC) 
Gentamycin 
(GM) 
Amikacin 
(AMK) 
Cefuroxime 
(CXM)  
Disk Content 10 μg 1.25/23.75 μg 10/10 μg 20/10 μg 10 μg 30 μg 30 μg 
Zone Diameter  
Breakpoints 
S ≥ 17 – R ≤ 13 S ≥ 19 – R ≤ 15 S ≥ 15 – R ≤ 11 S ≥ 18 – R ≤ 13 S ≥ 15 – R ≤ 12 S ≥ 17 – R ≤ 14 S ≥ 18 – R ≤ 14 
Clinical Isolate        
ABB01 R S S R S S R 
 
Antimicrobial  
Class 
Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Cephems 
(parenteral)
1
 
Quinolones
2
 Penems
1
 β-lactamase inhibitor  
combinations
1
 
Cephems 
(parenteral)
1
 
 
 
 
Antibiogram 
pattern 
Antimicrobial 
Generic Name  
Cefoperazone 
(CFP) 
Ceftazidime 
(CAZ) 
b
 
Ceftriaxone 
(CTR) 
Ciprofloxacin 
(CIP) 
Imipenem 
(IPM)  
Piperacillin- 
Tazobactam (TZP) 
Cefotaxime 
(CTX) 
b
 
Disk Content 75 μg 30 μg 30 μg 5μg 10 μg 100/10 μg 30 μg 
Zone Diameter  
Breakpoints 
S ≥ 21 – R ≤ 15 S ≥ 18 – R ≤ 14 S ≥ 21 – R ≤ 13 S ≥ 21 – R ≤ 15 S ≥ 16 – R ≤ 13 S ≥ 18 – R ≤ 17 S ≥ 23 – R ≤ 14 
Clinical Isolate        
ABB01 S S R S S S R RSSRSSRSSRSSSR 
 
 
 
